<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Genome editing</title><meta name="description" content="Genome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions, replacements, or modifications of genetic material to study gene function or treat diseases. These techniques rely on engineered nucleases that create double-strand breaks at specific genomic loci, which are then repaired by cellular mechanisms such as non-homologous end joining or homology-directed repair, often incorporating desired changes. Early approaches..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="gene editing, CRISPR"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Genome_editing"/><meta property="og:title" content="Genome editing"/><meta property="og:description" content="Genome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions, replacements, or modifications of genetic material to study gene function or treat diseases. These techniques rely on engineered nucleases that create double-strand breaks at specific genomic loci, which are then repaired by cellular mechanisms such as non-homologous end joining or homology-directed repair, often incorporating desired changes. Early approaches..."/><meta property="og:url" content="https://grokipedia.com/page/Genome_editing"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Genome editing"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:43.287Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Genome editing"/><meta name="twitter:description" content="Genome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions, replacements, or modifications of genetic material to study gene function or treat diseases. These techniques rely on engineered nucleases that create double-strand breaks at specific genomic loci, which are then repaired by cellular mechanisms such as non-homologous end joining or homology-directed repair, often incorporating desired changes. Early approaches..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="ae1086b255a988aefd98900c26f97f1d-6ff239987270080d-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=ae1086b255a988aefd98900c26f97f1d,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.2955908257469384,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#genome-editing" class="transition-opacity hover:opacity-100 opacity-50">Genome editing</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pre-engineered-nuclease-era" class="transition-opacity hover:opacity-100 opacity-50">Pre-Engineered Nuclease Era</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#development-of-site-specific-nucleases" class="transition-opacity hover:opacity-100 opacity-50">Development of Site-Specific Nucleases</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#crispr-breakthrough-and-rapid-adoption" class="transition-opacity hover:opacity-100 opacity-50">CRISPR Breakthrough and Rapid Adoption</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#post-2020-advancements-and-commercialization" class="transition-opacity hover:opacity-100 opacity-50">Post-2020 Advancements and Commercialization</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#biological-and-mechanistic-foundations" class="transition-opacity hover:opacity-100 opacity-50">Biological and Mechanistic Foundations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dna-repair-mechanisms-exploited-in-editing" class="transition-opacity hover:opacity-100 opacity-50">DNA Repair Mechanisms Exploited in Editing</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#principles-of-sequence-specific-targeting" class="transition-opacity hover:opacity-100 opacity-50">Principles of Sequence-Specific Targeting</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#primary-editing-technologies" class="transition-opacity hover:opacity-100 opacity-50">Primary Editing Technologies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#meganucleases" class="transition-opacity hover:opacity-100 opacity-50">Meganucleases</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#zinc-finger-nucleases" class="transition-opacity hover:opacity-100 opacity-50">Zinc Finger Nucleases</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#talens" class="transition-opacity hover:opacity-100 opacity-50">TALENs</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#crispr-cas-systems" class="transition-opacity hover:opacity-100 opacity-50">CRISPR-Cas Systems</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#base-editing-and-prime-editing" class="transition-opacity hover:opacity-100 opacity-50">Base Editing and Prime Editing</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#novel-and-hybrid-approaches" class="transition-opacity hover:opacity-100 opacity-50">Novel and Hybrid Approaches</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#delivery-systems-and-implementation-strategies" class="transition-opacity hover:opacity-100 opacity-50">Delivery Systems and Implementation Strategies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#viral-and-non-viral-delivery-methods" class="transition-opacity hover:opacity-100 opacity-50">Viral and Non-Viral Delivery Methods</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ex-vivo-versus-in-vivo-applications" class="transition-opacity hover:opacity-100 opacity-50">Ex Vivo versus In Vivo Applications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#technical-performance-metrics" class="transition-opacity hover:opacity-100 opacity-50">Technical Performance Metrics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#precision-efficiency-and-off-target-effects" class="transition-opacity hover:opacity-100 opacity-50">Precision, Efficiency, and Off-Target Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#strategies-for-enhancing-specificity-and-yield" class="transition-opacity hover:opacity-100 opacity-50">Strategies for Enhancing Specificity and Yield</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#practical-applications" class="transition-opacity hover:opacity-100 opacity-50">Practical Applications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#therapeutic-uses-in-human-medicine" class="transition-opacity hover:opacity-100 opacity-50">Therapeutic Uses in Human Medicine</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#agricultural-and-plant-breeding-improvements" class="transition-opacity hover:opacity-100 opacity-50">Agricultural and Plant Breeding Improvements</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#animal-models-and-basic-research" class="transition-opacity hover:opacity-100 opacity-50">Animal Models and Basic Research</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#industrial-biotechnology" class="transition-opacity hover:opacity-100 opacity-50">Industrial Biotechnology</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-translation-and-regulatory-milestones" class="transition-opacity hover:opacity-100 opacity-50">Clinical Translation and Regulatory Milestones</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#landmark-trials-and-approved-therapies" class="transition-opacity hover:opacity-100 opacity-50">Landmark Trials and Approved Therapies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#global-research-pipelines-and-challenges" class="transition-opacity hover:opacity-100 opacity-50">Global Research Pipelines and Challenges</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#risks-and-empirical-limitations" class="transition-opacity hover:opacity-100 opacity-50">Risks and Empirical Limitations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#biological-hazards-and-failure-modes" class="transition-opacity hover:opacity-100 opacity-50">Biological Hazards and Failure Modes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#long-term-safety-data-and-uncertainties" class="transition-opacity hover:opacity-100 opacity-50">Long-Term Safety Data and Uncertainties</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ethical-and-societal-dimensions" class="transition-opacity hover:opacity-100 opacity-50">Ethical and Societal Dimensions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#germline-editing-and-heritability-concerns" class="transition-opacity hover:opacity-100 opacity-50">Germline Editing and Heritability Concerns</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#enhancement-debates-and-equity-issues" class="transition-opacity hover:opacity-100 opacity-50">Enhancement Debates and Equity Issues</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#regulatory-responses-and-innovation-barriers" class="transition-opacity hover:opacity-100 opacity-50">Regulatory Responses and Innovation Barriers</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="genome-editing" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Genome editing<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions, replacements, or modifications of genetic material to study gene function or treat diseases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> These techniques rely on engineered nucleases that create double-strand breaks at specific genomic loci, which are then repaired by cellular mechanisms such as non-homologous end joining or homology-directed repair, often incorporating desired changes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Early approaches included zinc-finger nucleases (ZFNs) developed in the 1990s and transcription activator-like effector nucleases (TALENs) in the 2000s, but the clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) system, adapted from bacterial adaptive immunity and demonstrated for eukaryotic genome editing in 2012, has dominated due to its simplicity, efficiency, and versatility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Significant achievements include rapid gene knockout in model organisms for functional genomics, crop improvement for enhanced yield and resistance, and therapeutic applications in humans, such as the 2023 FDA approval of CRISPR-based ex vivo editing for sickle cell disease and beta-thalassemia, marking the first clinical use of the technology to correct pathogenic mutations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> These advances stem from empirical validation of editing precision in controlled trials, demonstrating causal links between corrected genotypes and phenotypic improvements without widespread off-target effects in targeted contexts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> However, challenges persist, including unintended mutations from incomplete specificity and delivery inefficiencies in vivo, necessitating ongoing refinements like base editing and prime editing for higher fidelity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Controversies arise primarily from germline editing, where changes are heritable, raising concerns over safety risks like mosaicism and long-term ecological impacts, as well as ethical debates on eugenics and inequality, though somatic applications avoid inheritance issues and focus on individual therapeutic benefits supported by clinical data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> The 2018 case of unauthorized human embryo editing by He Jiankui highlighted regulatory gaps but also underscored the technology&#x27;s potential when responsibly applied, with scientific consensus favoring paused heritable use until risks are empirically mitigated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="pre-engineered-nuclease-era" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pre-Engineered Nuclease Era<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Homologous recombination (HR), a conserved cellular mechanism for repairing double-strand breaks using a homologous DNA template, formed the basis of early genome editing efforts before the advent of engineered site-specific nucleases. In this era, spanning the 1970s to late 1980s, researchers introduced linear DNA constructs with flanking homology arms matching the target genomic locus, relying on spontaneous, low-frequency HR events to achieve precise insertions, deletions, or replacements without inducing targeted DNA breaks. This approach yielded high-fidelity modifications when successful but suffered from extreme inefficiency, typically 10^{-4} to 10^{-6} in mammalian cells, dominated by random non-homologous integrations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> To counter this, positive-negative selection strategies were developed, using markers like neomycin resistance for enrichment and herpes simplex virus thymidine kinase for counterselection against random integrants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pioneering work in yeast, where HR is naturally more efficient, demonstrated feasibility early on. In 1979, Scherer and Davis achieved targeted chromosomal segment replacement in <em>Saccharomyces cerevisiae</em> by transfecting hybrid plasmids, marking one of the first instances of precise genomic alteration via HR.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> This success in unicellular eukaryotes informed extensions to mammals. Oliver Smithies advanced the field in 1985 by reporting HR-mediated insertion of a functional gene into the human beta-globin locus in cultured mouse erythroleukemia cells, confirming targeted events at frequencies around 1 in 10^3 to 10^4 transformants under selection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The integration of mouse embryonic stem (ES) cells, first isolated in 1981 by Martin Evans and Matthew Kaufman, enabled heritable modifications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> By 1987, Smithies and Mario Capecchi independently applied HR in mouse ES cells to disrupt specific genes, such as <em>Aph-3</em>, using isogenic targeting vectors to boost efficiency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Capecchi&#x27;s group refined selection protocols, achieving targeted disruptions at rates improved to about 1 in 10^5 electroporated cells. These methods culminated in the first germline-transmissible gene knockouts in mice by 1989, allowing systematic functional analysis of genes via &quot;knockout&quot; models.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_104qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> Despite these advances, the absence of DSB induction limited scalability, confining applications largely to tractable systems like yeast and mouse ES cells for basic research into gene function and disease modeling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_184qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h3 id="development-of-site-specific-nucleases" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Development of Site-Specific Nucleases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Site-specific nucleases emerged as tools for targeted genome editing by inducing double-strand breaks (DSBs) at predetermined DNA sequences, leveraging cellular DNA repair pathways for precise modifications. Early efforts focused on meganucleases, naturally occurring homing endonucleases from microbes with recognition sites of 12-40 base pairs, first characterized in the 1980s such as I-SceI from yeast mitochondria.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> These enzymes demonstrated enhanced gene targeting via DSB-stimulated homologous recombination in yeast and mammalian cells by the early 1990s, but their rigid protein-DNA interfaces limited redesign for new specificities, restricting broad applicability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Engineering attempts in the 2000s involved semi-rational design and directed evolution to alter specificity, yet success remained low due to coupled recognition and cleavage domains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">To overcome meganuclease limitations, researchers developed modular nucleases by fusing customizable DNA-binding domains to separate, non-specific nuclease modules. Zinc finger nucleases (ZFNs), invented in 1996 by fusing zinc finger proteinsâ€”discovered in 1985â€”with the FokI endonuclease cleavage domain, enabled programmable targeting of 9-18 base pair sites as dimers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> Initial demonstrations achieved targeted DSBs and gene disruption in mammalian cells by 1998, with therapeutic applications emerging in the 2000s, including HIV resistance via CCR5 knockout in human cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> However, ZFNs required expertise in zinc finger assembly, often via phage display or structure-based design, and off-target effects arose from context-dependent binding affinities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_106abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Transcription activator-like effector nucleases (TALENs) advanced programmability in 2010, following the 2009 deciphering of the TALE DNA-binding code from Xanthomonas bacteria, where repeat-variable di-residues (RVDs) specify one base pair each.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> TALENs pair FokI domains flanking a central spacer for dimerization and cleavage, offering higher specificity than ZFNs due to independent modular recognition and reduced toxicity in applications like zebrafish and human cell editing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> First used for targeted gene knockouts and insertions in 2011, TALENs facilitated multiplex editing and expanded genome engineering to non-model organisms, though assembly of lengthy TALE arrays remained labor-intensive compared to later RNA-guided methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> These innovations established DSB-based editing principles, paving the way for scalable technologies while highlighting trade-offs in specificity, ease of design, and delivery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_106qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<h3 id="crispr-breakthrough-and-rapid-adoption" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">CRISPR Breakthrough and Rapid Adoption<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The CRISPR-Cas9 system emerged as a transformative tool for genome editing following a 2012 study by Emmanuelle Charpentier and Jennifer Doudna, who demonstrated in vitro that the Cas9 endonuclease from <em>Streptococcus pyogenes</em>, guided by a dual RNA structure (crRNA and tracrRNA, later simplified into single-guide RNA), could be reprogrammed to induce site-specific double-strand breaks in DNA.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> This work, published online on June 28, 2012, in <em>Science</em>, repurposed the bacterial adaptive immune mechanismâ€”previously characterized in the early 2000sâ€”for precise nucleic acid targeting, offering advantages in simplicity, multiplexing potential, and cost over prior nucleases like ZFNs and TALENs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_107qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> The system&#x27;s RNA-guided specificity stemmed from base-pairing between the guide RNA and target DNA, adjacent to a protospacer-adjacent motif (PAM) sequence, enabling predictable cleavage without protein engineering for each target.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_187qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Adaptation to cellular genome editing occurred rapidly, with demonstrations in prokaryotic and eukaryotic systems by early 2013. Independent studies by Feng Zhang&#x27;s group at the Broad Institute and George Church&#x27;s lab at Harvard achieved targeted modifications via non-homologous end joining (NHEJ) and homology-directed repair (HDR) in human and mouse cell lines, as reported in <em>Science</em> on January 3, 2013. These applications exploited the endogenous DNA repair pathways to introduce insertions, deletions, or precise substitutions, validating CRISPR-Cas9&#x27;s efficiency in mammalian genomes where off-target effects, though present, were manageable compared to earlier tools.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> Concurrently, Virginijus Å ikÅ¡nys&#x27;s group in Lithuania reported similar prokaryotic editing, underscoring the technology&#x27;s versatility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Adoption accelerated exponentially, evidenced by a surge in research output: CRISPR-related publications rose from fewer than 100 annually pre-2012 to over 3,900 by 2018, reflecting its integration into diverse fields like functional genomics and model organism engineering.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> Patent filings intensified, with the University of California (representing Doudna&#x27;s work) submitting the first provisional application in May 2012, followed by the Broad Institute&#x27;s December 2012 filingâ€”expedited to yield the initial U.S. patent in April 2014 for eukaryotic applicationsâ€”sparking ongoing interference proceedings that highlighted competing claims but did not impede lab proliferation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> By 2015, CRISPR had supplanted prior methods in most academic and industrial workflows due to its accessibility, enabling high-throughput screens and multiplexed edits unattainable with protein-based nucleases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<h3 id="post-2020-advancements-and-commercialization" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Post-2020 Advancements and Commercialization<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Following the rapid adoption of CRISPR-Cas9 in the late 2010s, post-2020 developments emphasized enhanced precision, reduced off-target effects, and in vivo delivery to expand therapeutic applicability. Researchers introduced refined Cas variants, such as smaller Cas12 and Cas13 orthologs, enabling better packaging into viral vectors for systemic administration and multiplex editing capabilities. These variants improved editing efficiency in non-dividing cells, addressing limitations in earlier systems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Base editing and prime editing matured as DSB-free alternatives, minimizing unwanted insertions or deletions. Base editors, which convert specific nucleotides via deaminase fusion, entered clinical trials post-2020 for conditions like alpha-1 antitrypsin deficiency, with early 2025 data showing successful single-base corrections in human subjects. Prime editing, leveraging a reverse transcriptase-pegsRNA complex, advanced to support diverse modifications including insertions up to dozens of bases, with preclinical models demonstrating up to 50% efficiency in therapeutically relevant genes by 2025. These tools expanded the editable genome fraction beyond traditional CRISPR&#x27;s reach.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Delivery innovations accelerated in vivo applications, with nanoparticle and lipid-conjugated systems achieving tissue-specific targeting, as shown in 2024 studies editing subsets of neurons or hepatocytes in animal models without broad toxicity. Clinical translation progressed, with over 15 base-editing trials registered by mid-2025 targeting immunodeficiencies and metabolic disorders.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Commercialization gained momentum with regulatory approvals validating ex vivo CRISPR therapies. In December 2023, the FDA approved Casgevy (exagamglogene autotemcel), a CRISPR-Cas9-edited autologous stem cell therapy from Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease in patients aged 12 and older with recurrent vaso-occlusive crises; approval for transfusion-dependent beta thalassemia followed in January 2024 for those aged 12 and older. Casgevy disrupts the BCL11A enhancer to reactivate fetal hemoglobin, achieving transfusion independence in 94% of beta thalassemia patients and reducing vaso-occlusive events by 91% in sickle cell cases across trials. This marked the first CRISPR-based therapy commercialization, though high costs exceeding $2 million per treatment and manufacturing complexities limited initial access.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By 2025, the sector saw expanded pipelines, with CRISPR Therapeutics prioritizing in vivo programs for cardiovascular and autoimmune diseases, alongside Phase 3 trials for hereditary angioedema. The global CRISPR gene-editing market reached $4.01 billion in 2024, projected to grow to $13.50 billion by 2033, driven by diagnostics, agriculture, and therapeutics, though intellectual property disputes and ethical concerns over germline editing persisted. Ongoing trials numbered over 50 worldwide, focusing on oncology, HIV, and rare diseases, signaling broader clinical maturation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<h2 id="biological-and-mechanistic-foundations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Biological and Mechanistic Foundations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="dna-repair-mechanisms-exploited-in-editing" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">DNA Repair Mechanisms Exploited in Editing<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genome editing technologies, such as those employing site-specific nucleases, induce double-strand breaks (DSBs) in DNA that are subsequently repaired by cellular pathways, enabling targeted genetic modifications. The primary pathways exploited are non-homologous end joining (NHEJ) and homology-directed repair (HDR), with NHEJ predominating in most cell types due to its efficiency and lack of requirement for a homologous template.01131-X) <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> NHEJ directly ligates DSB ends, often introducing small insertions or deletions (indels) at the junction, which frequently results in frameshift mutations that disrupt gene function and are harnessed for gene knockouts.00111-9) This pathway operates throughout the cell cycle, making it suitable for editing in both dividing and quiescent cells, though its error-prone nature limits applications to loss-of-function edits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_geabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In contrast, HDR utilizes a homologous donor template to accurately repair DSBs, facilitating precise insertions, deletions, or substitutions and is thus exploited for corrective edits or transgene integration. HDR, including subpathways like synthesis-dependent strand annealing and double Holliday junction resolution, is restricted to S and G2 phases when sister chromatids are available as templates, rendering it less efficientâ€”typically competing with NHEJ at ratios where NHEJ prevails in non-synchronized cells.00111-9) <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> To enhance HDR, strategies such as inhibiting NHEJ factors (e.g., DNA-PK) or synchronizing cells to proliferative phases have been developed, though HDR remains challenging in primary and non-dividing cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_geqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">An alternative DSB repair mechanism, microhomology-mediated end joining (MMEJ), serves as a backup pathway involving short homologous sequences (5-25 base pairs) flanking the break for annealing, leading to precise but error-prone joining with deletions of intervening sequences. In genome editing, MMEJ is leveraged in approaches like precise integration into target chromosomes (PITCh) for scarless insertions without long homology arms, particularly useful when HDR is inefficient, though it can also contribute to unintended large deletions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> MMEJ activity increases under conditions suppressing classical NHEJ, such as in certain cancer cells deficient in NHEJ components, highlighting its role in editing outcomes influenced by cellular context.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ofabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> These pathways&#x27; competition determines editing fidelity, with outcomes varying by locus, cell type, and DSB-end processing factors like end resection, which favors HDR over NHEJ.00200-6)</span>
<h3 id="principles-of-sequence-specific-targeting" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Principles of Sequence-Specific Targeting<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Sequence-specific targeting in genome editing fundamentally relies on engineered nucleases that bind to and cleave DNA at predetermined loci, exploiting endogenous repair pathways for modifications such as insertions, deletions, or substitutions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> This specificity is achieved through modular DNA-binding domains that recognize particular nucleotide sequences, typically 12â€“20 base pairs long, fused to a catalytic nuclease domain that induces double-strand breaks (DSBs).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> The binding domains operate via direct interactions with DNA bases, ensuring localized nuclease activity while minimizing off-target effects, though imperfect specificity remains a challenge requiring ongoing optimization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In protein-DNA recognition systems, such as those in zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), specificity arises from arrays of protein modules that contact DNA through hydrogen bonds and hydrophobic interactions. Each zinc finger module in ZFNs typically recognizes a 3â€“4 base pair subsite, with 3â€“6 fingers forming a recognition arm of 9â€“18 bp, though binding affinity is influenced by adjacent fingers and spacer sequences of 5â€“7 bp between dimerizing monomers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> TALENs utilize TALE repeats from plant pathogens, where each 34-amino-acid repeat&#x27;s repeat-variable di-residues (RVDs) specify a single nucleotideâ€”e.g., NI for adenineâ€”enabling straightforward programming of longer targets (12â€“20 bp) with spacers of 12â€“19 bp.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ggqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> These systems often employ FokI nuclease domains, which require dimerization for cleavage, enhancing specificity by necessitating paired binding events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ogqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">RNA-guided mechanisms, exemplified by CRISPR-Cas systems, achieve targeting through Watson-Crick base pairing between a single-guide RNA (sgRNA) and the target DNA, typically spanning 20 nucleotides adjacent to a protospacer-adjacent motif (PAM) required for Cas nuclease activation, such as NGG for Streptococcus pyogenes Cas9.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> This RNA-DNA hybridization simplifies programming compared to protein engineering, as only the sgRNA sequence needs alteration, but specificity depends on minimizing mismatches, with off-target cuts occurring at sites with partial complementarity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ghabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> Unlike protein-based dimers, Cas9 functions as a single polypeptide, scanning DNA for PAMs before R-loop formation and cleavage, though variants like high-fidelity Cas9 mutants reduce unintended activity by altering contact dynamics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ohabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> Across all approaches, target site accessibility, chromatin state, and cellular repair context influence editing efficiency, underscoring the need for empirical validation of specificity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<h2 id="primary-editing-technologies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Primary Editing Technologies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="meganucleases" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Meganucleases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Meganucleases, also known as homing endonucleases, are naturally occurring site-specific endonucleases derived primarily from microbial mobile genetic elements, such as introns and inteins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> These enzymes recognize extended DNA sequences, typically 12 to 40 base pairs in length, which enables highly precise cleavage with minimal off-target effects due to the rarity of such long motifs in genomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> Unlike modular nucleases, meganucleases integrate DNA-binding and catalytic activities within a single polypeptide, often exhibiting a saddle-shaped structure that cradles the DNA helix.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_siqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The adaptation of meganucleases for genome editing began in the early 1990s, with natural variants like I-SceI from yeast mitochondria used to induce double-strand breaks (DSBs) in mammalian cells as early as 1994, demonstrating enhanced homologous recombination efficiency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> Engineered custom meganucleases emerged in the late 1990s and early 2000s, pioneered by groups including those at Cellectis, which developed variants through protein engineering starting around 1999.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Redesign strategies, such as semi-rational mutagenesis and in vitro recombination of monomeric domains from dimeric scaffolds like I-CreI (a 22-base-pair recognizer from <em>Chlamydomonas reinhardtii</em>), allow tailoring to novel targets, though success rates remain low owing to the coupled evolution of recognition and cleavage domains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In editing applications, meganuclease-induced DSBs trigger cellular repair pathways, including error-prone non-homologous end joining for gene knockouts or homology-directed repair for precise insertions and corrections when donor templates are provided.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> Their specificity arises from multiple hydrogen bonds and van der Waals contacts across the target, conferring advantages like reduced toxicity and immunogenicity compared to heterologous fusion proteins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> However, engineering challengesâ€”such as the need for extensive screening to avoid partial specificities or catalytic inactivityâ€”limit versatility, with redesign often requiring months of iterative optimization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ojqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Early applications targeted therapeutic corrections, such as disrupting HIV proviral DNA or correcting mutations in severe combined immunodeficiency models, and agricultural modifications in plants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Despite these proofs-of-concept, meganucleases have seen limited clinical translation due to design complexity, paving the way for successor technologies like zinc finger nucleases that offer modular assembly.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Ongoing refinements, including machine learning-assisted design, aim to enhance predictability for bespoke nucleases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_skabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<h3 id="zinc-finger-nucleases" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Zinc Finger Nucleases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Zinc finger nucleases (ZFNs) are engineered restriction enzymes comprising zinc finger protein domains for sequence-specific DNA recognition fused to the non-specific DNA cleavage domain of the FokI endonuclease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_clabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup> These modular proteins induce targeted double-strand breaks (DSBs) at predetermined genomic loci, exploiting cellular DNA repair pathways such as non-homologous end joining (NHEJ) for gene disruption or homology-directed repair (HDR) for precise insertions or corrections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_klabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup> Each zinc finger module typically binds a 3-base-pair subsite, with arrays of 3â€“6 fingers providing specificity spanning 9â€“18 base pairs; FokI dimerization requires two adjacent ZFNs binding in a tail-to-tail orientation, spaced 4â€“6 base pairs apart, to generate the DSB.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_slabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Development of ZFNs began with the identification of zinc finger motifs in the transcription factor TFIIIA from Xenopus laevis in 1985, followed by demonstrations of their customizable DNA-binding properties in the early 1990s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Pioneering work in the late 1990s and early 2000s by researchers including Carlos Barbas and David Liu enabled the fusion of zinc finger arrays to FokI, achieving the first targeted DSBs in mammalian cells around 2002â€“2005.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_glqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Key milestones include the 2009 demonstration of efficient ZFN-mediated editing in human cells via modular assembly, facilitating broader adoption for gene targeting.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_olqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> Despite early promise as the first programmable genome editing tool, ZFN design proved labor-intensive due to context-dependent interactions between adjacent fingers, often requiring empirical selection or proprietary oligomerized assembly methods like OPEN or zinc finger phage display.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">ZFNs have been applied in preclinical models for gene knockouts, insertions, and corrections, notably in disrupting the CCR5 gene for HIV resistance in human cells and hematopoietic stem cells (HSCs).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> Clinically, Sangamo Therapeutics advanced ZFN-based therapies, with Phase 1/2 trials for HIV (SB-728) initiating in 2009, showing transient viral load reductions but limited long-term efficacy due to editing efficiency constraints.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> For hemophilia B, an in vivo ZFN approach via AAV delivery (SB-525/ST-920) entered trials in 2018, aiming to insert a factor IX transgene into the albumin locus; a 2022 first-in-human study reported safe dosing up to 5Ã—10^13 vg/kg with FIX activity increases, though no approvals have been granted as of 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_omabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> Recent studies in 2024 confirmed high-efficiency ZFN editing in HSCs for multilineage engraftment, underscoring persistent utility in ex vivo applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Advantages of ZFNs include proven clinical tolerability, reduced immunogenicity compared to some alternatives, and high specificity when optimized, with off-target effects mitigated by paired nuclease design and transient expression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> However, challenges persist: design complexity limits accessibility, potential FokI toxicity at high expression levels, and off-target cleavage at sites with partial homology, though rates are generally lower than early CRISPR iterations when using validated ZFNs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Persistent plasmid expression risks promiscuous binding, prompting strategies like mRNA electroporation for ephemeral activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_omqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> While eclipsed by simpler tools like CRISPR-Cas9 post-2012, ZFNs remain relevant for applications demanding compact payloads or established safety profiles in viral vectors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup></span>
<h3 id="talens" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">TALENs<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Transcription activator-like effector nucleases (TALENs) are engineered restriction enzymes consisting of a customizable DNA-binding domain derived from transcription activator-like (TAL) effectors of Xanthomonas bacteria fused to the nonspecific DNA cleavage domain of the FokI endonuclease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> TAL effectors, first characterized in 2009, contain tandem repeats with repeat-variable di-residues (RVDs) that confer nucleotide-specific DNA binding, where each RVD typically recognizes a single base pair.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup> The initial demonstration of TALEN-mediated genome editing was reported in 2010, with key publications in 2011 enabling targeted double-strand breaks (DSBs) in various organisms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ooabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_soabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">TALENs function by designing pairs of proteins that bind to adjacent DNA sequences separated by a spacer of 12-20 base pairs; the FokI domains dimerize across this spacer to generate a DSB, which is repaired via non-homologous end joining (NHEJ) for gene disruption or homology-directed repair (HDR) for precise edits when a donor template is provided.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> This modular one-to-one RVD-nucleotide recognition simplifies target design compared to zinc finger nucleases (ZFNs), which rely on zinc finger modules recognizing three nucleotides each, often requiring empirical optimization due to context-dependent binding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> TALEN assembly, though initially labor-intensive via methods like Golden Gate cloning, has been streamlined with kits allowing construction in 1-2 days.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ooqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">TALENs exhibit higher specificity than ZFNs, with studies showing reduced off-target cleavage at sites like CCR5; for instance, TALENs produced fewer unintended mutations than ZFNs targeting the same locus.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Relative to CRISPR-Cas9, TALENs demonstrate lower off-target activity in some contexts due to the absence of guide RNA mismatches and reliance on protein-DNA interactions, though CRISPR&#x27;s ease of use has led to its dominance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> However, TALENs&#x27; larger size (around 3 kb per monomer) complicates delivery, particularly in viral vectors, and multiplexing multiple targets remains challenging without custom engineering.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_spabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Applications of TALENs span basic research and therapeutics, including gene knockouts in human pluripotent stem cells for disease modeling, such as generating CCR5 mutants resistant to HIV.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> In agriculture, TALENs have conferred rice resistance to Xanthomonas oryzae by disrupting susceptibility genes and enabled the first genome-edited pigs in 2015 via embryo injection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup> Therapeutically, TALENs achieved the first cure of chronic lymphocytic leukemia in a patient in 2015 by editing T cells ex vivo for adoptive transfer, highlighting their clinical potential despite subsequent shifts toward CRISPR.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_opqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> TALENs also facilitate mitochondrial DNA editing for diseases like Leber&#x27;s hereditary optic neuropathy, exploiting their protein-based delivery to bypass nuclear RNA interference issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup></span>
<h3 id="crispr-cas-systems" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">CRISPR-Cas Systems<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
CRISPR-Cas systems derive from clustered regularly interspaced short palindromic repeats (CRISPR) and associated Cas proteins, which form an adaptive immune mechanism in bacteria and archaea to defend against invading bacteriophages and plasmids.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> These systems acquire short DNA sequences from foreign invaders, integrate them as spacers into the host CRISPR array, and transcribe them into CRISPR RNAs (crRNAs) that guide Cas effector proteins to cleave matching nucleic acids during subsequent exposures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> The functional role was first demonstrated in 2007 when spacers from phage DNA conferred resistance in <em>Streptococcus thermophilus</em>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Classified into two main classes, six types, and numerous subtypes, CRISPR-Cas systems vary in complexity and effectors; type II systems, prevalent in genome editing applications, rely on a single large Cas9 endonuclease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup> In natural type II systems, such as from <em>Streptococcus pyogenes</em>, Cas9 forms a complex with crRNA and trans-activating crRNA (tracrRNA), which base-pairs with the target DNA to form an R-loop structure, enabling double-strand breaks (DSBs) adjacent to a protospacer adjacent motif (PAM), typically 5&#x27;-NGG-3&#x27;.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_orabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> The dual crRNA-tracrRNA was simplified into a single guide RNA (sgRNA) for programmable targeting.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Adaptation for genome editing began with the 2012 demonstration that <em>S. pyogenes</em> Cas9 (SpCas9), guided by dual RNAs, cleaves plasmid DNA in vitro at sites specified by the crRNA spacer sequence, provided a PAM is present.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> This RNA-guided nuclease activity was harnessed for eukaryotic genome engineering in early 2013, when Cong et al. reported targeted cleavage and homology-directed repair in human and mouse cells using SpCas9 and sgRNA expressed from plasmids, achieving up to 25% modification efficiency at select loci.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_orqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> Independent work by Mali et al. confirmed multiplex editing capabilities, altering up to five endogenous sites simultaneously via NHEJ or HDR pathways.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The editing mechanism exploits Cas9-induced DSBs repaired by non-homologous end joining (NHEJ), often introducing insertions/deletions (indels) for gene disruption, or homology-directed repair (HDR) with donor templates for precise insertions or substitutions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup> Targeting specificity stems from ~20-nucleotide sgRNA-DNA complementarity, though mismatches can reduce efficiency; off-target effects arise from partial hybridization at non-canonical sites with compatible PAMs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> SpCas9 requires a 3&#x27; PAM, limiting accessible targets to ~12.5% of the human genome, prompting variants like SpCas9-NG (recognizing 5&#x27;-NG-3&#x27;) or smaller Cas12a (Cpf1) from <em>Francisella novicida</em>, which uses 5&#x27;-TTV-3&#x27; PAM and generates staggered cuts for scarless cloning.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cas13 variants, such as LwaCas13a, target and cleave single-stranded RNA rather than DNA, enabling transcript knockdown or editing without genomic alterations, though with collateral RNA cleavage upon activation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> These systems&#x27; simplicity, multiplexing potential, and low costâ€”relative to protein-based nucleases like ZFNs or TALENsâ€”drove rapid adoption, with over 10,000 publications by 2017 citing CRISPR for editing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gsqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup> Challenges include immunogenicity of bacterial Cas proteins and delivery barriers in vivo, addressed through humanized variants or alternative Cas orthologs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_osqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup></span>
<h3 id="base-editing-and-prime-editing" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Base Editing and Prime Editing<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Base editing, developed by Alexandrox Komor and colleagues in David Liu&#x27;s laboratory and first reported in 2016, enables the precise conversion of a target cytosine (C) to thymine (T) in DNA without generating double-strand breaks (DSBs). This approach fuses a catalytically impaired Cas9 proteinâ€”either a nickase variant (nCas9) that creates a single-strand nick or a dead Cas9 (dCas9) lacking nuclease activityâ€”with a cytidine deaminase enzyme, such as APOBEC1, to form a cytosine base editor (CBE).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> A single-guide RNA (sgRNA) directs the complex to the target site, where the deaminase chemically modifies cytosine to uracil (U) within a narrow editing window of 4-5 nucleotides; during replication or repair, U is recognized as T, resulting in a CÂ·G to TÂ·A conversion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup> This DSB-free mechanism substantially reduces insertions/deletions (indels) compared to traditional CRISPR-Cas9 editing, which relies on error-prone non-homologous end joining (NHEJ), though CBEs can produce bystander edits at adjacent cytosines and exhibit some off-target activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_otqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2017, Gaudelli et al. extended base editing to adenine (A) bases with an adenine base editor (ABE), fusing an evolved tRNA adenosine deaminase (TadA*) to nCas9, enabling programmable AÂ·T to GÂ·C changes via deamination of A to inosine (I), which is templated as G during replication.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup> Subsequent optimizations, including second- and third-generation editors with uracil glycosylase inhibitor (UGI) fusions to suppress base excision repair pathways that could revert edits, have improved efficiency to over 50% in mammalian cells for many targets while minimizing indels to below 1%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup> Base editors have demonstrated utility in correcting pathogenic point mutations, such as those in sickle cell disease models, but limitations persist, including restricted transition types (only CÂ·Gâ†’TÂ·A and AÂ·Tâ†’GÂ·C), PAM sequence constraints from Cas9, and potential RNA off-targeting from deaminase activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ouabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Prime editing, introduced by Andrew Anzalone and colleagues in David Liu&#x27;s group in 2019, represents an advanced iteration that permits &quot;search-and-replace&quot; modifications, including all four transition types, small insertions (up to 44 nucleotides), and deletions (up to 80 nucleotides), without DSBs or donor DNA templates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup> The system employs a prime editor proteinâ€”a fusion of nCas9 and a Moloney murine leukemia virus reverse transcriptase (M-MLV RT)â€”guided by a prime editing guide RNA (pegRNA) that extends beyond standard sgRNAs to include a reverse transcriptase template (RTT) specifying the desired edit and a primer binding site (PBS) for reverse transcription initiation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> Upon binding, nCas9 nicks the target strand (typically the non-template strand), the exposed 3&#x27; flap hybridizes to the PBS, and RT copies the RTT into a new DNA flap, which ligases into the genome after flap resolution, displacing the original sequence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ouqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup> Initial efficiencies reached 20-50% for transitions in human cells with minimal indels (&lt;1-5%), outperforming homology-directed repair (HDR) in non-dividing cells, though prime editing historically suffers from lower yields for insertions/deletions and sensitivity to pegRNA design.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Engineered variants, such as PE2 with an improved RT and PE3 incorporating an additional sgRNA for nicking the non-edited strand to bias repair, have boosted efficiencies up to 2.3-fold, while recent ePE and ProPE systems further expand the editing window and reduce byproducts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup> Prime editing&#x27;s versatility addresses base editing&#x27;s limitations by enabling transversions indirectly via multi-step edits or hybrid approaches, with off-target rates comparable to or lower than Cas9 due to the requirement for precise RT priming.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> However, challenges include pegRNA production complexity, potential cellular toxicity from RT activity, and efficiencies still lagging behind DSB-based methods for some large edits, prompting ongoing refinements like smaller Cas variants for delivery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ovabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup> Both technologies, recognized with the 2025 Breakthrough Prize in Life Sciences awarded to David Liu, exemplify a shift toward DSB-independent editing to enhance safety and precision in therapeutic contexts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup></span>
<h3 id="novel-and-hybrid-approaches" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Novel and Hybrid Approaches<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Novel approaches in genome editing extend beyond conventional nuclease-based systems by incorporating elements such as transposases, integrases, and retrons to enable precise insertions, reductions in double-strand breaks (DSBs), and multiplexing capabilities. Hybrid systems, which fuse CRISPR-Cas components with other molecular machinery, aim to mitigate off-target effects and DSB-associated risks like indels or chromosomal rearrangements, while facilitating large payload integrations up to several kilobases. These innovations, emerging prominently since the early 2020s, prioritize DNA repair-independent mechanisms to enhance efficiency in therapeutic and research applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">CRISPR-associated transposases (CASTs) represent a hybrid class that couples type I CRISPR RNA-guided targeting with transposase activity for programmable DNA insertion. Unlike DSB-dependent methods, CASTs catalyze strand transfer to insert payloads without breaks, achieving efficiencies up to 40% in bacterial systems and demonstrating adaptability to eukaryotic cells through laboratory evolution. For instance, evoCAST variants, optimized via directed evolution, have enabled precise integrations in human cell lines with minimal off-target activity. These systems, identified in diverse prokaryotes, bypass homology-directed repair limitations and support cargo sizes exceeding 10 kb, positioning them for applications in gene therapy where stable, large-scale modifications are required.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Programmable addition via site-specific targeting elements (PASTE) exemplifies a hybrid nuclease-integrase fusion, employing a CRISPR-Cas9 nickase linked to a reverse transcriptase and serine integrase for DSB-free large-sequence insertions. Developed in 2022, PASTE uses prime editing-inspired pegRNA to prime reverse transcription of donor DNA, followed by integrase-mediated attachment at nicked sites, yielding up to 25% efficiency for 36 kb inserts in human cells. This approach excels in replacing entire defective genes, such as modeling Duchenne muscular dystrophy by inserting micro-dystrophin cassettes, and avoids DSB toxicity, though delivery challenges persist for in vivo use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Retron-based editing leverages bacterial retronsâ€”RNA-templated reverse transcriptases producing multi-copy single-stranded DNA (ssDNA)â€”as donor templates for precise homology-directed repairs, often hybridized with CRISPR-Cas for targeting. In a 2025 advancement, retron systems corrected large disease-related mutations in vertebrate models by excising defective regions and inserting healthy sequences, achieving higher fidelity than traditional donors due to in situ ssDNA generation. Efficiencies reach over 50% in mammalian cells when paired with Cas9, with retrons enabling multiplex edits via parallel msDNA production, though optimization for payload size and host compatibility continues. This method&#x27;s repair independence from cell cycle phase broadens its utility across kingdoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Multiplex automated genome engineering (MAGE), a non-nuclease hybrid relying on recombineering with short ssDNA oligos and phage-derived recombinases, facilitates simultaneous edits at hundreds of loci in prokaryotes. Introduced around 2009 and refined for eukaryotes, MAGE cycles oligonucleotide electroporation with selection to evolve genomes rapidly, as seen in recoding <em>E. coli</em> with over 300 changes for non-canonical amino acid incorporation. While less reliant on sequence-specific nucleases, its integration with CRISPR hybrids enhances scalability for synthetic biology, though eukaryotic efficiencies lag at under 10% per site without further engineering.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup></span>
<h2 id="delivery-systems-and-implementation-strategies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Delivery Systems and Implementation Strategies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="viral-and-non-viral-delivery-methods" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Viral and Non-Viral Delivery Methods<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Viral vectors leverage the natural infectivity of viruses to deliver genome editing components, such as CRISPR-Cas nucleases and guide RNAs, into target cells with high efficiency. Adeno-associated viruses (AAVs), particularly serotypes like AAV2 and AAV9, are favored for their non-pathogenic nature, ability to transduce post-mitotic cells, and episomal persistence without genomic integration, supporting transient or long-term expression depending on the application. AAVs have a packaging limit of about 4.7-5 kb, restricting delivery to compact editing systems like SaCas9 or base editors, and have been used in over 150 clinical trials for gene therapies by 2023, including the FDA-approved Luxturna (voretigene neparvovec) in 2017 for RPE65-mediated retinal dystrophy via subretinal AAV delivery achieving sustained vision improvement. However, AAVs can elicit pre-existing neutralizing antibodies in up to 50-70% of humans, potentially reducing efficacy, and high doses may trigger innate immune responses or hepatotoxicity, as observed in a 2020 tragic trial outcome involving AAV for muscular dystrophy. Lentiviral vectors, derived from HIV-1, provide larger cargo capacity (up to 9 kb) and integrate into the host genome for stable expression, making them suitable for ex vivo editing of hematopoietic stem cells; they underpinned the FDA approval of Kymriah (tisagenlecleucel) in 2017 for leukemia via CD19 knockout. Drawbacks include risks of insertional oncogenesis, evidenced by rare leukemia cases in early SCID trials, and production scalability issues despite advances in integrase-defective variants that promote non-integrating episomal delivery to mitigate genotoxicity. Adenoviral vectors offer high transient expression and larger payloads but provoke strong inflammatory responses, limiting their use to short-term editing in non-immunoprivileged tissues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Non-viral delivery systems circumvent viral immunogenicity and integration risks by employing synthetic or physical carriers for editing components, often as mRNA, plasmids, or ribonucleoproteins (RNPs) to enable transient activity that curtails prolonged off-target editing. Lipid nanoparticles (LNPs), composed of ionizable lipids, cholesterol, and PEG-lipids, encapsulate Cas9 mRNA and guide RNA for systemic in vivo delivery, achieving biodegradability and endosomal escape; they facilitated the first in vivo human CRISPR trial in 2021 for transthyretin amyloidosis (NTLA-2001), with a single dose yielding up to 96% serum protein reduction at 87% liver editing efficiency in phase 1 data reported in 2023. LNPs excel in scalabilityâ€”billions of doses produced for COVID-19 mRNA vaccines by 2021â€”and lower mutagenesis risk, but suffer from hepatic tropism, transient expression (hours to days), and potential lipid toxicity at high doses, with editing efficiencies often below 50% in extrahepatic tissues without targeting ligands. Polymer-based nanoparticles, such as polyethyleneimine (PEI) or poly(lactic-co-glycolic acid) (PLGA), offer customizable surface modifications for tissue specificity and protection against nuclease degradation, demonstrating 30-70% editing in mouse glioblastoma models via intracranial injection in 2021 studies. Physical methods like electroporation apply electric pulses to transiently permeabilize membranes, achieving high ex vivo efficiencies (up to 90%) in hard-to-transfect cells like primary T lymphocytes or stem cells without chemical additives, as in Casgevy (exagamglogene autotemcel) approved in 2023 for sickle cell disease following electroporation-mediated BCL11A editing. Yet, electroporation induces cytotoxicity (10-30% cell death) and is impractical for in vivo use due to tissue damage, while hydrodynamic injection or ultrasound-mediated delivery remains experimental with variable yields. Microinjection and nucleofection variants enhance precision in embryos or organoids but scale poorly for therapeutics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup></span>























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Delivery Type</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Advantages</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Disadvantages</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Typical Applications</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Viral (e.g., AAV, Lentiviral)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">High transduction efficiency (50-90% in vivo); natural tropism for tissues like liver, retina, CNS</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Immunogenicity; limited cargo size (AAV); insertional risks (lentiviral); manufacturing complexity</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">In vivo therapeutics (e.g., ocular, hepatic editing); ex vivo stem cell modification</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Non-Viral (e.g., LNPs, Electroporation)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Reduced immunogenicity; transient expression minimizing off-targets; scalable production; no replication risk</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Lower efficiency (10-70%); poor in vivo targeting without modifications; potential cytotoxicity</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Ex vivo cell therapies (e.g., CAR-T); emerging in vivo mRNA/RNP delivery for systemic diseases</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Hybrid approaches, such as virus-like particles (VLPs) pseudotyped with viral envelopes but lacking genomes, combine viral entry efficiency with non-viral safety, delivering Cas9 RNPs with up to 40% editing in hepatocytes in 2024 preclinical models, though clinical translation lags due to optimization needs. Overall, viral methods dominate current clinical pipelines for their reliability, while non-viral innovations, propelled by mRNA vaccine successes, are advancing toward parity in efficiency and specificity, particularly for transient editing to enhance safety in therapeutic genome editing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup></span>
<h3 id="ex-vivo-versus-in-vivo-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Ex Vivo versus In Vivo Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Ex vivo genome editing involves extracting cells from a patient, modifying their genomes in a controlled laboratory environment using tools such as CRISPR-Cas9, and subsequently reintroducing the edited cells into the patient.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup> This approach allows for precise manipulation under optimized conditions, including electroporation or viral transduction for delivery, followed by selection or expansion of successfully edited cells to achieve high purity before transplantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> It is particularly suited for accessible cell types like hematopoietic stem and progenitor cells (HSPCs) or T cells, enabling applications in blood disorders and immunotherapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A primary advantage of ex vivo editing is the ability to mitigate off-target effects and immune responses by editing in isolation, with post-editing validation and enrichment ensuring only viable, correctly modified cells are used.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup> For instance, in the treatment of sickle cell disease (SCD) and transfusion-dependent beta-thalassemia, ex vivo CRISPR-Cas9 editing of patient-derived HSPCs to disrupt the BCL11A enhancer has led to approved therapies like Casgevy (exagamglogene autotemcel), authorized by the FDA in December 2023, demonstrating durable fetal hemoglobin induction and symptom amelioration in clinical trials with over 90% reduction in vaso-occlusive crises.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup> However, challenges include scalability of manufacturing, engraftment efficiency post-infusion, and limitation to ex vivo-accessible tissues, restricting broader use for non-hematopoietic conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In contrast, in vivo genome editing delivers editing componentsâ€”typically via lipid nanoparticles, adeno-associated virus (AAV) vectors, or other systemic/local methodsâ€”directly into the patient&#x27;s body to target cells in situ.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> This method holds potential for treating organs like the liver, retina, or muscle, where cell extraction is impractical, by achieving site-specific modifications without surgical intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup> Delivery innovations, such as liver-tropic AAVs or nanoparticle-encapsulated Cas9 ribonucleoproteins, have enabled transient expression to reduce prolonged off-target risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key benefits of in vivo approaches include broader tissue applicability and avoidance of ex vivo processing complexities, as evidenced by NTLA-2001, an in vivo CRISPR-Cas9 therapy targeting the TTR gene in hereditary transthyretin amyloidosis (hATTR), which achieved up to 87% serum TTR reduction in phase 1 trials via intravenous lipid nanoparticle delivery as of June 2021.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup> Early trials for Leber congenital amaurosis type 10 (LCA10) have also used subretinal AAV-CRISPR injections to edit CEP290 mutations, restoring partial visual function in preclinical models and initial human dosing by 2020.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup> Nonetheless, hurdles persist, including inefficient targeting of non-dividing cells, potential immunogenicity of bacterial-derived Cas proteins, and amplified safety concerns from systemic distribution, with most trials still in early phases compared to ex vivo successes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> Ongoing refinements in delivery specificity aim to bridge these gaps for scalable clinical translation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_117qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup></span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Aspect</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Ex Vivo</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">In Vivo</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Primary Applications</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Hematologic disorders (e.g., SCD, beta-thalassemia), T-cell therapies for cancer</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Liver diseases (e.g., hATTR), ocular disorders (e.g., LCA10), neuromuscular conditions</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Delivery Methods</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Electroporation, lentiviral/retroviral vectors in vitro</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">AAV vectors, lipid nanoparticles, direct injection</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Advantages</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">High editing purity via selection; controlled environment reduces immunogenicity</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Targets inaccessible tissues; no cell extraction needed</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Challenges</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Limited to harvestable cells; manufacturing and engraftment variability</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Delivery efficiency; off-target effects in vivo; immune clearance of editors</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Clinical Status (as of 2025)</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Multiple approvals (e.g., Casgevy, 2023); dozens of trials</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Phase 1/2 trials dominant (e.g., NTLA-2001, 2021 onward); no approvals yet</span></td></tr></tbody></table></div>
<h2 id="technical-performance-metrics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Technical Performance Metrics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="precision-efficiency-and-off-target-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Precision, Efficiency, and Off-Target Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Precision in genome editing refers to the accuracy with which a nuclease targets the intended DNA sequence, minimizing unintended modifications elsewhere in the genome. Early tools like meganucleases exhibit high specificity due to their large recognition domains spanning 12-40 base pairs, but their engineering is labor-intensive, limiting widespread use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) achieve greater specificity than initial CRISPR systems through modular protein-DNA interactionsâ€”ZFNs recognizing 9-18 base pairs via zinc finger arrays and TALENs targeting longer stretches with TALE repeatsâ€”resulting in off-target mutation rates often below 0.1% in optimized designs, though efficiencies typically range from 10-50% in mammalian cells due to delivery and repair pathway dependencies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">CRISPR-Cas9 systems revolutionized efficiency, enabling editing rates exceeding 80% in many cell types via simple guide RNA (gRNA) design, but early implementations showed off-target cleavage frequencies up to 93.6% at mismatched sites due to tolerance for 1-5 nucleotide mismatches and PAM-adjacent positioning.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_daabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup> GUIDE-seq and similar assays revealed off-target rates of 0.1-5% genome-wide in human cells, varying by gRNA sequence and Cas9 variant, with double-strand breaks (DSBs) at non-target sites triggering indels or rearrangements via non-homologous end joining (NHEJ).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_laabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> High-fidelity Cas9 mutants (e.g., SpCas9-HF1, eSpCas9) and paired nickases reduce these by 10- to 100-fold through enhanced gRNA-DNA hybridization stringency, though empirical validation remains essential as in silico predictions underestimate effects by up to 50%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_taabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Efficiency metrics, often measured as indel formation or homology-directed repair (HDR) yield, favor CRISPR over ZFNs and TALENsâ€”e.g., CRISPR achieving 2-10x higher on-target editing in HEK293 cellsâ€”but HDR remains low (1-20%) across platforms due to NHEJ dominance in dividing cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup>00111-9) Base editors and prime editors enhance precision by enabling single-base conversions or small indels without DSBs: cytosine base editors (CBEs) and adenine base editors (ABEs) convert CÂ·G to TÂ·A or AÂ·T to GÂ·C with off-target rates under 0.5%, while prime editors install diverse edits (insertions up to 44 bp, deletions) at 20-50% efficiency, minimizing bystander edits and genomic instability compared to DSB-based methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_haqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_laqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_paqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> These advances, validated in cellular and animal models, underscore causal links between nuclease architecture, mismatch tolerance, and repair outcomes, with ongoing quantification via unbiased sequencing essential for therapeutic viability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup></span>
<h3 id="strategies-for-enhancing-specificity-and-yield" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Strategies for Enhancing Specificity and Yield<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">One prominent strategy for improving specificity involves engineering high-fidelity variants of the Cas9 nuclease to reduce non-specific DNA binding. For instance, SpCas9-HF1 incorporates alanine substitutions at residues N497, R661, Q695, and Q926, which disrupt extraneous interactions with the phosphate backbone, leading to undetectable off-target cleavage events via GUIDE-seq for six out of seven tested single-guide RNAs (sgRNAs) in human cells, while preserving greater than 85% of wild-type on-target activity across 32 sgRNAs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup> Similarly, the Sniper2L variant, derived from directed evolution of predecessor Sniper-Cas9 with an E1007L mutation in the RuvC domain, maintains on-target indel frequencies comparable to wild-type SpCas9 (up to 50% in HEK293T cells) but exhibits markedly lower off-target indel rates across over 7,000 NGG PAM targets, quantified by a specificity metric of 1 minus the ratio of off-target to on-target frequencies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Additional molecular optimizations enhance specificity by altering guide RNA architecture or nuclease deployment. Truncated sgRNAs (12-18 nucleotides in the spacer) limit the editing window and mismatch tolerance, reducing off-target effects by up to 5-fold in some assays without substantially compromising on-target efficiency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup> Paired Cas9 nickases, utilizing dual sgRNAs to generate staggered single-strand nicks offset by 4-100 base pairs, further enforce dual-site recognition, achieving near-complete elimination of off-target double-strand breaks compared to wild-type Cas9 in human cell lines.14619-1) Protocol-level adjustments, such as transient delivery of Cas9 ribonucleoproteins (RNPs) at low concentrations or during specific cell cycle phases, temporally restrict nuclease activity to minimize prolonged exposure and bystander cuts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">To boost editing yield, particularly for homology-directed repair (HDR) pathways that enable precise insertions or substitutions but occur at rates below 10% in dividing cells due to competition from error-prone non-homologous end joining (NHEJ), strategies target repair pathway bias. Chemical inhibition of NHEJ factors, such as ligation with SCR7 (which blocks DNA ligase IV), combined with HDR-promoting agents like RS-1 (an RAD51 stimulator), has increased HDR efficiency 2- to 5-fold in HEK293T and K562 cells for targeted knock-ins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup> Cell cycle synchronization via nocodazole arrest in G2/M phase, where HDR machinery peaks, yields up to 3-fold HDR gains, as endogenous repair favors template-directed synthesis during mitosis preparation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup> Donor template optimizations, including single-stranded oligodeoxynucleotides (ssODNs) positioned within 20-100 base pairs of the cut site, further elevate yields by facilitating invasion of the Cas9-generated overhang.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Post-editing enrichment methods amplify yield by selecting edited subpopulations without relying solely on intrinsic efficiencies. HDR surrogate reporters, featuring a frameshifted coding sequence (e.g., BFP to GFP conversion) restored only via precise template integration, enable fluorescence-activated cell sorting to enrich knock-in events by 20.7-fold (from 2.22% to 45.93%) in human cell lines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup> NHEJ-based reporters similarly select for nuclease-proficient cells, achieving up to 39-fold increases in indel frequencies for genes like TP53.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup> Modular ssDNA donors paired with NHEJ inhibitors or HDR enhancers have reported HDR rates exceeding 90% in optimized systems, though scalability to primary cells remains context-dependent due to variable repair dynamics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup> These approaches, while effective, often involve trade-offs, such as potential toxicity from inhibitors or reduced multiplexing capacity.</span>
<h2 id="practical-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Practical Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="therapeutic-uses-in-human-medicine" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Therapeutic Uses in Human Medicine<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genome editing technologies, particularly CRISPR-Cas9, have enabled targeted correction of disease-causing mutations in human cells for therapeutic purposes, focusing initially on monogenic disorders amenable to ex vivo modification of accessible cell types like hematopoietic stem cells (HSCs). The pioneering approval of exagamglogene autotemcel (Casgevy) by the U.S. Food and Drug Administration on December 8, 2023, marked the first clinical use of CRISPR-based editing for sickle cell disease (SCD) and transfusion-dependent Î²-thalassemia (TDT).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> This therapy involves extracting patient HSCs, using CRISPR-Cas9 to disrupt the BCL11A enhancer to reactivate fetal hemoglobin (HbF) expression, and reinfusing the edited cells after myeloablative conditioning.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup> In phase 1/2 trials, 29 of 31 SCD patients remained free of severe vaso-occlusive crises for at least 12 months post-infusion, with HbF levels reaching 30-40% in most cases, demonstrating durable engraftment and clinical benefit.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond hemoglobinopathies, ex vivo editing targets other blood-related conditions and immunotherapies. CRISPR-edited allogeneic CAR-T cells are in trials for cancers like multiple myeloma and B-cell malignancies, aiming to enhance persistence by knocking out PD-1 or TCR genes to reduce exhaustion and graft-versus-host risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> For primary immunodeficiencies such as severe combined immunodeficiency (SCID), trials edit autologous HSCs to restore functional IL2RG expression, with early data showing immune reconstitution in X-SCID patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> These approaches leverage the accessibility of blood cells but require chemotherapy preconditioning, limiting applicability to non-hematopoietic tissues.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In vivo editing, delivering nucleases directly to target organs via lipid nanoparticles or AAV vectors, addresses systemic diseases but faces challenges in efficiency and off-target risks. Intellia&#x27;s NTLA-2001, targeting TTR mutations in hereditary transthyretin amyloidosis (ATTR), achieved up to 87% serum TTR reduction in phase 1/2 trials with a single dose, with phase 3 data expected by late 2025 supporting potential approval for cardiomyopathy and polyneuropathy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> For Leber congenital amaurosis type 10, Editas Medicine&#x27;s EDIT-101 (AAV-delivered CRISPR) improved visual acuity in 79% of treated eyes in the phase 1/2 BRILLIANCE trial, though long-term efficacy remains under evaluation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> Emerging pipelines explore in vivo applications for muscular dystrophy (e.g., editing DMD exons), cystic fibrosis (CFTR correction in lung epithelium), and HIV (CCR5 disruption in CD4+ T cells), with over 150 active CRISPR trials as of mid-2025 spanning these areas, though most remain in phases 1-2 due to delivery and immunogenicity hurdles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> Base and prime editing variants promise higher precision for point mutations, with preclinical advances in trials for SCD alternatives and alpha-1 antitrypsin deficiency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Therapeutic editing&#x27;s success hinges on disease biology favoring high editing rates (e.g., &gt;20% allelic correction in HSCs for HbF induction) and tolerable safety profiles, with adverse events primarily from conditioning rather than editing itself in approved cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup> Ongoing challenges include scalability for rare diseases and equitable access, as Casgevy&#x27;s list price exceeds $2 million per treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[145]</sup> No additional genome editing therapies have gained regulatory approval by October 2025, underscoring the field&#x27;s nascent stage despite rapid trial expansion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<h3 id="agricultural-and-plant-breeding-improvements" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Agricultural and Plant Breeding Improvements<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genome editing has revolutionized plant breeding by enabling precise modifications to endogenous genes, bypassing the lengthy cycles of conventional cross-breeding and reducing reliance on random mutagenesis. Technologies like CRISPR-Cas9 allow for targeted knockouts, insertions, or base edits that introduce traits such as enhanced yield or stress tolerance without incorporating foreign DNA, distinguishing them from transgenic GMOs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup> By 2024, over 25 plant species had been successfully edited across more than 100 genes, yielding improvements in agronomic performance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In disease resistance, CRISPR-mediated editing has targeted susceptibility genes to confer broad-spectrum protection. For instance, in wheat, multiplexed editing of TaMLO genes produced varieties resistant to powdery mildew, a fungal pathogen causing significant yield losses, with edited lines showing up to 90% reduced infection rates under field conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup> Similar approaches in rice have disrupted SWEET genes to enhance resistance to bacterial blight, while in bananas, editing of susceptibility loci has improved tolerance to Fusarium wilt, a devastating soil-borne disease threatening global production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[148]</sup> These modifications demonstrate causal links between gene disruption and pathogen evasion, validated through controlled inoculation trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_piabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[149]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For yield and abiotic stress tolerance, editing phytohormone pathways has shortened plant stature in barley via gibberellin-related mutants, reducing lodging and boosting harvest index without yield penalties.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[150]</sup> In maize and soybeans, CRISPR edits to flowering-time genes have accelerated maturity, enabling adaptation to shorter growing seasons amid climate variability, with field trials reporting 10-20% yield increases under drought stress.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[151]</sup> Nutritional enhancements include elevating Î²-carotene levels sixfold in rice and bananas through PSY gene activation, addressing vitamin A deficiencies in staple crops consumed by billions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_piqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[152]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regulatory frameworks influence deployment: the U.S. USDA exempts certain site-directed nuclease-1 (SDN-1) editsâ€”those mimicking natural mutationsâ€”from oversight if no plant pest risks are introduced, as revised in 2020 regulations, enabling commercialization of products like herbicide-tolerant canola by 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[153]</sup> In contrast, the EU&#x27;s precautionary approach classifies most edited plants as GMOs under Directive 2001/18/EC, imposing rigorous assessments despite absent transgenes, though a 2023 proposal seeks to deregulate &quot;NGT-1&quot; plants akin to conventional varieties.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[154]</sup> This disparity highlights how evidence-based risk assessments in the U.S. have accelerated adoption, with over a dozen edited crops entering markets by 2024, versus stalled EU pipelines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[155]</sup> Empirical data from multi-year field studies underscore the safety and efficacy of these edits, with no verified off-target effects leading to unintended traits in commercial lines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[156]</sup></span>
<h3 id="animal-models-and-basic-research" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Animal Models and Basic Research<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genome editing technologies, particularly CRISPR-Cas9, have enabled the rapid generation of genetically modified animal models that recapitulate human disease phenotypes and elucidate gene functions in vivo. Unlike earlier methods such as zinc-finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs), which required complex protein engineering, CRISPR systems use guide RNAs for programmable targeting, achieving higher efficiency in zygote injection and embryonic stem cell modification across species.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[157]</sup> This has accelerated basic research by allowing multiplexed knockoutsâ€”simultaneous disruption of multiple genesâ€”to study genetic interactions and pathways, as demonstrated in mouse models where CRISPR achieved editing efficiencies exceeding 80% in founder animals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In rodents, CRISPR-Cas9 has been pivotal for modeling monogenic and polygenic diseases. For instance, targeted knockouts in mice have revealed causal roles of specific genes in neurodegeneration, such as Apolipoprotein E variants in Alzheimer&#x27;s disease pathology, with models exhibiting amyloid plaque accumulation and tau hyperphosphorylation mirroring human autopsy findings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup> Rat models, optimized via electroporation of Cas9 protein and single-guide RNAs into zygotes, have improved behavioral assays for psychiatric disorders, yielding mutation rates up to 100% for single loci without off-target indels in coding regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup> These models surpass traditional transgenic approaches in speed, with full germline transmission achievable in one generation, facilitating causal inference through loss-of-function studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[160]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Zebrafish and Xenopus serve as high-throughput platforms for developmental and metabolic research due to their optical transparency and external fertilization, enabling real-time imaging of edited embryos. CRISPR-induced mutations in zebrafish have modeled skeletal dysplasias, such as those from Col2a1 disruptions, uncovering mechanisms of cartilage formation absent in cell culture systems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[161]</sup> Base editing variants, which introduce precise single-nucleotide changes without double-strand breaks, have expanded this to point mutation models of metabolic syndromes, achieving correction efficiencies of 20-50% in vivo and reducing mosaicism compared to standard CRISPR.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[162]</sup> In larger mammals like pigs, TALENs and CRISPR have generated models for cardiovascular diseases by knocking out PCSK9, resulting in hypercholesterolemia phenotypes validated against human lipid profiles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_plabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[163]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These animal models underscore genome editing&#x27;s utility in dissecting causal gene-environment interactions, though limitations persist: species-specific differences in DNA repair pathways can alter editing outcomes, and off-target effects, though minimized to below 1% with high-fidelity Cas9 variants, necessitate rigorous validation via whole-genome sequencing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[164]</sup> Ongoing refinements, including prime editing for scarless insertions, promise even greater fidelity for basic research into complex traits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[165]</sup></span>
<h3 id="industrial-biotechnology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Industrial Biotechnology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In industrial biotechnology, genome editing technologies such as CRISPR-Cas9 have enabled precise modifications to microbial genomes, optimizing metabolic pathways for the scalable production of biofuels, biochemicals, enzymes, and amino acids. These tools facilitate targeted knockouts, insertions, and promoter optimizations in organisms like <em>Escherichia coli</em>, <em>Saccharomyces cerevisiae</em>, and <em>Clostridium</em> species, which are commonly used in fermentation processes. By altering genes involved in substrate utilization, byproduct inhibition, and product flux, editing enhances yields and process efficiency, reducing reliance on chemical synthesis and fossil fuels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[166]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[167]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For biofuel production, CRISPR-Cas9 has been applied to improve solventogenesis in anaerobic bacteria. In <em>Clostridium beijerinckii</em>, editing alcohol dehydrogenase genes (<em>adhE1</em> and <em>adhE2</em>) increased n-butanol titers while maintaining strain stability, addressing acid buildup that hampers industrial scalability. Similarly, in <em>Clostridium acetobutylicum</em>, disruption of acid formation pathways shifted metabolism toward butanol, elevating the butanol-to-acetate ratio and supporting higher solvent yields. In yeast, overexpression of lipid elongation genes via CRISPR boosted ethanol productivity, with reported improvements in <em>S. cerevisiae</em> strains for bioethanol fermentation as of 2021.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1hnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[166]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Chemical production has seen notable gains through microbial chassis engineering. CRISPR-mediated deletions of eight genes in <em>S. cerevisiae</em> amplified fatty acid output by 30-fold, enabling efficient conversion of glucose to lipids for bioderived fuels or materials. In <em>Klebsiella pneumoniae</em>, pathway optimizations yielded a ~50% increase in 1,3-propanediol, a precursor for polymers, demonstrated in 2022 studies. For <em>E. coli</em>, editing lactate dehydrogenase (<em>ldhA</em>), alcohol dehydrogenase (<em>adhE</em>), and related genes raised succinate production to 80 g/L, a key dicarboxylic acid for bioplastics. Bacterial strains engineered for squalene from glucose achieved high-efficiency terpenoid synthesis by 2019.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1hnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[168]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1lnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[166]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Enzyme and amino acid biosynthesis benefit from cofactor balancing and secretion enhancements. In <em>Corynebacterium glutamicum</em>, CRISPR targeting NADPH supply genes and promoters improved L-glutamate titers for feed and pharmaceuticals, with advancements reported in 2021. <em>Bacillus subtilis</em> strains edited at the <em>PrsA</em> chaperone locus exhibited enhanced amylase secretion in 2024, streamlining industrial enzyme production for detergents and biofuels. Tryptophan yields in <em>E. coli</em> rose ~40% via enzyme pathway tweaks in 2019, while <em>Aspergillus niger</em> optimizations for citric acid fermentation improved efficiency by 2019. Companies like Ginkgo Bioworks leverage these techniques for custom microbial factories producing pharmaceuticals and fine chemicals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1hoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[168]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1loabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[166]</sup></span>
<h2 id="clinical-translation-and-regulatory-milestones" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Translation and Regulatory Milestones<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="landmark-trials-and-approved-therapies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Landmark Trials and Approved Therapies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The first approved genome editing therapy utilizing CRISPR-Cas9, Casgevy (exagamglogene autotemcel), received U.S. Food and Drug Administration (FDA) approval on December 8, 2023, for sickle cell disease (SCD) in patients aged 12 years and older with recurrent vaso-occlusive crises requiring annual intravenous infusions. Developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy employs ex vivo editing to disrupt the BCL11A enhancer in hematopoietic stem cells, thereby reactivating fetal hemoglobin production to mitigate SCD&#x27;s pathological effects. Approval for transfusion-dependent beta-thalassemia (TDT) followed on January 16, 2024, based on phase 1/2/3 trials (CLIMB-121 for SCD and CLIMB-131 for TDT) demonstrating 96.6% of SCD patients free from severe vaso-occlusive crises at 12 months post-infusion and 93.5% of TDT patients achieving transfusion independence at the same interval, though outcomes required myeloablative chemotherapy preconditioning with associated risks including infertility and secondary malignancies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[170]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Preceding Casgevy&#x27;s approval, the inaugural human application of CRISPR occurred in October 2016 at Sichuan University in China, where three patients with advanced non-small-cell lung cancer received autologous T cells edited via CRISPR-Cas9 to knock out the PD-1 gene, aiming to enhance antitumor immunity; phase 1 data reported in 2020 confirmed feasibility and absence of severe off-target effects or oncogenic insertions, though clinical responses were modest with no complete remissions observed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[171]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup> In the United States, the first CRISPR trial commenced in 2019 under University of Pennsylvania leadership, infusing patients with refractory cancers (melanoma, synovial sarcoma, multiple myeloma) with T cells edited to express a NY-ESO-1-specific T-cell receptor alongside knockouts of PD-1 and TRAC loci; interim phase 1 results indicated durable persistence of edited cells and objective responses in some participants, establishing safety for multiplex editing without unanticipated genotoxicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[173]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[174]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A pivotal advancement in in vivo genome editing materialized in March 2020 at Oregon Health &amp; Science University (OHSU), marking the first direct intraocular injection of CRISPR-Cas9 components (via AAV5 vector) to treat Leber congenital amaurosis caused by CEP290 mutations; the phase 1/2 trial (NCT03872479) targeted the IVS26 intronic variant, with initial safety data from the first cohort showing no serious adverse events and modest visual acuity improvements in some eyes at 6 months, though efficacy varied and long-term immunogenicity risks persisted.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[175]</sup> Complementing ex vivo successes, Intellia Therapeutics and Regeneron&#x27;s NTLA-2001 trial in 2021 represented the first systemic in vivo CRISPR application for transthyretin amyloidosis, achieving up to 87% serum protein reduction at single 0.3 mg/kg doses in phase 1, with durable effects through 24 months and no dose-limiting toxicities, underscoring CRISPR&#x27;s potential for liver-directed editing without cell extraction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[176]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By 2025, Casgevy remained the sole fully approved CRISPR-based therapy globally, with conditional authorizations from the European Medicines Agency for TDT in December 2023 and SCD thereafter, alongside Saudi FDA approval in January 2024 for both indications in patients 12 and older; no additional approvals had materialized despite over 250 ongoing trials, many targeting oncology and autoimmune disorders via allogeneic edited cells like CRISPR Therapeutics&#x27; CTX112.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[177]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_drabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[178]</sup> A notable 2025 milestone involved the first personalized CRISPR therapy administered to a pediatric patient with a rare metabolic disorder at Children&#x27;s Hospital of Philadelphia and Penn Medicine, using base editing to correct a unique patient-specific mutation ex vivo, demonstrating rapid metabolic normalization without evident toxicity in this single-case intervention reported in May.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lrabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[179]</sup> These developments highlight empirical progress in safety and targeted efficacy, tempered by challenges in scalability, preconditioning toxicities, and off-target editing verification across diverse genetic backgrounds.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_trabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<h3 id="global-research-pipelines-and-challenges" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Global Research Pipelines and Challenges<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Global research pipelines in genome editing, particularly CRISPR-based therapies, have expanded rapidly, with approximately 250 clinical trials registered worldwide as of February 2025, of which over 150 remain active, primarily targeting blood disorders, cancers, and inherited conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> Leading efforts are concentrated in the United States, where companies like CRISPR Therapeutics advance in vivo editing programs such as CTX310 (Phase 1 trial initiated for cardiovascular disease via ANGPTL3 targeting, with data expected in late 2025) and CTX320 (ongoing Phase 1 for hereditary angioedema).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[180]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[181]</sup> In Europe and China, pipelines focus on ex vivo applications, including Editas Medicine&#x27;s use of Cas9 and Cas12a nucleases for ocular and blood disorders, while Chinese trials emphasize scalable manufacturing for hemoglobinopathies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[182]</sup> By late 2024, over 50 active treatment centers operated globally, spanning at least 46 countries, though the U.S. hosts the majority of advanced-stage trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> Broader gene editing efforts contribute to nearly 3,500 preclinical and clinical programs in cell and gene therapies, reflecting a shift toward multiplex editing and prime editing for complex diseases like HIV and diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1dsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[183]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1hsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key pipelines integrate diverse editing modalities, with CRISPR Therapeutics pursuing immuno-oncology and regenerative medicine alongside approved ex vivo therapies like Casgevy for sickle cell disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[178]</sup> Emerging in vivo trials, such as those targeting lipid disorders, demonstrate progress in non-viral delivery systems, though most remain in early phases (Phase 1/2).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hsqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[184]</sup> International collaborations, including those under the Innovative Genomics Institute, aim to standardize protocols, but pipelines vary by region: U.S.-led efforts prioritize FDA-aligned safety data, while China&#x27;s National Medical Products Administration (NMPA) has approved faster tracks for certain ZFNs and CRISPR applications in oncology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_psqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Challenges in clinical translation persist across technical, regulatory, and logistical domains. Off-target edits and structural variations, including unintended deletions of regulatory elements, pose genotoxic risks that demand enhanced specificity assays beyond standard sequencing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Delivery remains a bottleneck, with viral vectors facing immune responses and scalability issues, while non-viral alternatives like lipid nanoparticles yield lower efficiencies in vivo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_htabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[185]</sup> Regulatory hurdles exacerbate delays: disparate frameworks between the FDA, EMA, and NMPA complicate multinational trials, with unclear guidelines on good manufacturing practice (GMP) reagents and long-term biodistribution data hindering approvals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ptabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[186]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ttabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[187]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Manufacturing scalability and cost represent additional barriers, as personalized ex vivo editing inflates expensesâ€”often exceeding $2 million per patientâ€”limiting access despite curative potential in trials for blood cancers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup> Ethical and safety considerations, including non-clinical requirements for germline off-target scrutiny even in somatic applications, slow progression, with calls for platform-based regulatory solutions to harmonize global standards.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_htqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[188]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ltqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[189]</sup> Despite these, empirical successes in Phase 3 trials underscore feasibility, though unresolved uncertainties in durable editing efficacy necessitate rigorous, multi-year follow-up.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ttqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[190]</sup></span>
<h2 id="risks-and-empirical-limitations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Risks and Empirical Limitations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="biological-hazards-and-failure-modes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Biological Hazards and Failure Modes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Genome editing via CRISPR-Cas9 induces double-strand breaks that are primarily repaired by error-prone non-homologous end joining (NHEJ), leading to insertions or deletions (indels) that frequently cause frameshift mutations and gene disruption.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[191]</sup> Off-target effects arise from Cas9 cleaving unintended sites due to sequence mismatches tolerated up to three base pairs, resulting in unintended mutations at frequencies as low as 0.03% but potentially higher depending on guide RNA design.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> Mosaicism occurs when editing efficiency varies across cells, particularly in embryos, producing heterogeneous populations with mixed edited and unedited genotypes, complicating therapeutic outcomes and germline transmission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[192]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">On-target aberrations include large-scale structural variations such as kilobase- to megabase-scale deletions, chromosomal truncations, and chromothripsis, often undetected by short-read sequencing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Chromosomal translocations between homologous or heterologous sites can form unstable dicentric or acentric chromosomes, with frequencies amplified up to 1000-fold by certain DNA repair inhibitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> In clinical contexts, such as BCL11A editing in exa-cel therapy for sickle cell disease, kilobase deletions have been observed, potentially disrupting erythropoiesis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Biological hazards encompass immune responses against Cas9 proteins, particularly in patients with pre-existing antibodies, which can destroy edited cells and undermine efficacy in vivo applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[193]</sup> These failure modes heighten oncogenic risks if edits affect proto-oncogenes or tumor suppressors, as unintended structural changes or indels may promote genomic instability and tumorigenesis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Large DNA insertions or deletions induced by CRISPR have been empirically linked to increased cancer risk in cell models.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[194]</sup> Overall, while mitigation strategies like high-fidelity Cas9 variants reduce off-target rates by up to 98.7%, persistent uncertainties in long-read detection underscore the need for comprehensive safety assessments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_120abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup></span>
<h3 id="long-term-safety-data-and-uncertainties" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Long-Term Safety Data and Uncertainties<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">As of 2025, long-term safety data for genome editing technologies, particularly CRISPR-Cas systems, remains limited due to their relatively recent development and deployment, with most human applications initiated post-2018. Animal studies provide the primary longitudinal evidence; for instance, in mouse models of retinal editing, CRISPR-Cas9 modifications demonstrated sustained efficacy and low off-target mutation rates (1.28% at 196 days post-injection, rising modestly to 2.27% at 585 days), with no overt toxicity observed over nearly two years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[194]</sup> Similarly, non-human primate trials for conditions like hemophilia have shown stable edits persisting for over a year without systemic adverse effects, though sample sizes are small and follow-up durations rarely exceed three years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> These findings suggest short- to medium-term stability in controlled somatic applications, but extrapolation to humans requires caution given species-specific differences in DNA repair and immune responses.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In human clinical contexts, approved therapies like exagamglogene autotemcel (Casgevy) for sickle cell disease and beta-thalassemia, authorized by the FDA in December 2023, have reported no off-target-related adverse events in initial follow-ups of up to two years, with patients achieving durable hemoglobin corrections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> However, these datasets derive from small cohorts (e.g., 44 patients in pivotal trials), and long-term monitoringâ€”essential for detecting delayed risks such as oncogenesis from unrepaired double-strand breaksâ€”is ongoing but incomplete, with median follow-up under three years as of mid-2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[195]</sup> Peer-reviewed analyses of early trials emphasize that while base editing and prime editing variants reduce off-target frequencies to below 1% in vitro, real-world genomic instability, including large deletions or translocations, has been documented in up to 5% of edited human cell lines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[196]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key uncertainties stem from potential cumulative effects of off-target edits, which could induce chromosomal rearrangements or activate proto-oncogenes, as evidenced by in vitro studies showing persistent DNA aberrations even with high-fidelity Cas9 variants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> In germline editing, absent from approved uses but pursued in research, mosaicism and heritable mutations pose amplified risks, with animal models revealing unintended structural variants propagating across generations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Delivery vectors like AAV may trigger immune-mediated clearance or insertional mutagenesis over decades, untested in humans beyond preliminary data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> Reviews highlight epistemic gaps, including understudied epigenetic perturbations and interactions with environmental factors, underscoring the need for multi-decade observational studies to quantify risks empirically rather than rely on predictive models.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_122abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> While no causal links to cancer or other late-onset pathologies have been confirmed in edited organisms to date, the absence of evidence does not equate to evidence of absence, given the technology&#x27;s decade-long timeline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1a2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup></span>
<h2 id="ethical-and-societal-dimensions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Ethical and Societal Dimensions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="germline-editing-and-heritability-concerns" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Germline Editing and Heritability Concerns<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Germline editing refers to the application of genome editing technologies, such as CRISPR-Cas9, to germ cells, zygotes, or early-stage embryos, resulting in modifications that are incorporated into the heritable genome and transmitted to subsequent generations.00560-3/fulltext) Unlike somatic editing, which affects only the treated individual, germline alterations propagate through the population, amplifying the consequences of any errors or unintended outcomes across familial lineages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[197]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A primary concern with heritable editing is the persistence and potential accumulation of off-target effects, where the editing machinery induces unintended mutations at non-target genomic sites. Studies have demonstrated that CRISPR-Cas9 can generate large structural variants, deletions, or insertions both on-target and off-target, with detection challenges in early embryos due to cellular heterogeneity and mosaicismâ€”where not all cells in an embryo carry the same edit.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[198]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[199]</sup> In germline contexts, such mutations could lead to novel genetic disorders in offspring or descendants, as empirical data from model organisms indicate that off-target rates, though reduced by high-fidelity variants, remain non-zero and context-dependent.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> Heritability exacerbates these risks, as a single viable edited embryo implanted for reproduction could disseminate alterations unpredictably, without the selective pressures that mitigate harmful mutations in natural reproduction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_124abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The 2018 case of He Jiankui illustrates these heritability perils empirically. He, a Chinese biophysicist, announced the birth of twin girls whose embryos he edited using CRISPR to disrupt the CCR5 gene, aiming to confer HIV resistance by mimicking a natural delta-32 mutation. Subsequent analysis revealed mosaicism in the embryos, incomplete biallelic editing, and potential off-target risks, with no long-term health data available as of 2023; He was convicted in 2019 of illegal medical practice and sentenced to three years in prison.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[200]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[201]</sup> This incident underscored causal uncertainties: while the intended edit might offer partial protection, heritable mosaicism could result in variable expressivity across generations, potentially introducing fitness costs or oncogenic risks not observable in the initial cohort.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[202]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regulatory frameworks reflect these concerns, with heritable genome editing prohibited in the vast majority of jurisdictions due to unresolved safety and heritability issues. As of 2020, 75 of 96 surveyed countries explicitly ban the use of genetically modified embryos to initiate pregnancy, including statutory prohibitions in nations like Germany, Canada, Australia, and the European Union under the Oviedo Convention; no country permits clinical reproduction via germline edits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[203]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[204]</sup> International bodies, including a 2019 call from scientific summits, advocate moratoriums until empirical evidence demonstrates negligible off-target rates and predictable intergenerational outcomes, prioritizing causal verification over speculative benefits.01260-0/fulltext) Despite theoretical potential for preventing monogenic diseases, the absence of comprehensive long-term human dataâ€”coupled with evidence of persistent editing inaccuraciesâ€”renders heritable applications empirically unjustified at present.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[205]</sup></span>
<h3 id="enhancement-debates-and-equity-issues" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Enhancement Debates and Equity Issues<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The debate over human enhancement through genome editing distinguishes therapeutic applications, which aim to correct genetic diseases, from non-therapeutic enhancements that seek to improve traits such as intelligence, physical prowess, or disease resistance beyond normal human variation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[206]</sup> Proponents of enhancement, including some bioethicists, contend that individuals should have autonomy to pursue genetic improvements, analogous to existing enhancements like education or nutrition, provided risks are managed and consent is informed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[207]</sup> Critics argue that enhancements risk commodifying human life, eroding genetic diversity, and reviving eugenic practices, with empirical precedents like the 2018 He Jiankui experimentâ€”where embryos were edited for HIV resistance via CCR5 deletionâ€”illustrating blurred lines, as the modification may confer unintended advantages like West Nile virus protection but also potential cognitive drawbacks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[208]</sup> These concerns are amplified in germline editing, where changes are heritable, prompting calls for moratoriums from bodies like the World Health Organization until safety and societal impacts are better understood.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_126abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A central contention is the &quot;slippery slope&quot; argument, positing that permitting somatic (non-heritable) therapies inevitably leads to germline enhancements due to technological convergence and shifting norms, as the boundary between alleviating deficits and optimizing traits proves arbitraryâ€”e.g., editing for severe intellectual disability versus mild cognitive boosts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[207]</sup> Empirical analysis of this slope reveals logical weaknesses, as regulatory distinctions can be maintained through evidence-based criteria, yet historical precedents in reproductive technologies suggest normative drift where initial therapeutic intents expand to elective uses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[209]</sup> Philosophically, enhancement challenges egalitarian principles by potentially creating a genetic underclass, with first-principles reasoning highlighting causal risks: unequal adoption could entrench heritability of advantage, as modeled in population genetics simulations showing rapid divergence in trait distributions under selective editing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Despite these debates, no verified human enhancements beyond therapeutic trials exist as of 2025, confining discussions largely to prospective ethics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_126qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Equity issues arise from genome editing&#x27;s high development and delivery costs, restricting access primarily to affluent populations and high-income countries, thereby widening global health disparities. The first approved CRISPR therapy, Casgevy for sickle cell disease and beta-thalassemia, launched in 2023 at $2.2 million per patient, exceeds lifetime conventional treatment costs ($4-6 million for sickle cell) yet remains unaffordable for most, particularly in sub-Saharan Africa where sickle cell prevalence reaches 1-2% of births.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[210]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[211]</sup> This pricing, driven by manufacturing complexities like ex vivo cell editing and chemotherapy conditioning, disadvantages low-resource settings despite the technology&#x27;s potential to address endemic genetic burdens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[212]</sup> For enhancements, equity concerns intensify: if viable, they could exacerbate class divides, as only elites afford &quot;designer&quot; traits, fostering a bifurcated society where genetic haves outcompete have-nots in labor markets and reproduction, per economic models of technological inequality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[213]</sup> Proposals for equitable scaling include value-based pricing and international funding mechanisms, but implementation lags, underscoring causal realism that without deliberate access reforms, editing reinforces existing socioeconomic gradients rather than mitigating them.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_167abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[214]</sup></span>
<h3 id="regulatory-responses-and-innovation-barriers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Regulatory Responses and Innovation Barriers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Following the 2018 revelation of unauthorized germline editing by He Jiankui in China, which resulted in the birth of edited infants, international bodies responded with calls for enhanced oversight. The World Health Organization&#x27;s 2021 governance framework for human genome editing emphasized institutional, national, and global mechanisms to promote safety, transparency, and equity, while advising against heritable edits until scientific, ethical, and societal consensus is achieved.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[215]</sup> This framework, developed by an expert advisory committee, prioritizes risk assessment and public engagement but lacks enforceable authority, relying on voluntary adoption by member states.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[216]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, the Food and Drug Administration (FDA) oversees genome editing under its human gene therapy regulations, treating CRISPR-based products as biologics subject to Investigational New Drug applications and phased clinical trials. A March 2024 FDA guidance specifically addresses human gene therapy products incorporating genome editing of somatic cells, recommending preclinical assessments for off-target effects, immunogenicity, and genotoxicity to mitigate risks like unintended mutations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[217]</sup> Germline editing remains prohibited by congressional acts, with no federal protocols permitting heritable modifications, though somatic applications advanced with the December 2023 approval of Casgevy (exagamglogene autotemcel), the first CRISPR therapy for sickle cell disease and beta-thalassemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[218]</sup> FDA clinical holds, such as the temporary pause on Verve Therapeutics&#x27; VERVE-101 in 2022 due to delivery concerns (lifted in October 2023), exemplify precautionary scrutiny that delays trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The European Union applies its 2001 GMO Directive to genome-edited organisms, classifying most edits as equivalent to transgenic GMOs requiring rigorous risk assessments, labeling, and traceability, which has stifled agricultural innovation by equating precise edits to foreign DNA insertions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[219]</sup> A February 2024 European Parliament vote proposed easing regulations for edits without foreign DNA or unintended changes, exempting them from GMO rules to foster competitiveness, but implementation remains pending amid member state opt-outs and environmental NGO opposition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[220]</sup> For human applications, heritable editing is banned under the 2001 Clinical Trials Directive and Oviedo Convention protocols ratified by several members.</span>
<span class="mb-4 block break-words text-[1em] leading-7">China intensified restrictions post-He Jiankui, issuing a 2019 interim ban on heritable editing and enacting 2021 civil code provisions criminalizing clinical germline use, followed by a July 2024 Ministry of Science and Technology prohibition on all clinical germline research as &quot;irresponsible&quot; due to safety uncertainties.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[221]</sup> These measures, enforced through institutional ethics reviews, contrast with permissive somatic trials but reflect reactive centralization amid prior lax oversight.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Such frameworks impose innovation barriers by creating regulatory asymmetry, prompting forum-shopping where researchers and firms relocate to jurisdictions like the US or Argentina with lighter crop editing rules, reducing European investment in biotech by an estimated 20-30% in affected sectors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[222]</sup> Precautionary standards, including lengthy approvals (often 10-15 years for FDA gene therapies) and ambiguity in non-human applications like livestock, deter venture capital; a 2024 analysis linked stringent EU GMO equivalence to fewer commercialized gene-edited products and heightened R&amp;D costs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[223]</sup> Germline prohibitions, while addressing heritable risks, foreclose enhancements or population-level interventions, with empirical data showing off-target rates below 1% in optimized CRISPR systems yet insufficient for policy shifts amid uncertainty.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[224]</sup> Proponents argue risk-proportionate rules could accelerate benefits, as somatic therapies demonstrate, but institutional inertiaâ€”exacerbated by biases toward alarmism in academic and media sourcesâ€”perpetuates barriers over evidence-based calibration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[225]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6454098/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6454098/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6454098/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5733845/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5733845/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5733845/</a></span></div></li><li id="https://journals.asm.org/doi/10.1128/jb.00580-17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.asm.org/doi/10.1128/jb.00580-17" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.asm.org/doi/10.1128/jb.00580-17</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/</a></span></div></li><li id="https://www.science.org/doi/10.1126/science.add8643" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/doi/10.1126/science.add8643" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/doi/10.1126/science.add8643</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8992613/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8992613/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8992613/</a></span></div></li><li id="https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9793437/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9793437/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9793437/</a></span></div></li><li id="https://www.nature.com/articles/s41599-022-01147-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41599-022-01147-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41599-022-01147-y</a></span></div></li><li id="https://doi.org/10.1073/pnas.76.10.4951" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1073/pnas.76.10.4951" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1073/pnas.76.10.4951</a></span></div></li><li id="https://doi.org/10.1038/317230a0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1038/317230a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1038/317230a0</a></span></div></li><li id="https://doi.org/10.1038/292154a0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1038/292154a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1038/292154a0</a></span></div></li><li id="https://journals.sagepub.com/doi/10.1177/0023677221994613" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.sagepub.com/doi/10.1177/0023677221994613" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.sagepub.com/doi/10.1177/0023677221994613</a></span></div></li><li id="https://www.nobelprize.org/prizes/medicine/2007/advanced-information/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nobelprize.org/prizes/medicine/2007/advanced-information/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nobelprize.org/prizes/medicine/2007/advanced-information/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4798875/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4798875/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4798875/</a></span></div></li><li id="https://www.nso-journal.org/articles/nso/full_html/2023/05/NSO20220072/NSO20220072.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nso-journal.org/articles/nso/full_html/2023/05/NSO20220072/NSO20220072.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nso-journal.org/articles/nso/full_html/2023/05/NSO20220072/NSO20220072.html</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/20478078/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/20478078/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/20478078/</a></span></div></li><li id="https://www.researchgate.net/publication/44607123_The_discovery_of_zinc_fingers_and_their_development_for_practical_applications_in_gene_regulation_and_genome_manipulation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/publication/44607123_The_discovery_of_zinc_fingers_and_their_development_for_practical_applications_in_gene_regulation_and_genome_manipulation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/publication/44607123_The_discovery_of_zinc_fingers_and_their_development_for_practical_applications_in_gene_regulation_and_genome_manipulation</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11113862/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11113862/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11113862/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2666388021000071" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2666388021000071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2666388021000071</a></span></div></li><li id="https://www.the-scientist.com/a-tale-of-how-talens-launched-the-genome-editing-revolution-72719" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.the-scientist.com/a-tale-of-how-talens-launched-the-genome-editing-revolution-72719" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.the-scientist.com/a-tale-of-how-talens-launched-the-genome-editing-revolution-72719</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4207558/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4207558/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4207558/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2666388021000022" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2666388021000022" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2666388021000022</a></span></div></li><li id="https://www.science.org/doi/10.1126/science.1225829" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/doi/10.1126/science.1225829" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/doi/10.1126/science.1225829</a></span></div></li><li id="https://www.nobelprize.org/prizes/chemistry/2020/press-release/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nobelprize.org/prizes/chemistry/2020/press-release/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nobelprize.org/prizes/chemistry/2020/press-release/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/22745249/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/22745249/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/22745249/</a></span></div></li><li id="https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline</a></span></div></li><li id="https://www.nature.com/articles/s41580-020-00307-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41580-020-00307-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41580-020-00307-9</a></span></div></li><li id="https://media.market.us/crispr-statistics/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://media.market.us/crispr-statistics/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://media.market.us/crispr-statistics/</a></span></div></li><li id="https://www.broadinstitute.org/news/broad-institute-awarded-first-patent-engineered-crispr-cas9-system" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.broadinstitute.org/news/broad-institute-awarded-first-patent-engineered-crispr-cas9-system" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.broadinstitute.org/news/broad-institute-awarded-first-patent-engineered-crispr-cas9-system</a></span></div></li><li id="https://www.cell.com/cell/fulltext/S0092-8674%2824%2900111-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cell.com/cell/fulltext/S0092-8674%2824%2900111-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cell.com/cell/fulltext/S0092-8674%2824%2900111-9</a></span></div></li><li id="https://www.nature.com/articles/s41467-025-62606-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-025-62606-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-025-62606-z</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12322275/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12322275/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12322275/</a></span></div></li><li id="https://www.science.org/content/blog-post/single-base-editing-seems-work" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/content/blog-post/single-base-editing-seems-work" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/content/blog-post/single-base-editing-seems-work</a></span></div></li><li id="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1039315/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1039315/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1039315/full</a></span></div></li><li id="https://www.universityofcalifornia.edu/news/highly-targeted-crispr-delivery-advances-gene-editing-living-animals" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.universityofcalifornia.edu/news/highly-targeted-crispr-delivery-advances-gene-editing-living-animals" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.universityofcalifornia.edu/news/highly-targeted-crispr-delivery-advances-gene-editing-living-animals</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S152500162500200X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S152500162500200X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S152500162500200X</a></span></div></li><li id="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease</a></span></div></li><li id="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration</a></span></div></li><li id="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene</a></span></div></li><li id="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and</a></span></div></li><li id="https://www.grandviewresearch.com/industry-analysis/crispr-based-gene-editing-market-report" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grandviewresearch.com/industry-analysis/crispr-based-gene-editing-market-report" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grandviewresearch.com/industry-analysis/crispr-based-gene-editing-market-report</a></span></div></li><li id="https://innovativegenomics.org/news/crispr-clinical-trials-2025/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://innovativegenomics.org/news/crispr-clinical-trials-2025/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://innovativegenomics.org/news/crispr-clinical-trials-2025/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8187289/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8187289/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8187289/</a></span></div></li><li id="https://www.nature.com/articles/s41467-022-28771-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-022-28771-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-022-28771-1</a></span></div></li><li id="https://www.nature.com/articles/s41467-023-40344-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-023-40344-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-023-40344-4</a></span></div></li><li id="https://www.nature.com/articles/ncomms6560" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/ncomms6560" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/ncomms6560</a></span></div></li><li id="https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-024-01896-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-024-01896-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-024-01896-z</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4638128/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4638128/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4638128/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/</a></span></div></li><li id="https://www.nature.com/articles/s41392-024-01750-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41392-024-01750-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41392-024-01750-2</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3267165/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3267165/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3267165/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0168365916305466" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0168365916305466" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0168365916305466</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4786926/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4786926/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4786926/</a></span></div></li><li id="https://www.genengnews.com/topics/genome-editing/back-to-the-future-pre-crispr-systems-are-driving-therapies-to-the-clinic/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.genengnews.com/topics/genome-editing/back-to-the-future-pre-crispr-systems-are-driving-therapies-to-the-clinic/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.genengnews.com/topics/genome-editing/back-to-the-future-pre-crispr-systems-are-driving-therapies-to-the-clinic/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4416406/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4416406/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4416406/</a></span></div></li><li id="https://www.pnas.org/doi/10.1073/pnas.1321030111" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pnas.org/doi/10.1073/pnas.1321030111" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pnas.org/doi/10.1073/pnas.1321030111</a></span></div></li><li id="https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-191" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-191" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-191</a></span></div></li><li id="https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1370675/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1370675/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1370675/full</a></span></div></li><li id="https://www.nature.com/articles/nrg2842" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nrg2842" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nrg2842</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3176093/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3176093/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3176093/</a></span></div></li><li id="https://www.nature.com/articles/s41467-019-08867-x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-019-08867-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-019-08867-x</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11113831/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11113831/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11113831/</a></span></div></li><li id="https://investor.sangamo.com/news-releases/news-release-details/sangamo-receives-fast-track-designation-fda-sb-318-and-sb-913" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investor.sangamo.com/news-releases/news-release-details/sangamo-receives-fast-track-designation-fda-sb-318-and-sb-913" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investor.sangamo.com/news-releases/news-release-details/sangamo-receives-fast-track-designation-fda-sb-318-and-sb-913</a></span></div></li><li id="https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016%2822%2900622-0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016%2822%2900622-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016%2822%2900622-0</a></span></div></li><li id="https://www.nature.com/articles/s41598-024-74716-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-024-74716-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-024-74716-7</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.155" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.155" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.155</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5736148/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5736148/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5736148/</a></span></div></li><li id="https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-cons-of-znfs-talens-and-crispr-cas" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-cons-of-znfs-talens-and-crispr-cas" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-cons-of-znfs-talens-and-crispr-cas</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8380213/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8380213/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8380213/</a></span></div></li><li id="https://academicworks.cuny.edu/cgi/viewcontent.cgi?article=1536&amp;context=cc_pubs" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academicworks.cuny.edu/cgi/viewcontent.cgi?article=1536&amp;context=cc_pubs" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academicworks.cuny.edu/cgi/viewcontent.cgi?article=1536&amp;context=cc_pubs</a></span></div></li><li id="https://whatisbiotechnology.org/index.php/science/summary/TALENs" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://whatisbiotechnology.org/index.php/science/summary/TALENs" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://whatisbiotechnology.org/index.php/science/summary/TALENs</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3570604/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3570604/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3570604/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S216225312100202X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S216225312100202X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S216225312100202X</a></span></div></li><li id="https://dash.harvard.edu/bitstreams/7312037d-9d8e-6bd4-e053-0100007fdf3b/download" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://dash.harvard.edu/bitstreams/7312037d-9d8e-6bd4-e053-0100007fdf3b/download" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://dash.harvard.edu/bitstreams/7312037d-9d8e-6bd4-e053-0100007fdf3b/download</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3547402/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3547402/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3547402/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1687157X23006571" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1687157X23006571" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1687157X23006571</a></span></div></li><li id="https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-019-0317-x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-019-0317-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-019-0317-x</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5052741/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5052741/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5052741/</a></span></div></li><li id="https://innovativegenomics.org/crisprpedia/crispr-in-nature/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://innovativegenomics.org/crisprpedia/crispr-in-nature/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://innovativegenomics.org/crisprpedia/crispr-in-nature/</a></span></div></li><li id="https://royalsocietypublishing.org/doi/10.1098/rstb.2018.0087" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://royalsocietypublishing.org/doi/10.1098/rstb.2018.0087" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://royalsocietypublishing.org/doi/10.1098/rstb.2018.0087</a></span></div></li><li id="https://www.synthego.com/learn/crispr" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.synthego.com/learn/crispr" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.synthego.com/learn/crispr</a></span></div></li><li id="https://www.science.org/doi/10.1126/science.1231143" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/doi/10.1126/science.1231143" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/doi/10.1126/science.1231143</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3795411/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3795411/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3795411/</a></span></div></li><li id="https://www.addgene.org/guides/crispr/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.addgene.org/guides/crispr/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.addgene.org/guides/crispr/</a></span></div></li><li id="https://www.synthego.com/guide/how-to-use-crispr/pam-sequence" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.synthego.com/guide/how-to-use-crispr/pam-sequence" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.synthego.com/guide/how-to-use-crispr/pam-sequence</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9512960/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9512960/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9512960/</a></span></div></li><li id="https://blog.addgene.org/crispr-101-cas9-vs.-the-other-cass" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://blog.addgene.org/crispr-101-cas9-vs.-the-other-cass" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://blog.addgene.org/crispr-101-cas9-vs.-the-other-cass</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6466564/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6466564/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6466564/</a></span></div></li><li id="https://www.nature.com/articles/s41467-023-35886-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-023-35886-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-023-35886-6</a></span></div></li><li id="https://www.nature.com/articles/s41576-018-0059-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41576-018-0059-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41576-018-0059-1</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4873371/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4873371/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4873371/</a></span></div></li><li id="https://www.nature.com/articles/s41573-020-0084-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41573-020-0084-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41573-020-0084-6</a></span></div></li><li id="https://www.nature.com/articles/nature24644" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nature24644" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nature24644</a></span></div></li><li id="https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05957-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05957-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05957-3</a></span></div></li><li id="https://www.nature.com/articles/s41586-019-1711-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41586-019-1711-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41586-019-1711-4</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10989687/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10989687/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10989687/</a></span></div></li><li id="https://www.nature.com/articles/s41929-025-01406-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41929-025-01406-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41929-025-01406-6</a></span></div></li><li id="https://www.the-scientist.com/david-liu-wins-2025-breakthrough-prize-for-base-editing-and-prime-editing-72888" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.the-scientist.com/david-liu-wins-2025-breakthrough-prize-for-base-editing-and-prime-editing-72888" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.the-scientist.com/david-liu-wins-2025-breakthrough-prize-for-base-editing-and-prime-editing-72888</a></span></div></li><li id="https://www.nature.com/articles/s41587-025-02720-x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41587-025-02720-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41587-025-02720-x</a></span></div></li><li id="https://www.nature.com/articles/s41587-022-01527-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41587-022-01527-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41587-022-01527-4</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/40393858/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/40393858/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/40393858/</a></span></div></li><li id="https://www.sciencedaily.com/releases/2025/10/251025084545.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedaily.com/releases/2025/10/251025084545.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedaily.com/releases/2025/10/251025084545.htm</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8892976/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8892976/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8892976/</a></span></div></li><li id="https://phys.org/news/2025-10-gene-tech-repurposes-bacterial-retrons.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://phys.org/news/2025-10-gene-tech-repurposes-bacterial-retrons.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://phys.org/news/2025-10-gene-tech-repurposes-bacterial-retrons.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4590770/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4590770/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4590770/</a></span></div></li><li id="https://www.nature.com/articles/nrg.2017.103" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nrg.2017.103" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nrg.2017.103</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/</a></span></div></li><li id="https://www.nature.com/articles/s41392-021-00487-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41392-021-00487-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41392-021-00487-6</a></span></div></li><li id="https://www.nature.com/articles/s41392-023-01309-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41392-023-01309-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41392-023-01309-7</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2162253125000113" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2162253125000113" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2162253125000113</a></span></div></li><li id="https://www.nature.com/articles/s41565-024-01851-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41565-024-01851-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41565-024-01851-7</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8444435/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8444435/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8444435/</a></span></div></li><li id="https://www.liebertpub.com/doi/10.1089/crispr.2024.0036" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.liebertpub.com/doi/10.1089/crispr.2024.0036" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.liebertpub.com/doi/10.1089/crispr.2024.0036</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/40086687/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/40086687/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/40086687/</a></span></div></li><li id="https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2023.1248904/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2023.1248904/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2023.1248904/full</a></span></div></li><li id="https://innovativegenomics.org/news/crispr-clinical-trials-2024/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://innovativegenomics.org/news/crispr-clinical-trials-2024/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://innovativegenomics.org/news/crispr-clinical-trials-2024/</a></span></div></li><li id="https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501%2825%2900175-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501%2825%2900175-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501%2825%2900175-5</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0092867422003956" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0092867422003956" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0092867422003956</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10867117/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10867117/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10867117/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2107454" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2107454" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2107454</a></span></div></li><li id="https://edhub.ama-assn.org/jn-learning/video-player/18468298" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://edhub.ama-assn.org/jn-learning/video-player/18468298" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://edhub.ama-assn.org/jn-learning/video-player/18468298</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10018374/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10018374/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10018374/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8655392/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8655392/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8655392/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S216225311630049X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S216225311630049X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S216225311630049X</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10266473/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10266473/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10266473/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10802171/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10802171/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10802171/</a></span></div></li><li id="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8968349/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8968349/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8968349/</a></span></div></li><li id="https://www.nature.com/articles/s12276-025-01463-8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s12276-025-01463-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s12276-025-01463-8</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4851738/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4851738/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4851738/</a></span></div></li><li id="https://www.nature.com/articles/s41589-023-01279-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41589-023-01279-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41589-023-01279-5</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1097276516303318" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1097276516303318" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1097276516303318</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1525001620306079" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1525001620306079" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1525001620306079</a></span></div></li><li id="https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00691/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00691/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00691/full</a></span></div></li><li id="https://blog.addgene.org/3-tips-for-improving-hdr-efficiency-for-editing-human-cells-with-crispr" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://blog.addgene.org/3-tips-for-improving-hdr-efficiency-for-editing-human-cells-with-crispr" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://blog.addgene.org/3-tips-for-improving-hdr-efficiency-for-editing-human-cells-with-crispr</a></span></div></li><li id="https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00943-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00943-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00943-1</a></span></div></li><li id="https://www.nature.com/articles/s41467-024-50788-x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-024-50788-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-024-50788-x</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2031054" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2031054" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2031054</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10425811/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10425811/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10425811/</a></span></div></li><li id="https://crisprmedicinenews.com/clinical-trials/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://crisprmedicinenews.com/clinical-trials/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://crisprmedicinenews.com/clinical-trials/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/</a></span></div></li><li id="https://thalassemia.org/FDA-Approves-Vertex-CRISPRs-Gene-Editing-Therapy" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://thalassemia.org/FDA-Approves-Vertex-CRISPRs-Gene-Editing-Therapy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://thalassemia.org/FDA-Approves-Vertex-CRISPRs-Gene-Editing-Therapy</a></span></div></li><li id="https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1478398/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1478398/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1478398/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11164064/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11164064/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11164064/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11362101/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11362101/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11362101/</a></span></div></li><li id="https://genomebiology.biomedcentral.com/articles/10.1186/s13059-020-02204-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://genomebiology.biomedcentral.com/articles/10.1186/s13059-020-02204-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://genomebiology.biomedcentral.com/articles/10.1186/s13059-020-02204-y</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2666154324001698" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2666154324001698" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2666154324001698</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8929161/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8929161/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8929161/</a></span></div></li><li id="https://nhsjs.com/2025/crispr-cas9-application-in-crop-biotechnology-a-decade-of-research-2014-to-2024-toward-food-security-in-developing-countries/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nhsjs.com/2025/crispr-cas9-application-in-crop-biotechnology-a-decade-of-research-2014-to-2024-toward-food-security-in-developing-countries/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nhsjs.com/2025/crispr-cas9-application-in-crop-biotechnology-a-decade-of-research-2014-to-2024-toward-food-security-in-developing-countries/</a></span></div></li><li id="https://www.congress.gov/crs-product/R47683" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.congress.gov/crs-product/R47683" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.congress.gov/crs-product/R47683</a></span></div></li><li id="https://www.europarl.europa.eu/RegData/etudes/BRIE/2023/754549/EPRS_BRI%282023%29754549_EN.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.europarl.europa.eu/RegData/etudes/BRIE/2023/754549/EPRS_BRI%282023%29754549_EN.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.europarl.europa.eu/RegData/etudes/BRIE/2023/754549/EPRS_BRI%282023%29754549_EN.pdf</a></span></div></li><li id="https://innovativegenomics.org/news/crispr-in-agriculture-2024/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://innovativegenomics.org/news/crispr-in-agriculture-2024/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://innovativegenomics.org/news/crispr-in-agriculture-2024/</a></span></div></li><li id="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/biot.70113" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/biot.70113" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/biot.70113</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S1877117317301205" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S1877117317301205" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S1877117317301205</a></span></div></li><li id="https://www.nature.com/articles/s41598-017-16328-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-017-16328-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-017-16328-y</a></span></div></li><li id="https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-015-0031-x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-015-0031-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-015-0031-x</a></span></div></li><li id="https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1409-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1409-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1409-1</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2001037019300443" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2001037019300443" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2001037019300443</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12133889/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12133889/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12133889/</a></span></div></li><li id="https://www.mdpi.com/1467-3045/47/5/330" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/1467-3045/47/5/330" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/1467-3045/47/5/330</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0278584617300386" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0278584617300386" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0278584617300386</a></span></div></li><li id="https://www.nature.com/articles/s12276-025-01514-0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s12276-025-01514-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s12276-025-01514-0</a></span></div></li><li id="https://www.mdpi.com/2311-5637/11/7/410" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2311-5637/11/7/410" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2311-5637/11/7/410</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2667370323000334" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2667370323000334" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2667370323000334</a></span></div></li><li id="https://www.genengnews.com/resources/crispr-made-greener-products-and-processes-in-industrial-biotechnology/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.genengnews.com/resources/crispr-made-greener-products-and-processes-in-industrial-biotechnology/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.genengnews.com/resources/crispr-made-greener-products-and-processes-in-industrial-biotechnology/</a></span></div></li><li id="https://news.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/</a></span></div></li><li id="https://www.nature.com/articles/s41392-020-00283-8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41392-020-00283-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41392-020-00283-8</a></span></div></li><li id="https://crisprmedicinenews.com/news/first-chinese-crispr-gene-therapy-trial-demonstrates-safety/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://crisprmedicinenews.com/news/first-chinese-crispr-gene-therapy-trial-demonstrates-safety/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://crisprmedicinenews.com/news/first-chinese-crispr-gene-therapy-trial-demonstrates-safety/</a></span></div></li><li id="https://www.npr.org/sections/health-shots/2019/04/16/712402435/first-u-s-patients-treated-with-crispr-as-gene-editing-human-trials-get-underway" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.npr.org/sections/health-shots/2019/04/16/712402435/first-u-s-patients-treated-with-crispr-as-gene-editing-human-trials-get-underway" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.npr.org/sections/health-shots/2019/04/16/712402435/first-u-s-patients-treated-with-crispr-as-gene-editing-human-trials-get-underway</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/29173170/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/29173170/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/29173170/</a></span></div></li><li id="https://news.ohsu.edu/2020/03/04/ohsu-performs-first-ever-crispr-gene-editing-within-human-body" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.ohsu.edu/2020/03/04/ohsu-performs-first-ever-crispr-gene-editing-within-human-body" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.ohsu.edu/2020/03/04/ohsu-performs-first-ever-crispr-gene-editing-within-human-body</a></span></div></li><li id="https://www.nature.com/articles/d41586-021-01776-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/d41586-021-01776-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/d41586-021-01776-4</a></span></div></li><li id="https://thalassaemia.org.cy/clinical-trial-updates-scd/exa-cel-gene-editing/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://thalassaemia.org.cy/clinical-trial-updates-scd/exa-cel-gene-editing/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://thalassaemia.org.cy/clinical-trial-updates-scd/exa-cel-gene-editing/</a></span></div></li><li id="https://crisprtx.com/pipeline" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://crisprtx.com/pipeline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://crisprtx.com/pipeline</a></span></div></li><li id="https://www.chop.edu/news/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chop.edu/news/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chop.edu/news/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital</a></span></div></li><li id="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-late-breaking-data-american-heart" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-late-breaking-data-american-heart" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-late-breaking-data-american-heart</a></span></div></li><li id="https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-first-quarter-2025-financial" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-first-quarter-2025-financial" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-first-quarter-2025-financial</a></span></div></li><li id="https://www.editasmedicine.com/gene-editing-pipeline/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.editasmedicine.com/gene-editing-pipeline/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.editasmedicine.com/gene-editing-pipeline/</a></span></div></li><li id="https://www.asgct.org/news-publications/landscape-report" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.asgct.org/news-publications/landscape-report" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.asgct.org/news-publications/landscape-report</a></span></div></li><li id="https://www.synthego.com/blog/crispr-clinical-trials" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.synthego.com/blog/crispr-clinical-trials" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.synthego.com/blog/crispr-clinical-trials</a></span></div></li><li id="https://advanced.onlinelibrary.wiley.com/doi/10.1002/adfm.202402630" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://advanced.onlinelibrary.wiley.com/doi/10.1002/adfm.202402630" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://advanced.onlinelibrary.wiley.com/doi/10.1002/adfm.202402630</a></span></div></li><li id="https://www.synthego.com/blog/crispr-cell-gene-therapy-obstacles" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.synthego.com/blog/crispr-cell-gene-therapy-obstacles" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.synthego.com/blog/crispr-cell-gene-therapy-obstacles</a></span></div></li><li id="https://www.synthego.com/blog/regulatory-trends-therapies" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.synthego.com/blog/regulatory-trends-therapies" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.synthego.com/blog/regulatory-trends-therapies</a></span></div></li><li id="https://www.liebertpub.com/doi/10.1089/crispr.2025.0049" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.liebertpub.com/doi/10.1089/crispr.2025.0049" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.liebertpub.com/doi/10.1089/crispr.2025.0049</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2352304225002740" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2352304225002740" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2352304225002740</a></span></div></li><li id="https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0475-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0475-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0475-4</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0092867424001119" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0092867424001119" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0092867424001119</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0012160618302513" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0012160618302513" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0012160618302513</a></span></div></li><li id="https://www.nature.com/articles/s41467-018-05843-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-018-05843-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-018-05843-9</a></span></div></li><li id="https://www.nature.com/articles/s42003-021-01942-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s42003-021-01942-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s42003-021-01942-4</a></span></div></li><li id="https://www.labiotech.eu/in-depth/crispr-cas9-review-gene-editing-tool/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.labiotech.eu/in-depth/crispr-cas9-review-gene-editing-tool/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.labiotech.eu/in-depth/crispr-cas9-review-gene-editing-tool/</a></span></div></li><li id="https://frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6791475/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6791475/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6791475/</a></span></div></li><li id="https://www.nature.com/articles/s41467-022-28244-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-022-28244-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-022-28244-5</a></span></div></li><li id="https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-020-00487-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-020-00487-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-020-00487-1</a></span></div></li><li id="https://www.science.org/content/article/chinese-scientist-who-produced-genetically-altered-babies-sentenced-3-years-jail" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/content/article/chinese-scientist-who-produced-genetically-altered-babies-sentenced-3-years-jail" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/content/article/chinese-scientist-who-produced-genetically-altered-babies-sentenced-3-years-jail</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6813942/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6813942/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6813942/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1098360021044956" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1098360021044956" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1098360021044956</a></span></div></li><li id="https://www.liebertpub.com/doi/10.1089/crispr.2020.0082" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.liebertpub.com/doi/10.1089/crispr.2020.0082" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.liebertpub.com/doi/10.1089/crispr.2020.0082</a></span></div></li><li id="https://www.forbes.com/sites/farahqaiser/2020/10/31/study-there-is-no-country-where-heritable-human-genome-editing-is-permitted/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forbes.com/sites/farahqaiser/2020/10/31/study-there-is-no-country-where-heritable-human-genome-editing-is-permitted/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forbes.com/sites/farahqaiser/2020/10/31/study-there-is-no-country-where-heritable-human-genome-editing-is-permitted/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0015028225002535" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0015028225002535" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0015028225002535</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7747319/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7747319/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7747319/</a></span></div></li><li id="https://link.springer.com/article/10.1007/s11948-018-0048-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/s11948-018-0048-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/s11948-018-0048-y</a></span></div></li><li id="https://elsihub.org/collection/human-gene-editing-and-ethics-enhancement" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://elsihub.org/collection/human-gene-editing-and-ethics-enhancement" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://elsihub.org/collection/human-gene-editing-and-ethics-enhancement</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/8201288/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/8201288/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/8201288/</a></span></div></li><li id="https://www.liebertpub.com/doi/10.1089/crispr.2024.0042" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.liebertpub.com/doi/10.1089/crispr.2024.0042" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.liebertpub.com/doi/10.1089/crispr.2024.0042</a></span></div></li><li id="https://sites.brown.edu/publichealthjournal/2024/03/21/gene-editing-for-rare-genetic-diseases-is-an-equitable-future-possible/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://sites.brown.edu/publichealthjournal/2024/03/21/gene-editing-for-rare-genetic-diseases-is-an-equitable-future-possible/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://sites.brown.edu/publichealthjournal/2024/03/21/gene-editing-for-rare-genetic-diseases-is-an-equitable-future-possible/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11024294/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11024294/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11024294/</a></span></div></li><li id="https://thebulletin.org/2024/10/crispr-therapies-can-treat-disease-but-cost-millions-an-equity-based-approach-could-bring-them-to-more-people/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://thebulletin.org/2024/10/crispr-therapies-can-treat-disease-but-cost-millions-an-equity-based-approach-could-bring-them-to-more-people/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://thebulletin.org/2024/10/crispr-therapies-can-treat-disease-but-cost-millions-an-equity-based-approach-could-bring-them-to-more-people/</a></span></div></li><li id="https://www.nature.com/articles/s41434-023-00392-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41434-023-00392-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41434-023-00392-3</a></span></div></li><li id="https://www.who.int/publications/i/item/9789240030060" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.who.int/publications/i/item/9789240030060" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.who.int/publications/i/item/9789240030060</a></span></div></li><li id="https://www.who.int/publications/i/item/9789240030381" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.who.int/publications/i/item/9789240030381" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.who.int/publications/i/item/9789240030381</a></span></div></li><li id="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing</a></span></div></li><li id="https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-embryonic-germline-gene-editing/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-embryonic-germline-gene-editing/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-embryonic-germline-gene-editing/</a></span></div></li><li id="https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/european-union-crops-food/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/european-union-crops-food/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/european-union-crops-food/</a></span></div></li><li id="https://www.science.org/content/article/european-parliament-votes-ease-regulation-gene-edited-crops" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.science.org/content/article/european-parliament-votes-ease-regulation-gene-edited-crops" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.science.org/content/article/european-parliament-votes-ease-regulation-gene-edited-crops</a></span></div></li><li id="https://www.chemistryworld.com/news/all-clinical-research-using-germline-genome-editing-banned-in-china/4019847.article" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chemistryworld.com/news/all-clinical-research-using-germline-genome-editing-banned-in-china/4019847.article" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chemistryworld.com/news/all-clinical-research-using-germline-genome-editing-banned-in-china/4019847.article</a></span></div></li><li id="https://www.tylerbpratt.com/s/Genes_August2022.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tylerbpratt.com/s/Genes_August2022.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tylerbpratt.com/s/Genes_August2022.pdf</a></span></div></li><li id="https://www.tandfonline.com/doi/full/10.1080/21645698.2023.2293510" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/full/10.1080/21645698.2023.2293510" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/full/10.1080/21645698.2023.2293510</a></span></div></li><li id="https://eurofaang.eu/wp-content/uploads/2024/02/D5.3-Public.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://eurofaang.eu/wp-content/uploads/2024/02/D5.3-Public.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://eurofaang.eu/wp-content/uploads/2024/02/D5.3-Public.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12169205/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12169205/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12169205/</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2" id="_R_" async=""></script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Genome_editing\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Genome_editing\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Genome_editing\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T1bea8,"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"# Genome editing\n\n![Engineered nucleases for genome editing](./_assets_/Engineered_Nucleases.jpg)\n\nGenome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions, replacements, or modifications of genetic material to study gene function or treat diseases.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6454098/) These techniques rely on engineered nucleases that create double-strand breaks at specific genomic loci, which are then repaired by cellular mechanisms such as non-homologous end joining or homology-directed repair, often incorporating desired changes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5733845/) Early approaches included zinc-finger nucleases (ZFNs) developed in the 1990s and transcription activator-like effector nucleases (TALENs) in the 2000s, but the clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) system, adapted from bacterial adaptive immunity and demonstrated for eukaryotic genome editing in 2012, has dominated due to its simplicity, efficiency, and versatility.[](https://journals.asm.org/doi/10.1128/jb.00580-17)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/)\n\nSignificant achievements include rapid gene knockout in model organisms for functional genomics, crop improvement for enhanced yield and resistance, and therapeutic applications in humans, such as the 2023 FDA approval of CRISPR-based ex vivo editing for sickle cell disease and beta-thalassemia, marking the first clinical use of the technology to correct pathogenic mutations.[](https://www.science.org/doi/10.1126/science.add8643) These advances stem from empirical validation of editing precision in controlled trials, demonstrating causal links between corrected genotypes and phenotypic improvements without widespread off-target effects in targeted contexts.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8992613/) However, challenges persist, including unintended mutations from incomplete specificity and delivery inefficiencies in vivo, necessitating ongoing refinements like base editing and prime editing for higher fidelity.[](https://www.science.org/doi/10.1126/science.add8643)\n\nControversies arise primarily from germline editing, where changes are heritable, raising concerns over safety risks like mosaicism and long-term ecological impacts, as well as ethical debates on eugenics and inequality, though somatic applications avoid inheritance issues and focus on individual therapeutic benefits supported by clinical data.[](https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9793437/) The 2018 case of unauthorized human embryo editing by He Jiankui highlighted regulatory gaps but also underscored the technology's potential when responsibly applied, with scientific consensus favoring paused heritable use until risks are empirically mitigated.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/)[](https://www.nature.com/articles/s41599-022-01147-y)\n\n## History\n\n### Pre-Engineered Nuclease Era\n\nHomologous recombination (HR), a conserved cellular mechanism for repairing double-strand breaks using a homologous DNA template, formed the basis of early genome editing efforts before the advent of engineered site-specific nucleases. In this era, spanning the 1970s to late 1980s, researchers introduced linear DNA constructs with flanking homology arms matching the target genomic locus, relying on spontaneous, low-frequency HR events to achieve precise insertions, deletions, or replacements without inducing targeted DNA breaks. This approach yielded high-fidelity modifications when successful but suffered from extreme inefficiency, typically 10^{-4} to 10^{-6} in mammalian cells, dominated by random non-homologous integrations.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5733845/) To counter this, positive-negative selection strategies were developed, using markers like neomycin resistance for enrichment and herpes simplex virus thymidine kinase for counterselection against random integrants.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5733845/)\n\nPioneering work in yeast, where HR is naturally more efficient, demonstrated feasibility early on. In 1979, Scherer and Davis achieved targeted chromosomal segment replacement in *Saccharomyces cerevisiae* by transfecting hybrid plasmids, marking one of the first instances of precise genomic alteration via HR.[](https://doi.org/10.1073/pnas.76.10.4951) This success in unicellular eukaryotes informed extensions to mammals. Oliver Smithies advanced the field in 1985 by reporting HR-mediated insertion of a functional gene into the human beta-globin locus in cultured mouse erythroleukemia cells, confirming targeted events at frequencies around 1 in 10^3 to 10^4 transformants under selection.[](https://doi.org/10.1038/317230a0)\n\nThe integration of mouse embryonic stem (ES) cells, first isolated in 1981 by Martin Evans and Matthew Kaufman, enabled heritable modifications.[](https://doi.org/10.1038/292154a0) By 1987, Smithies and Mario Capecchi independently applied HR in mouse ES cells to disrupt specific genes, such as *Aph-3*, using isogenic targeting vectors to boost efficiency.[](https://journals.sagepub.com/doi/10.1177/0023677221994613) Capecchi's group refined selection protocols, achieving targeted disruptions at rates improved to about 1 in 10^5 electroporated cells. These methods culminated in the first germline-transmissible gene knockouts in mice by 1989, allowing systematic functional analysis of genes via \"knockout\" models.[](https://www.nobelprize.org/prizes/medicine/2007/advanced-information/) Despite these advances, the absence of DSB induction limited scalability, confining applications largely to tractable systems like yeast and mouse ES cells for basic research into gene function and disease modeling.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5733845/)\n\n### Development of Site-Specific Nucleases\n\n![Evolution of site-specific nucleases from meganucleases to TALENs and beyond](./_assets_/MEGANUCLEASE-ZFN-TALEN-CRISPR-text-to-path.svg.png)\nSite-specific nucleases emerged as tools for targeted genome editing by inducing double-strand breaks (DSBs) at predetermined DNA sequences, leveraging cellular DNA repair pathways for precise modifications. Early efforts focused on meganucleases, naturally occurring homing endonucleases from microbes with recognition sites of 12-40 base pairs, first characterized in the 1980s such as I-SceI from yeast mitochondria.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4798875/) These enzymes demonstrated enhanced gene targeting via DSB-stimulated homologous recombination in yeast and mammalian cells by the early 1990s, but their rigid protein-DNA interfaces limited redesign for new specificities, restricting broad applicability.[](https://journals.sagepub.com/doi/10.1177/0023677221994613) Engineering attempts in the 2000s involved semi-rational design and directed evolution to alter specificity, yet success remained low due to coupled recognition and cleavage domains.[](https://www.nso-journal.org/articles/nso/full_html/2023/05/NSO20220072/NSO20220072.html)\n\nTo overcome meganuclease limitations, researchers developed modular nucleases by fusing customizable DNA-binding domains to separate, non-specific nuclease modules. Zinc finger nucleases (ZFNs), invented in 1996 by fusing zinc finger proteinsâ€”discovered in 1985â€”with the FokI endonuclease cleavage domain, enabled programmable targeting of 9-18 base pair sites as dimers.[](https://pubmed.ncbi.nlm.nih.gov/20478078/) [](https://www.researchgate.net/publication/44607123_The_discovery_of_zinc_fingers_and_their_development_for_practical_applications_in_gene_regulation_and_genome_manipulation) Initial demonstrations achieved targeted DSBs and gene disruption in mammalian cells by 1998, with therapeutic applications emerging in the 2000s, including HIV resistance via CCR5 knockout in human cells.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11113862/) However, ZFNs required expertise in zinc finger assembly, often via phage display or structure-based design, and off-target effects arose from context-dependent binding affinities.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4798875/)\n\nTranscription activator-like effector nucleases (TALENs) advanced programmability in 2010, following the 2009 deciphering of the TALE DNA-binding code from Xanthomonas bacteria, where repeat-variable di-residues (RVDs) specify one base pair each.[](https://www.sciencedirect.com/science/article/pii/S2666388021000071) TALENs pair FokI domains flanking a central spacer for dimerization and cleavage, offering higher specificity than ZFNs due to independent modular recognition and reduced toxicity in applications like zebrafish and human cell editing.[](https://www.the-scientist.com/a-tale-of-how-talens-launched-the-genome-editing-revolution-72719) First used for targeted gene knockouts and insertions in 2011, TALENs facilitated multiplex editing and expanded genome engineering to non-model organisms, though assembly of lengthy TALE arrays remained labor-intensive compared to later RNA-guided methods.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4207558/) These innovations established DSB-based editing principles, paving the way for scalable technologies while highlighting trade-offs in specificity, ease of design, and delivery.[](https://www.sciencedirect.com/science/article/pii/S2666388021000022)\n\n### CRISPR Breakthrough and Rapid Adoption\n\nThe CRISPR-Cas9 system emerged as a transformative tool for genome editing following a 2012 study by Emmanuelle Charpentier and Jennifer Doudna, who demonstrated in vitro that the Cas9 endonuclease from *Streptococcus pyogenes*, guided by a dual RNA structure (crRNA and tracrRNA, later simplified into single-guide RNA), could be reprogrammed to induce site-specific double-strand breaks in DNA.[](https://www.science.org/doi/10.1126/science.1225829) This work, published online on June 28, 2012, in *Science*, repurposed the bacterial adaptive immune mechanismâ€”previously characterized in the early 2000sâ€”for precise nucleic acid targeting, offering advantages in simplicity, multiplexing potential, and cost over prior nucleases like ZFNs and TALENs.[](https://www.nobelprize.org/prizes/chemistry/2020/press-release/) The system's RNA-guided specificity stemmed from base-pairing between the guide RNA and target DNA, adjacent to a protospacer-adjacent motif (PAM) sequence, enabling predictable cleavage without protein engineering for each target.[](https://pubmed.ncbi.nlm.nih.gov/22745249/)\n\nAdaptation to cellular genome editing occurred rapidly, with demonstrations in prokaryotic and eukaryotic systems by early 2013. Independent studies by Feng Zhang's group at the Broad Institute and George Church's lab at Harvard achieved targeted modifications via non-homologous end joining (NHEJ) and homology-directed repair (HDR) in human and mouse cell lines, as reported in *Science* on January 3, 2013. These applications exploited the endogenous DNA repair pathways to introduce insertions, deletions, or precise substitutions, validating CRISPR-Cas9's efficiency in mammalian genomes where off-target effects, though present, were manageable compared to earlier tools.[](https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline) Concurrently, Virginijus Å ikÅ¡nys's group in Lithuania reported similar prokaryotic editing, underscoring the technology's versatility.[](https://www.nature.com/articles/s41580-020-00307-9)\n\nAdoption accelerated exponentially, evidenced by a surge in research output: CRISPR-related publications rose from fewer than 100 annually pre-2012 to over 3,900 by 2018, reflecting its integration into diverse fields like functional genomics and model organism engineering.[](https://media.market.us/crispr-statistics/) Patent filings intensified, with the University of California (representing Doudna's work) submitting the first provisional application in May 2012, followed by the Broad Institute's December 2012 filingâ€”expedited to yield the initial U.S. patent in April 2014 for eukaryotic applicationsâ€”sparking ongoing interference proceedings that highlighted competing claims but did not impede lab proliferation.[](https://www.broadinstitute.org/news/broad-institute-awarded-first-patent-engineered-crispr-cas9-system) By 2015, CRISPR had supplanted prior methods in most academic and industrial workflows due to its accessibility, enabling high-throughput screens and multiplexed edits unattainable with protein-based nucleases.[](https://www.science.org/doi/10.1126/science.add8643)\n\n![CRISPR-based genome editing mechanism](./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png)\n\n### Post-2020 Advancements and Commercialization\n\nFollowing the rapid adoption of CRISPR-Cas9 in the late 2010s, post-2020 developments emphasized enhanced precision, reduced off-target effects, and in vivo delivery to expand therapeutic applicability. Researchers introduced refined Cas variants, such as smaller Cas12 and Cas13 orthologs, enabling better packaging into viral vectors for systemic administration and multiplex editing capabilities. These variants improved editing efficiency in non-dividing cells, addressing limitations in earlier systems.[](https://www.cell.com/cell/fulltext/S0092-8674%2824%2900111-9)[](https://www.nature.com/articles/s41467-025-62606-z)\n\nBase editing and prime editing matured as DSB-free alternatives, minimizing unwanted insertions or deletions. Base editors, which convert specific nucleotides via deaminase fusion, entered clinical trials post-2020 for conditions like alpha-1 antitrypsin deficiency, with early 2025 data showing successful single-base corrections in human subjects. Prime editing, leveraging a reverse transcriptase-pegsRNA complex, advanced to support diverse modifications including insertions up to dozens of bases, with preclinical models demonstrating up to 50% efficiency in therapeutically relevant genes by 2025. These tools expanded the editable genome fraction beyond traditional CRISPR's reach.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12322275/)[](https://www.science.org/content/blog-post/single-base-editing-seems-work)[](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1039315/full)\n\nDelivery innovations accelerated in vivo applications, with nanoparticle and lipid-conjugated systems achieving tissue-specific targeting, as shown in 2024 studies editing subsets of neurons or hepatocytes in animal models without broad toxicity. Clinical translation progressed, with over 15 base-editing trials registered by mid-2025 targeting immunodeficiencies and metabolic disorders.[](https://www.universityofcalifornia.edu/news/highly-targeted-crispr-delivery-advances-gene-editing-living-animals)[](https://www.sciencedirect.com/science/article/pii/S152500162500200X)\n\nCommercialization gained momentum with regulatory approvals validating ex vivo CRISPR therapies. In December 2023, the FDA approved Casgevy (exagamglogene autotemcel), a CRISPR-Cas9-edited autologous stem cell therapy from Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease in patients aged 12 and older with recurrent vaso-occlusive crises; approval for transfusion-dependent beta thalassemia followed in January 2024 for those aged 12 and older. Casgevy disrupts the BCL11A enhancer to reactivate fetal hemoglobin, achieving transfusion independence in 94% of beta thalassemia patients and reducing vaso-occlusive events by 91% in sickle cell cases across trials. This marked the first CRISPR-based therapy commercialization, though high costs exceeding $2 million per treatment and manufacturing complexities limited initial access.[](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease)[](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration)[](https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene)\n\nBy 2025, the sector saw expanded pipelines, with CRISPR Therapeutics prioritizing in vivo programs for cardiovascular and autoimmune diseases, alongside Phase 3 trials for hereditary angioedema. The global CRISPR gene-editing market reached $4.01 billion in 2024, projected to grow to $13.50 billion by 2033, driven by diagnostics, agriculture, and therapeutics, though intellectual property disputes and ethical concerns over germline editing persisted. Ongoing trials numbered over 50 worldwide, focusing on oncology, HIV, and rare diseases, signaling broader clinical maturation.[](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and)[](https://www.grandviewresearch.com/industry-analysis/crispr-based-gene-editing-market-report)[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/)\n\n## Biological and Mechanistic Foundations\n\n### DNA Repair Mechanisms Exploited in Editing\n\n![Double-strand break repair and CRISPR-based genome editing](./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png)\n\nGenome editing technologies, such as those employing site-specific nucleases, induce double-strand breaks (DSBs) in DNA that are subsequently repaired by cellular pathways, enabling targeted genetic modifications. The primary pathways exploited are non-homologous end joining (NHEJ) and homology-directed repair (HDR), with NHEJ predominating in most cell types due to its efficiency and lack of requirement for a homologous template.01131-X) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8187289/) NHEJ directly ligates DSB ends, often introducing small insertions or deletions (indels) at the junction, which frequently results in frameshift mutations that disrupt gene function and are harnessed for gene knockouts.00111-9) This pathway operates throughout the cell cycle, making it suitable for editing in both dividing and quiescent cells, though its error-prone nature limits applications to loss-of-function edits.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8187289/)\n\nIn contrast, HDR utilizes a homologous donor template to accurately repair DSBs, facilitating precise insertions, deletions, or substitutions and is thus exploited for corrective edits or transgene integration. HDR, including subpathways like synthesis-dependent strand annealing and double Holliday junction resolution, is restricted to S and G2 phases when sister chromatids are available as templates, rendering it less efficientâ€”typically competing with NHEJ at ratios where NHEJ prevails in non-synchronized cells.00111-9) [](https://www.nature.com/articles/s41467-022-28771-1) To enhance HDR, strategies such as inhibiting NHEJ factors (e.g., DNA-PK) or synchronizing cells to proliferative phases have been developed, though HDR remains challenging in primary and non-dividing cells.[](https://www.nature.com/articles/s41467-023-40344-4)\n\nAn alternative DSB repair mechanism, microhomology-mediated end joining (MMEJ), serves as a backup pathway involving short homologous sequences (5-25 base pairs) flanking the break for annealing, leading to precise but error-prone joining with deletions of intervening sequences. In genome editing, MMEJ is leveraged in approaches like precise integration into target chromosomes (PITCh) for scarless insertions without long homology arms, particularly useful when HDR is inefficient, though it can also contribute to unintended large deletions.[](https://www.nature.com/articles/ncomms6560) [](https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-024-01896-z) MMEJ activity increases under conditions suppressing classical NHEJ, such as in certain cancer cells deficient in NHEJ components, highlighting its role in editing outcomes influenced by cellular context.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4638128/) These pathways' competition determines editing fidelity, with outcomes varying by locus, cell type, and DSB-end processing factors like end resection, which favors HDR over NHEJ.00200-6)\n\n### Principles of Sequence-Specific Targeting\n\n![Evolution of sequence-specific targeting in nucleases](./_assets_/MEGANUCLEASE-ZFN-TALEN-CRISPR-text-to-path.svg.png)\nSequence-specific targeting in genome editing fundamentally relies on engineered nucleases that bind to and cleave DNA at predetermined loci, exploiting endogenous repair pathways for modifications such as insertions, deletions, or substitutions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/) This specificity is achieved through modular DNA-binding domains that recognize particular nucleotide sequences, typically 12â€“20 base pairs long, fused to a catalytic nuclease domain that induces double-strand breaks (DSBs).[](https://www.nature.com/articles/s41392-024-01750-2) The binding domains operate via direct interactions with DNA bases, ensuring localized nuclease activity while minimizing off-target effects, though imperfect specificity remains a challenge requiring ongoing optimization.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/)\n\nIn protein-DNA recognition systems, such as those in zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), specificity arises from arrays of protein modules that contact DNA through hydrogen bonds and hydrophobic interactions. Each zinc finger module in ZFNs typically recognizes a 3â€“4 base pair subsite, with 3â€“6 fingers forming a recognition arm of 9â€“18 bp, though binding affinity is influenced by adjacent fingers and spacer sequences of 5â€“7 bp between dimerizing monomers.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/) TALENs utilize TALE repeats from plant pathogens, where each 34-amino-acid repeat's repeat-variable di-residues (RVDs) specify a single nucleotideâ€”e.g., NI for adenineâ€”enabling straightforward programming of longer targets (12â€“20 bp) with spacers of 12â€“19 bp.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/) These systems often employ FokI nuclease domains, which require dimerization for cleavage, enhancing specificity by necessitating paired binding events.[](https://www.nature.com/articles/s41392-024-01750-2)\n\nRNA-guided mechanisms, exemplified by CRISPR-Cas systems, achieve targeting through Watson-Crick base pairing between a single-guide RNA (sgRNA) and the target DNA, typically spanning 20 nucleotides adjacent to a protospacer-adjacent motif (PAM) required for Cas nuclease activation, such as NGG for Streptococcus pyogenes Cas9.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/) This RNA-DNA hybridization simplifies programming compared to protein engineering, as only the sgRNA sequence needs alteration, but specificity depends on minimizing mismatches, with off-target cuts occurring at sites with partial complementarity.[](https://www.nature.com/articles/s41392-024-01750-2) Unlike protein-based dimers, Cas9 functions as a single polypeptide, scanning DNA for PAMs before R-loop formation and cleavage, though variants like high-fidelity Cas9 mutants reduce unintended activity by altering contact dynamics.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/) Across all approaches, target site accessibility, chromatin state, and cellular repair context influence editing efficiency, underscoring the need for empirical validation of specificity.[](https://www.nature.com/articles/s41392-024-01750-2)\n\n## Primary Editing Technologies\n\n### Meganucleases\n\n![Engineered nucleases for genome editing](./_assets_/Engineered_Nucleases.jpg)\nMeganucleases, also known as homing endonucleases, are naturally occurring site-specific endonucleases derived primarily from microbial mobile genetic elements, such as introns and inteins.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3267165/) These enzymes recognize extended DNA sequences, typically 12 to 40 base pairs in length, which enables highly precise cleavage with minimal off-target effects due to the rarity of such long motifs in genomes.[](https://www.sciencedirect.com/science/article/abs/pii/S0168365916305466) Unlike modular nucleases, meganucleases integrate DNA-binding and catalytic activities within a single polypeptide, often exhibiting a saddle-shaped structure that cradles the DNA helix.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786926/)\n\nThe adaptation of meganucleases for genome editing began in the early 1990s, with natural variants like I-SceI from yeast mitochondria used to induce double-strand breaks (DSBs) in mammalian cells as early as 1994, demonstrating enhanced homologous recombination efficiency.[](https://www.genengnews.com/topics/genome-editing/back-to-the-future-pre-crispr-systems-are-driving-therapies-to-the-clinic/) Engineered custom meganucleases emerged in the late 1990s and early 2000s, pioneered by groups including those at Cellectis, which developed variants through protein engineering starting around 1999.[](https://journals.sagepub.com/doi/10.1177/0023677221994613) Redesign strategies, such as semi-rational mutagenesis and in vitro recombination of monomeric domains from dimeric scaffolds like I-CreI (a 22-base-pair recognizer from *Chlamydomonas reinhardtii*), allow tailoring to novel targets, though success rates remain low owing to the coupled evolution of recognition and cleavage domains.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4416406/)[](https://www.pnas.org/doi/10.1073/pnas.1321030111)\n\nIn editing applications, meganuclease-induced DSBs trigger cellular repair pathways, including error-prone non-homologous end joining for gene knockouts or homology-directed repair for precise insertions and corrections when donor templates are provided.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3267165/) Their specificity arises from multiple hydrogen bonds and van der Waals contacts across the target, conferring advantages like reduced toxicity and immunogenicity compared to heterologous fusion proteins.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6454098/) However, engineering challengesâ€”such as the need for extensive screening to avoid partial specificities or catalytic inactivityâ€”limit versatility, with redesign often requiring months of iterative optimization.[](https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-191)[](https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1370675/full)\n\nEarly applications targeted therapeutic corrections, such as disrupting HIV proviral DNA or correcting mutations in severe combined immunodeficiency models, and agricultural modifications in plants.[](https://www.nso-journal.org/articles/nso/full_html/2023/05/NSO20220072/NSO20220072.html)[](https://journals.sagepub.com/doi/10.1177/0023677221994613) Despite these proofs-of-concept, meganucleases have seen limited clinical translation due to design complexity, paving the way for successor technologies like zinc finger nucleases that offer modular assembly.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4798875/) Ongoing refinements, including machine learning-assisted design, aim to enhance predictability for bespoke nucleases.[](https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-191)\n\n### Zinc Finger Nucleases\n\n![Engineered nucleases diagram](./_assets_/Engineered_Nucleases.jpg)\nZinc finger nucleases (ZFNs) are engineered restriction enzymes comprising zinc finger protein domains for sequence-specific DNA recognition fused to the non-specific DNA cleavage domain of the FokI endonuclease.[](https://www.nature.com/articles/nrg2842) These modular proteins induce targeted double-strand breaks (DSBs) at predetermined genomic loci, exploiting cellular DNA repair pathways such as non-homologous end joining (NHEJ) for gene disruption or homology-directed repair (HDR) for precise insertions or corrections.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3176093/) Each zinc finger module typically binds a 3-base-pair subsite, with arrays of 3â€“6 fingers providing specificity spanning 9â€“18 base pairs; FokI dimerization requires two adjacent ZFNs binding in a tail-to-tail orientation, spaced 4â€“6 base pairs apart, to generate the DSB.[](https://www.nature.com/articles/nrg2842)\n\nDevelopment of ZFNs began with the identification of zinc finger motifs in the transcription factor TFIIIA from Xenopus laevis in 1985, followed by demonstrations of their customizable DNA-binding properties in the early 1990s.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4798875/) Pioneering work in the late 1990s and early 2000s by researchers including Carlos Barbas and David Liu enabled the fusion of zinc finger arrays to FokI, achieving the first targeted DSBs in mammalian cells around 2002â€“2005.[](https://www.sciencedirect.com/science/article/pii/S2666388021000022) Key milestones include the 2009 demonstration of efficient ZFN-mediated editing in human cells via modular assembly, facilitating broader adoption for gene targeting.[](https://www.nature.com/articles/s41467-019-08867-x) Despite early promise as the first programmable genome editing tool, ZFN design proved labor-intensive due to context-dependent interactions between adjacent fingers, often requiring empirical selection or proprietary oligomerized assembly methods like OPEN or zinc finger phage display.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/)\n\nZFNs have been applied in preclinical models for gene knockouts, insertions, and corrections, notably in disrupting the CCR5 gene for HIV resistance in human cells and hematopoietic stem cells (HSCs).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11113831/) Clinically, Sangamo Therapeutics advanced ZFN-based therapies, with Phase 1/2 trials for HIV (SB-728) initiating in 2009, showing transient viral load reductions but limited long-term efficacy due to editing efficiency constraints.[](https://investor.sangamo.com/news-releases/news-release-details/sangamo-receives-fast-track-designation-fda-sb-318-and-sb-913) For hemophilia B, an in vivo ZFN approach via AAV delivery (SB-525/ST-920) entered trials in 2018, aiming to insert a factor IX transgene into the albumin locus; a 2022 first-in-human study reported safe dosing up to 5Ã—10^13 vg/kg with FIX activity increases, though no approvals have been granted as of 2025.[](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016%2822%2900622-0) Recent studies in 2024 confirmed high-efficiency ZFN editing in HSCs for multilineage engraftment, underscoring persistent utility in ex vivo applications.[](https://www.nature.com/articles/s41598-024-74716-7)\n\nAdvantages of ZFNs include proven clinical tolerability, reduced immunogenicity compared to some alternatives, and high specificity when optimized, with off-target effects mitigated by paired nuclease design and transient expression.[](https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.155) However, challenges persist: design complexity limits accessibility, potential FokI toxicity at high expression levels, and off-target cleavage at sites with partial homology, though rates are generally lower than early CRISPR iterations when using validated ZFNs.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/) Persistent plasmid expression risks promiscuous binding, prompting strategies like mRNA electroporation for ephemeral activity.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5736148/) While eclipsed by simpler tools like CRISPR-Cas9 post-2012, ZFNs remain relevant for applications demanding compact payloads or established safety profiles in viral vectors.[](https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-cons-of-znfs-talens-and-crispr-cas)\n\n### TALENs\n\n![Overview of TALENs](./_assets_/Overview_of_TALENs.png)\n\nTranscription activator-like effector nucleases (TALENs) are engineered restriction enzymes consisting of a customizable DNA-binding domain derived from transcription activator-like (TAL) effectors of Xanthomonas bacteria fused to the nonspecific DNA cleavage domain of the FokI endonuclease.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4207558/) TAL effectors, first characterized in 2009, contain tandem repeats with repeat-variable di-residues (RVDs) that confer nucleotide-specific DNA binding, where each RVD typically recognizes a single base pair.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8380213/) The initial demonstration of TALEN-mediated genome editing was reported in 2010, with key publications in 2011 enabling targeted double-strand breaks (DSBs) in various organisms.[](https://academicworks.cuny.edu/cgi/viewcontent.cgi?article=1536\u0026context=cc_pubs)[](https://whatisbiotechnology.org/index.php/science/summary/TALENs)\n\nTALENs function by designing pairs of proteins that bind to adjacent DNA sequences separated by a spacer of 12-20 base pairs; the FokI domains dimerize across this spacer to generate a DSB, which is repaired via non-homologous end joining (NHEJ) for gene disruption or homology-directed repair (HDR) for precise edits when a donor template is provided.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4207558/) This modular one-to-one RVD-nucleotide recognition simplifies target design compared to zinc finger nucleases (ZFNs), which rely on zinc finger modules recognizing three nucleotides each, often requiring empirical optimization due to context-dependent binding.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/) TALEN assembly, though initially labor-intensive via methods like Golden Gate cloning, has been streamlined with kits allowing construction in 1-2 days.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3570604/)\n\nTALENs exhibit higher specificity than ZFNs, with studies showing reduced off-target cleavage at sites like CCR5; for instance, TALENs produced fewer unintended mutations than ZFNs targeting the same locus.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/) Relative to CRISPR-Cas9, TALENs demonstrate lower off-target activity in some contexts due to the absence of guide RNA mismatches and reliance on protein-DNA interactions, though CRISPR's ease of use has led to its dominance.[](https://www.sciencedirect.com/science/article/pii/S216225312100202X)[](https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-cons-of-znfs-talens-and-crispr-cas) However, TALENs' larger size (around 3 kb per monomer) complicates delivery, particularly in viral vectors, and multiplexing multiple targets remains challenging without custom engineering.[](https://dash.harvard.edu/bitstreams/7312037d-9d8e-6bd4-e053-0100007fdf3b/download)\n\nApplications of TALENs span basic research and therapeutics, including gene knockouts in human pluripotent stem cells for disease modeling, such as generating CCR5 mutants resistant to HIV.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3570604/) In agriculture, TALENs have conferred rice resistance to Xanthomonas oryzae by disrupting susceptibility genes and enabled the first genome-edited pigs in 2015 via embryo injection.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3547402/) Therapeutically, TALENs achieved the first cure of chronic lymphocytic leukemia in a patient in 2015 by editing T cells ex vivo for adoptive transfer, highlighting their clinical potential despite subsequent shifts toward CRISPR.[](https://www.sciencedirect.com/science/article/pii/S2666388021000071) TALENs also facilitate mitochondrial DNA editing for diseases like Leber's hereditary optic neuropathy, exploiting their protein-based delivery to bypass nuclear RNA interference issues.[](https://www.sciencedirect.com/science/article/pii/S1687157X23006571)\n\n### CRISPR-Cas Systems\n\n![CRISPR-based genome editing](./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png)\nCRISPR-Cas systems derive from clustered regularly interspaced short palindromic repeats (CRISPR) and associated Cas proteins, which form an adaptive immune mechanism in bacteria and archaea to defend against invading bacteriophages and plasmids.[](https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-019-0317-x) These systems acquire short DNA sequences from foreign invaders, integrate them as spacers into the host CRISPR array, and transcribe them into CRISPR RNAs (crRNAs) that guide Cas effector proteins to cleave matching nucleic acids during subsequent exposures.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5052741/) The functional role was first demonstrated in 2007 when spacers from phage DNA conferred resistance in *Streptococcus thermophilus*.[](https://innovativegenomics.org/crisprpedia/crispr-in-nature/)\n\nClassified into two main classes, six types, and numerous subtypes, CRISPR-Cas systems vary in complexity and effectors; type II systems, prevalent in genome editing applications, rely on a single large Cas9 endonuclease.[](https://royalsocietypublishing.org/doi/10.1098/rstb.2018.0087) In natural type II systems, such as from *Streptococcus pyogenes*, Cas9 forms a complex with crRNA and trans-activating crRNA (tracrRNA), which base-pairs with the target DNA to form an R-loop structure, enabling double-strand breaks (DSBs) adjacent to a protospacer adjacent motif (PAM), typically 5'-NGG-3'.[](https://www.science.org/doi/10.1126/science.1225829) The dual crRNA-tracrRNA was simplified into a single guide RNA (sgRNA) for programmable targeting.[](https://www.synthego.com/learn/crispr)\n\nAdaptation for genome editing began with the 2012 demonstration that *S. pyogenes* Cas9 (SpCas9), guided by dual RNAs, cleaves plasmid DNA in vitro at sites specified by the crRNA spacer sequence, provided a PAM is present.[](https://www.science.org/doi/10.1126/science.1225829) This RNA-guided nuclease activity was harnessed for eukaryotic genome engineering in early 2013, when Cong et al. reported targeted cleavage and homology-directed repair in human and mouse cells using SpCas9 and sgRNA expressed from plasmids, achieving up to 25% modification efficiency at select loci.[](https://www.science.org/doi/10.1126/science.1231143) Independent work by Mali et al. confirmed multiplex editing capabilities, altering up to five endogenous sites simultaneously via NHEJ or HDR pathways.\n\nThe editing mechanism exploits Cas9-induced DSBs repaired by non-homologous end joining (NHEJ), often introducing insertions/deletions (indels) for gene disruption, or homology-directed repair (HDR) with donor templates for precise insertions or substitutions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3795411/) Targeting specificity stems from ~20-nucleotide sgRNA-DNA complementarity, though mismatches can reduce efficiency; off-target effects arise from partial hybridization at non-canonical sites with compatible PAMs.[](https://www.addgene.org/guides/crispr/) SpCas9 requires a 3' PAM, limiting accessible targets to ~12.5% of the human genome, prompting variants like SpCas9-NG (recognizing 5'-NG-3') or smaller Cas12a (Cpf1) from *Francisella novicida*, which uses 5'-TTV-3' PAM and generates staggered cuts for scarless cloning.[](https://www.synthego.com/guide/how-to-use-crispr/pam-sequence)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9512960/)\n\nCas13 variants, such as LwaCas13a, target and cleave single-stranded RNA rather than DNA, enabling transcript knockdown or editing without genomic alterations, though with collateral RNA cleavage upon activation.[](https://blog.addgene.org/crispr-101-cas9-vs.-the-other-cass) These systems' simplicity, multiplexing potential, and low costâ€”relative to protein-based nucleases like ZFNs or TALENsâ€”drove rapid adoption, with over 10,000 publications by 2017 citing CRISPR for editing.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6466564/) Challenges include immunogenicity of bacterial Cas proteins and delivery barriers in vivo, addressed through humanized variants or alternative Cas orthologs.[](https://www.nature.com/articles/s41467-023-35886-6)\n\n### Base Editing and Prime Editing\n\nBase editing, developed by Alexandrox Komor and colleagues in David Liu's laboratory and first reported in 2016, enables the precise conversion of a target cytosine (C) to thymine (T) in DNA without generating double-strand breaks (DSBs). This approach fuses a catalytically impaired Cas9 proteinâ€”either a nickase variant (nCas9) that creates a single-strand nick or a dead Cas9 (dCas9) lacking nuclease activityâ€”with a cytidine deaminase enzyme, such as APOBEC1, to form a cytosine base editor (CBE).[](https://www.nature.com/articles/s41576-018-0059-1) A single-guide RNA (sgRNA) directs the complex to the target site, where the deaminase chemically modifies cytosine to uracil (U) within a narrow editing window of 4-5 nucleotides; during replication or repair, U is recognized as T, resulting in a CÂ·G to TÂ·A conversion.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4873371/) This DSB-free mechanism substantially reduces insertions/deletions (indels) compared to traditional CRISPR-Cas9 editing, which relies on error-prone non-homologous end joining (NHEJ), though CBEs can produce bystander edits at adjacent cytosines and exhibit some off-target activity.[](https://www.nature.com/articles/s41573-020-0084-6)\n\nIn 2017, Gaudelli et al. extended base editing to adenine (A) bases with an adenine base editor (ABE), fusing an evolved tRNA adenosine deaminase (TadA*) to nCas9, enabling programmable AÂ·T to GÂ·C changes via deamination of A to inosine (I), which is templated as G during replication.[](https://www.nature.com/articles/nature24644) Subsequent optimizations, including second- and third-generation editors with uracil glycosylase inhibitor (UGI) fusions to suppress base excision repair pathways that could revert edits, have improved efficiency to over 50% in mammalian cells for many targets while minimizing indels to below 1%.[](https://www.nature.com/articles/s41573-020-0084-6) Base editors have demonstrated utility in correcting pathogenic point mutations, such as those in sickle cell disease models, but limitations persist, including restricted transition types (only CÂ·Gâ†’TÂ·A and AÂ·Tâ†’GÂ·C), PAM sequence constraints from Cas9, and potential RNA off-targeting from deaminase activity.[](https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05957-3)\n\nPrime editing, introduced by Andrew Anzalone and colleagues in David Liu's group in 2019, represents an advanced iteration that permits \"search-and-replace\" modifications, including all four transition types, small insertions (up to 44 nucleotides), and deletions (up to 80 nucleotides), without DSBs or donor DNA templates.[](https://www.nature.com/articles/s41586-019-1711-4) The system employs a prime editor proteinâ€”a fusion of nCas9 and a Moloney murine leukemia virus reverse transcriptase (M-MLV RT)â€”guided by a prime editing guide RNA (pegRNA) that extends beyond standard sgRNAs to include a reverse transcriptase template (RTT) specifying the desired edit and a primer binding site (PBS) for reverse transcription initiation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10989687/) Upon binding, nCas9 nicks the target strand (typically the non-template strand), the exposed 3' flap hybridizes to the PBS, and RT copies the RTT into a new DNA flap, which ligases into the genome after flap resolution, displacing the original sequence.[](https://www.nature.com/articles/s41586-019-1711-4) Initial efficiencies reached 20-50% for transitions in human cells with minimal indels (\u003c1-5%), outperforming homology-directed repair (HDR) in non-dividing cells, though prime editing historically suffers from lower yields for insertions/deletions and sensitivity to pegRNA design.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10989687/)\n\nEngineered variants, such as PE2 with an improved RT and PE3 incorporating an additional sgRNA for nicking the non-edited strand to bias repair, have boosted efficiencies up to 2.3-fold, while recent ePE and ProPE systems further expand the editing window and reduce byproducts.[](https://www.nature.com/articles/s41929-025-01406-6) Prime editing's versatility addresses base editing's limitations by enabling transversions indirectly via multi-step edits or hybrid approaches, with off-target rates comparable to or lower than Cas9 due to the requirement for precise RT priming.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10989687/) However, challenges include pegRNA production complexity, potential cellular toxicity from RT activity, and efficiencies still lagging behind DSB-based methods for some large edits, prompting ongoing refinements like smaller Cas variants for delivery.[](https://www.nature.com/articles/s41586-019-1711-4) Both technologies, recognized with the 2025 Breakthrough Prize in Life Sciences awarded to David Liu, exemplify a shift toward DSB-independent editing to enhance safety and precision in therapeutic contexts.[](https://www.the-scientist.com/david-liu-wins-2025-breakthrough-prize-for-base-editing-and-prime-editing-72888)\n\n### Novel and Hybrid Approaches\n\nNovel approaches in genome editing extend beyond conventional nuclease-based systems by incorporating elements such as transposases, integrases, and retrons to enable precise insertions, reductions in double-strand breaks (DSBs), and multiplexing capabilities. Hybrid systems, which fuse CRISPR-Cas components with other molecular machinery, aim to mitigate off-target effects and DSB-associated risks like indels or chromosomal rearrangements, while facilitating large payload integrations up to several kilobases. These innovations, emerging prominently since the early 2020s, prioritize DNA repair-independent mechanisms to enhance efficiency in therapeutic and research applications.[](https://www.nature.com/articles/s41587-025-02720-x)[](https://www.nature.com/articles/s41587-022-01527-4)\n\nCRISPR-associated transposases (CASTs) represent a hybrid class that couples type I CRISPR RNA-guided targeting with transposase activity for programmable DNA insertion. Unlike DSB-dependent methods, CASTs catalyze strand transfer to insert payloads without breaks, achieving efficiencies up to 40% in bacterial systems and demonstrating adaptability to eukaryotic cells through laboratory evolution. For instance, evoCAST variants, optimized via directed evolution, have enabled precise integrations in human cell lines with minimal off-target activity. These systems, identified in diverse prokaryotes, bypass homology-directed repair limitations and support cargo sizes exceeding 10 kb, positioning them for applications in gene therapy where stable, large-scale modifications are required.[](https://www.nature.com/articles/s41587-025-02720-x)[](https://pubmed.ncbi.nlm.nih.gov/40393858/)[](https://www.nature.com/articles/s41587-025-02720-x)\n\nProgrammable addition via site-specific targeting elements (PASTE) exemplifies a hybrid nuclease-integrase fusion, employing a CRISPR-Cas9 nickase linked to a reverse transcriptase and serine integrase for DSB-free large-sequence insertions. Developed in 2022, PASTE uses prime editing-inspired pegRNA to prime reverse transcription of donor DNA, followed by integrase-mediated attachment at nicked sites, yielding up to 25% efficiency for 36 kb inserts in human cells. This approach excels in replacing entire defective genes, such as modeling Duchenne muscular dystrophy by inserting micro-dystrophin cassettes, and avoids DSB toxicity, though delivery challenges persist for in vivo use.[](https://www.nature.com/articles/s41587-022-01527-4)[](https://www.nature.com/articles/s41587-022-01527-4)[](https://www.nature.com/articles/s41587-022-01527-4)\n\nRetron-based editing leverages bacterial retronsâ€”RNA-templated reverse transcriptases producing multi-copy single-stranded DNA (ssDNA)â€”as donor templates for precise homology-directed repairs, often hybridized with CRISPR-Cas for targeting. In a 2025 advancement, retron systems corrected large disease-related mutations in vertebrate models by excising defective regions and inserting healthy sequences, achieving higher fidelity than traditional donors due to in situ ssDNA generation. Efficiencies reach over 50% in mammalian cells when paired with Cas9, with retrons enabling multiplex edits via parallel msDNA production, though optimization for payload size and host compatibility continues. This method's repair independence from cell cycle phase broadens its utility across kingdoms.[](https://www.sciencedaily.com/releases/2025/10/251025084545.htm)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8892976/)[](https://phys.org/news/2025-10-gene-tech-repurposes-bacterial-retrons.html)\n\nMultiplex automated genome engineering (MAGE), a non-nuclease hybrid relying on recombineering with short ssDNA oligos and phage-derived recombinases, facilitates simultaneous edits at hundreds of loci in prokaryotes. Introduced around 2009 and refined for eukaryotes, MAGE cycles oligonucleotide electroporation with selection to evolve genomes rapidly, as seen in recoding *E. coli* with over 300 changes for non-canonical amino acid incorporation. While less reliant on sequence-specific nucleases, its integration with CRISPR hybrids enhances scalability for synthetic biology, though eukaryotic efficiencies lag at under 10% per site without further engineering.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4590770/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4590770/)[](https://www.nature.com/articles/nrg.2017.103)\n\n## Delivery Systems and Implementation Strategies\n\n### Viral and Non-Viral Delivery Methods\n\nViral vectors leverage the natural infectivity of viruses to deliver genome editing components, such as CRISPR-Cas nucleases and guide RNAs, into target cells with high efficiency. Adeno-associated viruses (AAVs), particularly serotypes like AAV2 and AAV9, are favored for their non-pathogenic nature, ability to transduce post-mitotic cells, and episomal persistence without genomic integration, supporting transient or long-term expression depending on the application. AAVs have a packaging limit of about 4.7-5 kb, restricting delivery to compact editing systems like SaCas9 or base editors, and have been used in over 150 clinical trials for gene therapies by 2023, including the FDA-approved Luxturna (voretigene neparvovec) in 2017 for RPE65-mediated retinal dystrophy via subretinal AAV delivery achieving sustained vision improvement. However, AAVs can elicit pre-existing neutralizing antibodies in up to 50-70% of humans, potentially reducing efficacy, and high doses may trigger innate immune responses or hepatotoxicity, as observed in a 2020 tragic trial outcome involving AAV for muscular dystrophy. Lentiviral vectors, derived from HIV-1, provide larger cargo capacity (up to 9 kb) and integrate into the host genome for stable expression, making them suitable for ex vivo editing of hematopoietic stem cells; they underpinned the FDA approval of Kymriah (tisagenlecleucel) in 2017 for leukemia via CD19 knockout. Drawbacks include risks of insertional oncogenesis, evidenced by rare leukemia cases in early SCID trials, and production scalability issues despite advances in integrase-defective variants that promote non-integrating episomal delivery to mitigate genotoxicity. Adenoviral vectors offer high transient expression and larger payloads but provoke strong inflammatory responses, limiting their use to short-term editing in non-immunoprivileged tissues.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/)[](https://www.nature.com/articles/s41392-021-00487-6)\n\nNon-viral delivery systems circumvent viral immunogenicity and integration risks by employing synthetic or physical carriers for editing components, often as mRNA, plasmids, or ribonucleoproteins (RNPs) to enable transient activity that curtails prolonged off-target editing. Lipid nanoparticles (LNPs), composed of ionizable lipids, cholesterol, and PEG-lipids, encapsulate Cas9 mRNA and guide RNA for systemic in vivo delivery, achieving biodegradability and endosomal escape; they facilitated the first in vivo human CRISPR trial in 2021 for transthyretin amyloidosis (NTLA-2001), with a single dose yielding up to 96% serum protein reduction at 87% liver editing efficiency in phase 1 data reported in 2023. LNPs excel in scalabilityâ€”billions of doses produced for COVID-19 mRNA vaccines by 2021â€”and lower mutagenesis risk, but suffer from hepatic tropism, transient expression (hours to days), and potential lipid toxicity at high doses, with editing efficiencies often below 50% in extrahepatic tissues without targeting ligands. Polymer-based nanoparticles, such as polyethyleneimine (PEI) or poly(lactic-co-glycolic acid) (PLGA), offer customizable surface modifications for tissue specificity and protection against nuclease degradation, demonstrating 30-70% editing in mouse glioblastoma models via intracranial injection in 2021 studies. Physical methods like electroporation apply electric pulses to transiently permeabilize membranes, achieving high ex vivo efficiencies (up to 90%) in hard-to-transfect cells like primary T lymphocytes or stem cells without chemical additives, as in Casgevy (exagamglogene autotemcel) approved in 2023 for sickle cell disease following electroporation-mediated BCL11A editing. Yet, electroporation induces cytotoxicity (10-30% cell death) and is impractical for in vivo use due to tissue damage, while hydrodynamic injection or ultrasound-mediated delivery remains experimental with variable yields. Microinjection and nucleofection variants enhance precision in embryos or organoids but scale poorly for therapeutics.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/)[](https://www.nature.com/articles/s41392-023-01309-7)[](https://www.sciencedirect.com/science/article/pii/S2162253125000113)\n\n| Delivery Type | Key Advantages | Key Disadvantages | Typical Applications |\n|---------------|----------------|-------------------|----------------------|\n| Viral (e.g., AAV, Lentiviral) | High transduction efficiency (50-90% in vivo); natural tropism for tissues like liver, retina, CNS | Immunogenicity; limited cargo size (AAV); insertional risks (lentiviral); manufacturing complexity | In vivo therapeutics (e.g., ocular, hepatic editing); ex vivo stem cell modification |\n| Non-Viral (e.g., LNPs, Electroporation) | Reduced immunogenicity; transient expression minimizing off-targets; scalable production; no replication risk | Lower efficiency (10-70%); poor in vivo targeting without modifications; potential cytotoxicity | Ex vivo cell therapies (e.g., CAR-T); emerging in vivo mRNA/RNP delivery for systemic diseases |[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/)[](https://www.sciencedirect.com/science/article/pii/S2162253125000113)\n\nHybrid approaches, such as virus-like particles (VLPs) pseudotyped with viral envelopes but lacking genomes, combine viral entry efficiency with non-viral safety, delivering Cas9 RNPs with up to 40% editing in hepatocytes in 2024 preclinical models, though clinical translation lags due to optimization needs. Overall, viral methods dominate current clinical pipelines for their reliability, while non-viral innovations, propelled by mRNA vaccine successes, are advancing toward parity in efficiency and specificity, particularly for transient editing to enhance safety in therapeutic genome editing.[](https://www.nature.com/articles/s41565-024-01851-7)\n\n### Ex Vivo versus In Vivo Applications\n\nEx vivo genome editing involves extracting cells from a patient, modifying their genomes in a controlled laboratory environment using tools such as CRISPR-Cas9, and subsequently reintroducing the edited cells into the patient.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444435/) This approach allows for precise manipulation under optimized conditions, including electroporation or viral transduction for delivery, followed by selection or expansion of successfully edited cells to achieve high purity before transplantation.[](https://www.liebertpub.com/doi/10.1089/crispr.2024.0036) It is particularly suited for accessible cell types like hematopoietic stem and progenitor cells (HSPCs) or T cells, enabling applications in blood disorders and immunotherapies.[](https://pubmed.ncbi.nlm.nih.gov/40086687/)\n\nA primary advantage of ex vivo editing is the ability to mitigate off-target effects and immune responses by editing in isolation, with post-editing validation and enrichment ensuring only viable, correctly modified cells are used.[](https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2023.1248904/full) For instance, in the treatment of sickle cell disease (SCD) and transfusion-dependent beta-thalassemia, ex vivo CRISPR-Cas9 editing of patient-derived HSPCs to disrupt the BCL11A enhancer has led to approved therapies like Casgevy (exagamglogene autotemcel), authorized by the FDA in December 2023, demonstrating durable fetal hemoglobin induction and symptom amelioration in clinical trials with over 90% reduction in vaso-occlusive crises.[](https://innovativegenomics.org/news/crispr-clinical-trials-2024/) However, challenges include scalability of manufacturing, engraftment efficiency post-infusion, and limitation to ex vivo-accessible tissues, restricting broader use for non-hematopoietic conditions.[](https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501%2825%2900175-5)\n\nIn contrast, in vivo genome editing delivers editing componentsâ€”typically via lipid nanoparticles, adeno-associated virus (AAV) vectors, or other systemic/local methodsâ€”directly into the patient's body to target cells in situ.[](https://www.sciencedirect.com/science/article/pii/S0092867422003956) This method holds potential for treating organs like the liver, retina, or muscle, where cell extraction is impractical, by achieving site-specific modifications without surgical intervention.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867117/) Delivery innovations, such as liver-tropic AAVs or nanoparticle-encapsulated Cas9 ribonucleoproteins, have enabled transient expression to reduce prolonged off-target risks.[](https://www.sciencedirect.com/science/article/pii/S0092867422003956)\n\nKey benefits of in vivo approaches include broader tissue applicability and avoidance of ex vivo processing complexities, as evidenced by NTLA-2001, an in vivo CRISPR-Cas9 therapy targeting the TTR gene in hereditary transthyretin amyloidosis (hATTR), which achieved up to 87% serum TTR reduction in phase 1 trials via intravenous lipid nanoparticle delivery as of June 2021.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2107454) Early trials for Leber congenital amaurosis type 10 (LCA10) have also used subretinal AAV-CRISPR injections to edit CEP290 mutations, restoring partial visual function in preclinical models and initial human dosing by 2020.[](https://edhub.ama-assn.org/jn-learning/video-player/18468298) Nonetheless, hurdles persist, including inefficient targeting of non-dividing cells, potential immunogenicity of bacterial-derived Cas proteins, and amplified safety concerns from systemic distribution, with most trials still in early phases compared to ex vivo successes.[](https://www.sciencedirect.com/science/article/pii/S0092867422003956) Ongoing refinements in delivery specificity aim to bridge these gaps for scalable clinical translation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10018374/)\n\n| Aspect | Ex Vivo | In Vivo |\n|--------|---------|---------|\n| **Primary Applications** | Hematologic disorders (e.g., SCD, beta-thalassemia), T-cell therapies for cancer | Liver diseases (e.g., hATTR), ocular disorders (e.g., LCA10), neuromuscular conditions |\n| **Delivery Methods** | Electroporation, lentiviral/retroviral vectors in vitro | AAV vectors, lipid nanoparticles, direct injection |\n| **Advantages** | High editing purity via selection; controlled environment reduces immunogenicity | Targets inaccessible tissues; no cell extraction needed |\n| **Challenges** | Limited to harvestable cells; manufacturing and engraftment variability | Delivery efficiency; off-target effects in vivo; immune clearance of editors |\n| **Clinical Status (as of 2025)** | Multiple approvals (e.g., Casgevy, 2023); dozens of trials | Phase 1/2 trials dominant (e.g., NTLA-2001, 2021 onward); no approvals yet |[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/)[](https://www.nejm.org/doi/full/10.1056/NEJMoa2107454)\n\n## Technical Performance Metrics\n\n### Precision, Efficiency, and Off-Target Effects\n\nPrecision in genome editing refers to the accuracy with which a nuclease targets the intended DNA sequence, minimizing unintended modifications elsewhere in the genome. Early tools like meganucleases exhibit high specificity due to their large recognition domains spanning 12-40 base pairs, but their engineering is labor-intensive, limiting widespread use.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/) Zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) achieve greater specificity than initial CRISPR systems through modular protein-DNA interactionsâ€”ZFNs recognizing 9-18 base pairs via zinc finger arrays and TALENs targeting longer stretches with TALE repeatsâ€”resulting in off-target mutation rates often below 0.1% in optimized designs, though efficiencies typically range from 10-50% in mammalian cells due to delivery and repair pathway dependencies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/)[](https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-cons-of-znfs-talens-and-crispr-cas)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8655392/)\n\nCRISPR-Cas9 systems revolutionized efficiency, enabling editing rates exceeding 80% in many cell types via simple guide RNA (gRNA) design, but early implementations showed off-target cleavage frequencies up to 93.6% at mismatched sites due to tolerance for 1-5 nucleotide mismatches and PAM-adjacent positioning.[](https://www.sciencedirect.com/science/article/pii/S216225311630049X)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10266473/) GUIDE-seq and similar assays revealed off-target rates of 0.1-5% genome-wide in human cells, varying by gRNA sequence and Cas9 variant, with double-strand breaks (DSBs) at non-target sites triggering indels or rearrangements via non-homologous end joining (NHEJ).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/) High-fidelity Cas9 mutants (e.g., SpCas9-HF1, eSpCas9) and paired nickases reduce these by 10- to 100-fold through enhanced gRNA-DNA hybridization stringency, though empirical validation remains essential as in silico predictions underestimate effects by up to 50%.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10802171/)[](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full)\n\nEfficiency metrics, often measured as indel formation or homology-directed repair (HDR) yield, favor CRISPR over ZFNs and TALENsâ€”e.g., CRISPR achieving 2-10x higher on-target editing in HEK293 cellsâ€”but HDR remains low (1-20%) across platforms due to NHEJ dominance in dividing cells.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8655392/)00111-9) Base editors and prime editors enhance precision by enabling single-base conversions or small indels without DSBs: cytosine base editors (CBEs) and adenine base editors (ABEs) convert CÂ·G to TÂ·A or AÂ·T to GÂ·C with off-target rates under 0.5%, while prime editors install diverse edits (insertions up to 44 bp, deletions) at 20-50% efficiency, minimizing bystander edits and genomic instability compared to DSB-based methods.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8968349/)[](https://www.nature.com/articles/s12276-025-01463-8)[](https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05957-3) These advances, validated in cellular and animal models, underscore causal links between nuclease architecture, mismatch tolerance, and repair outcomes, with ongoing quantification via unbiased sequencing essential for therapeutic viability.[](https://www.nature.com/articles/s41392-024-01750-2)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10989687/)\n\n### Strategies for Enhancing Specificity and Yield\n\nOne prominent strategy for improving specificity involves engineering high-fidelity variants of the Cas9 nuclease to reduce non-specific DNA binding. For instance, SpCas9-HF1 incorporates alanine substitutions at residues N497, R661, Q695, and Q926, which disrupt extraneous interactions with the phosphate backbone, leading to undetectable off-target cleavage events via GUIDE-seq for six out of seven tested single-guide RNAs (sgRNAs) in human cells, while preserving greater than 85% of wild-type on-target activity across 32 sgRNAs.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4851738/) Similarly, the Sniper2L variant, derived from directed evolution of predecessor Sniper-Cas9 with an E1007L mutation in the RuvC domain, maintains on-target indel frequencies comparable to wild-type SpCas9 (up to 50% in HEK293T cells) but exhibits markedly lower off-target indel rates across over 7,000 NGG PAM targets, quantified by a specificity metric of 1 minus the ratio of off-target to on-target frequencies.[](https://www.nature.com/articles/s41589-023-01279-5)\n\nAdditional molecular optimizations enhance specificity by altering guide RNA architecture or nuclease deployment. Truncated sgRNAs (12-18 nucleotides in the spacer) limit the editing window and mismatch tolerance, reducing off-target effects by up to 5-fold in some assays without substantially compromising on-target efficiency.[](https://www.sciencedirect.com/science/article/pii/S1097276516303318) Paired Cas9 nickases, utilizing dual sgRNAs to generate staggered single-strand nicks offset by 4-100 base pairs, further enforce dual-site recognition, achieving near-complete elimination of off-target double-strand breaks compared to wild-type Cas9 in human cell lines.14619-1) Protocol-level adjustments, such as transient delivery of Cas9 ribonucleoproteins (RNPs) at low concentrations or during specific cell cycle phases, temporally restrict nuclease activity to minimize prolonged exposure and bystander cuts.[](https://www.sciencedirect.com/science/article/pii/S1525001620306079)\n\nTo boost editing yield, particularly for homology-directed repair (HDR) pathways that enable precise insertions or substitutions but occur at rates below 10% in dividing cells due to competition from error-prone non-homologous end joining (NHEJ), strategies target repair pathway bias. Chemical inhibition of NHEJ factors, such as ligation with SCR7 (which blocks DNA ligase IV), combined with HDR-promoting agents like RS-1 (an RAD51 stimulator), has increased HDR efficiency 2- to 5-fold in HEK293T and K562 cells for targeted knock-ins.[](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00691/full) Cell cycle synchronization via nocodazole arrest in G2/M phase, where HDR machinery peaks, yields up to 3-fold HDR gains, as endogenous repair favors template-directed synthesis during mitosis preparation.[](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00691/full) Donor template optimizations, including single-stranded oligodeoxynucleotides (ssODNs) positioned within 20-100 base pairs of the cut site, further elevate yields by facilitating invasion of the Cas9-generated overhang.[](https://blog.addgene.org/3-tips-for-improving-hdr-efficiency-for-editing-human-cells-with-crispr)\n\nPost-editing enrichment methods amplify yield by selecting edited subpopulations without relying solely on intrinsic efficiencies. HDR surrogate reporters, featuring a frameshifted coding sequence (e.g., BFP to GFP conversion) restored only via precise template integration, enable fluorescence-activated cell sorting to enrich knock-in events by 20.7-fold (from 2.22% to 45.93%) in human cell lines.[](https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00943-1) NHEJ-based reporters similarly select for nuclease-proficient cells, achieving up to 39-fold increases in indel frequencies for genes like TP53.[](https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00943-1) Modular ssDNA donors paired with NHEJ inhibitors or HDR enhancers have reported HDR rates exceeding 90% in optimized systems, though scalability to primary cells remains context-dependent due to variable repair dynamics.[](https://www.nature.com/articles/s41467-024-50788-x) These approaches, while effective, often involve trade-offs, such as potential toxicity from inhibitors or reduced multiplexing capacity.\n\n## Practical Applications\n\n### Therapeutic Uses in Human Medicine\n\nGenome editing technologies, particularly CRISPR-Cas9, have enabled targeted correction of disease-causing mutations in human cells for therapeutic purposes, focusing initially on monogenic disorders amenable to ex vivo modification of accessible cell types like hematopoietic stem cells (HSCs). The pioneering approval of exagamglogene autotemcel (Casgevy) by the U.S. Food and Drug Administration on December 8, 2023, marked the first clinical use of CRISPR-based editing for sickle cell disease (SCD) and transfusion-dependent Î²-thalassemia (TDT).[](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease) This therapy involves extracting patient HSCs, using CRISPR-Cas9 to disrupt the BCL11A enhancer to reactivate fetal hemoglobin (HbF) expression, and reinfusing the edited cells after myeloablative conditioning.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2031054) In phase 1/2 trials, 29 of 31 SCD patients remained free of severe vaso-occlusive crises for at least 12 months post-infusion, with HbF levels reaching 30-40% in most cases, demonstrating durable engraftment and clinical benefit.\n\nBeyond hemoglobinopathies, ex vivo editing targets other blood-related conditions and immunotherapies. CRISPR-edited allogeneic CAR-T cells are in trials for cancers like multiple myeloma and B-cell malignancies, aiming to enhance persistence by knocking out PD-1 or TCR genes to reduce exhaustion and graft-versus-host risks.[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/) For primary immunodeficiencies such as severe combined immunodeficiency (SCID), trials edit autologous HSCs to restore functional IL2RG expression, with early data showing immune reconstitution in X-SCID patients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425811/) These approaches leverage the accessibility of blood cells but require chemotherapy preconditioning, limiting applicability to non-hematopoietic tissues.\n\nIn vivo editing, delivering nucleases directly to target organs via lipid nanoparticles or AAV vectors, addresses systemic diseases but faces challenges in efficiency and off-target risks. Intellia's NTLA-2001, targeting TTR mutations in hereditary transthyretin amyloidosis (ATTR), achieved up to 87% serum TTR reduction in phase 1/2 trials with a single dose, with phase 3 data expected by late 2025 supporting potential approval for cardiomyopathy and polyneuropathy.[](https://crisprmedicinenews.com/clinical-trials/) For Leber congenital amaurosis type 10, Editas Medicine's EDIT-101 (AAV-delivered CRISPR) improved visual acuity in 79% of treated eyes in the phase 1/2 BRILLIANCE trial, though long-term efficacy remains under evaluation.[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/) Emerging pipelines explore in vivo applications for muscular dystrophy (e.g., editing DMD exons), cystic fibrosis (CFTR correction in lung epithelium), and HIV (CCR5 disruption in CD4+ T cells), with over 150 active CRISPR trials as of mid-2025 spanning these areas, though most remain in phases 1-2 due to delivery and immunogenicity hurdles.[](https://crisprmedicinenews.com/clinical-trials/) Base and prime editing variants promise higher precision for point mutations, with preclinical advances in trials for SCD alternatives and alpha-1 antitrypsin deficiency.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/)\n\n![CRISPR-based genome editing in therapeutic contexts](./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png)\n\nTherapeutic editing's success hinges on disease biology favoring high editing rates (e.g., \u003e20% allelic correction in HSCs for HbF induction) and tolerable safety profiles, with adverse events primarily from conditioning rather than editing itself in approved cases.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2031054) Ongoing challenges include scalability for rare diseases and equitable access, as Casgevy's list price exceeds $2 million per treatment.[](https://thalassemia.org/FDA-Approves-Vertex-CRISPRs-Gene-Editing-Therapy) No additional genome editing therapies have gained regulatory approval by October 2025, underscoring the field's nascent stage despite rapid trial expansion.[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/)\n\n### Agricultural and Plant Breeding Improvements\n\nGenome editing has revolutionized plant breeding by enabling precise modifications to endogenous genes, bypassing the lengthy cycles of conventional cross-breeding and reducing reliance on random mutagenesis. Technologies like CRISPR-Cas9 allow for targeted knockouts, insertions, or base edits that introduce traits such as enhanced yield or stress tolerance without incorporating foreign DNA, distinguishing them from transgenic GMOs.[](https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1478398/full) By 2024, over 25 plant species had been successfully edited across more than 100 genes, yielding improvements in agronomic performance.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11164064/)\n\nIn disease resistance, CRISPR-mediated editing has targeted susceptibility genes to confer broad-spectrum protection. For instance, in wheat, multiplexed editing of TaMLO genes produced varieties resistant to powdery mildew, a fungal pathogen causing significant yield losses, with edited lines showing up to 90% reduced infection rates under field conditions.[](https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1478398/full) Similar approaches in rice have disrupted SWEET genes to enhance resistance to bacterial blight, while in bananas, editing of susceptibility loci has improved tolerance to Fusarium wilt, a devastating soil-borne disease threatening global production.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11362101/) These modifications demonstrate causal links between gene disruption and pathogen evasion, validated through controlled inoculation trials.[](https://genomebiology.biomedcentral.com/articles/10.1186/s13059-020-02204-y)\n\nFor yield and abiotic stress tolerance, editing phytohormone pathways has shortened plant stature in barley via gibberellin-related mutants, reducing lodging and boosting harvest index without yield penalties.[](https://www.sciencedirect.com/science/article/pii/S2666154324001698) In maize and soybeans, CRISPR edits to flowering-time genes have accelerated maturity, enabling adaptation to shorter growing seasons amid climate variability, with field trials reporting 10-20% yield increases under drought stress.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8929161/) Nutritional enhancements include elevating Î²-carotene levels sixfold in rice and bananas through PSY gene activation, addressing vitamin A deficiencies in staple crops consumed by billions.[](https://nhsjs.com/2025/crispr-cas9-application-in-crop-biotechnology-a-decade-of-research-2014-to-2024-toward-food-security-in-developing-countries/)\n\nRegulatory frameworks influence deployment: the U.S. USDA exempts certain site-directed nuclease-1 (SDN-1) editsâ€”those mimicking natural mutationsâ€”from oversight if no plant pest risks are introduced, as revised in 2020 regulations, enabling commercialization of products like herbicide-tolerant canola by 2023.[](https://www.congress.gov/crs-product/R47683) In contrast, the EU's precautionary approach classifies most edited plants as GMOs under Directive 2001/18/EC, imposing rigorous assessments despite absent transgenes, though a 2023 proposal seeks to deregulate \"NGT-1\" plants akin to conventional varieties.[](https://www.europarl.europa.eu/RegData/etudes/BRIE/2023/754549/EPRS_BRI%282023%29754549_EN.pdf) This disparity highlights how evidence-based risk assessments in the U.S. have accelerated adoption, with over a dozen edited crops entering markets by 2024, versus stalled EU pipelines.[](https://innovativegenomics.org/news/crispr-in-agriculture-2024/) Empirical data from multi-year field studies underscore the safety and efficacy of these edits, with no verified off-target effects leading to unintended traits in commercial lines.[](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/biot.70113)\n\n### Animal Models and Basic Research\n\nGenome editing technologies, particularly CRISPR-Cas9, have enabled the rapid generation of genetically modified animal models that recapitulate human disease phenotypes and elucidate gene functions in vivo. Unlike earlier methods such as zinc-finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs), which required complex protein engineering, CRISPR systems use guide RNAs for programmable targeting, achieving higher efficiency in zygote injection and embryonic stem cell modification across species.[](https://www.sciencedirect.com/science/article/abs/pii/S1877117317301205) This has accelerated basic research by allowing multiplexed knockoutsâ€”simultaneous disruption of multiple genesâ€”to study genetic interactions and pathways, as demonstrated in mouse models where CRISPR achieved editing efficiencies exceeding 80% in founder animals.[](https://www.nature.com/articles/s41598-017-16328-y)\n\nIn rodents, CRISPR-Cas9 has been pivotal for modeling monogenic and polygenic diseases. For instance, targeted knockouts in mice have revealed causal roles of specific genes in neurodegeneration, such as Apolipoprotein E variants in Alzheimer's disease pathology, with models exhibiting amyloid plaque accumulation and tau hyperphosphorylation mirroring human autopsy findings.[](https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-015-0031-x) Rat models, optimized via electroporation of Cas9 protein and single-guide RNAs into zygotes, have improved behavioral assays for psychiatric disorders, yielding mutation rates up to 100% for single loci without off-target indels in coding regions.[](https://www.nature.com/articles/s41598-017-16328-y) These models surpass traditional transgenic approaches in speed, with full germline transmission achievable in one generation, facilitating causal inference through loss-of-function studies.[](https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1409-1)\n\nZebrafish and Xenopus serve as high-throughput platforms for developmental and metabolic research due to their optical transparency and external fertilization, enabling real-time imaging of edited embryos. CRISPR-induced mutations in zebrafish have modeled skeletal dysplasias, such as those from Col2a1 disruptions, uncovering mechanisms of cartilage formation absent in cell culture systems.[](https://www.sciencedirect.com/science/article/pii/S2001037019300443) Base editing variants, which introduce precise single-nucleotide changes without double-strand breaks, have expanded this to point mutation models of metabolic syndromes, achieving correction efficiencies of 20-50% in vivo and reducing mosaicism compared to standard CRISPR.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12133889/) In larger mammals like pigs, TALENs and CRISPR have generated models for cardiovascular diseases by knocking out PCSK9, resulting in hypercholesterolemia phenotypes validated against human lipid profiles.[](https://www.mdpi.com/1467-3045/47/5/330)\n\nThese animal models underscore genome editing's utility in dissecting causal gene-environment interactions, though limitations persist: species-specific differences in DNA repair pathways can alter editing outcomes, and off-target effects, though minimized to below 1% with high-fidelity Cas9 variants, necessitate rigorous validation via whole-genome sequencing.[](https://www.sciencedirect.com/science/article/abs/pii/S0278584617300386) Ongoing refinements, including prime editing for scarless insertions, promise even greater fidelity for basic research into complex traits.[](https://www.nature.com/articles/s12276-025-01514-0)\n\n### Industrial Biotechnology\n\nIn industrial biotechnology, genome editing technologies such as CRISPR-Cas9 have enabled precise modifications to microbial genomes, optimizing metabolic pathways for the scalable production of biofuels, biochemicals, enzymes, and amino acids. These tools facilitate targeted knockouts, insertions, and promoter optimizations in organisms like *Escherichia coli*, *Saccharomyces cerevisiae*, and *Clostridium* species, which are commonly used in fermentation processes. By altering genes involved in substrate utilization, byproduct inhibition, and product flux, editing enhances yields and process efficiency, reducing reliance on chemical synthesis and fossil fuels.[](https://www.mdpi.com/2311-5637/11/7/410)[](https://www.sciencedirect.com/science/article/pii/S2667370323000334)\n\nFor biofuel production, CRISPR-Cas9 has been applied to improve solventogenesis in anaerobic bacteria. In *Clostridium beijerinckii*, editing alcohol dehydrogenase genes (*adhE1* and *adhE2*) increased n-butanol titers while maintaining strain stability, addressing acid buildup that hampers industrial scalability. Similarly, in *Clostridium acetobutylicum*, disruption of acid formation pathways shifted metabolism toward butanol, elevating the butanol-to-acetate ratio and supporting higher solvent yields. In yeast, overexpression of lipid elongation genes via CRISPR boosted ethanol productivity, with reported improvements in *S. cerevisiae* strains for bioethanol fermentation as of 2021.[](https://www.mdpi.com/2311-5637/11/7/410)\n\nChemical production has seen notable gains through microbial chassis engineering. CRISPR-mediated deletions of eight genes in *S. cerevisiae* amplified fatty acid output by 30-fold, enabling efficient conversion of glucose to lipids for bioderived fuels or materials. In *Klebsiella pneumoniae*, pathway optimizations yielded a ~50% increase in 1,3-propanediol, a precursor for polymers, demonstrated in 2022 studies. For *E. coli*, editing lactate dehydrogenase (*ldhA*), alcohol dehydrogenase (*adhE*), and related genes raised succinate production to 80 g/L, a key dicarboxylic acid for bioplastics. Bacterial strains engineered for squalene from glucose achieved high-efficiency terpenoid synthesis by 2019.[](https://www.genengnews.com/resources/crispr-made-greener-products-and-processes-in-industrial-biotechnology/)[](https://www.mdpi.com/2311-5637/11/7/410)\n\nEnzyme and amino acid biosynthesis benefit from cofactor balancing and secretion enhancements. In *Corynebacterium glutamicum*, CRISPR targeting NADPH supply genes and promoters improved L-glutamate titers for feed and pharmaceuticals, with advancements reported in 2021. *Bacillus subtilis* strains edited at the *PrsA* chaperone locus exhibited enhanced amylase secretion in 2024, streamlining industrial enzyme production for detergents and biofuels. Tryptophan yields in *E. coli* rose ~40% via enzyme pathway tweaks in 2019, while *Aspergillus niger* optimizations for citric acid fermentation improved efficiency by 2019. Companies like Ginkgo Bioworks leverage these techniques for custom microbial factories producing pharmaceuticals and fine chemicals.[](https://www.genengnews.com/resources/crispr-made-greener-products-and-processes-in-industrial-biotechnology/)[](https://www.mdpi.com/2311-5637/11/7/410)\n\n## Clinical Translation and Regulatory Milestones\n\n### Landmark Trials and Approved Therapies\n\nThe first approved genome editing therapy utilizing CRISPR-Cas9, Casgevy (exagamglogene autotemcel), received U.S. Food and Drug Administration (FDA) approval on December 8, 2023, for sickle cell disease (SCD) in patients aged 12 years and older with recurrent vaso-occlusive crises requiring annual intravenous infusions. Developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy employs ex vivo editing to disrupt the BCL11A enhancer in hematopoietic stem cells, thereby reactivating fetal hemoglobin production to mitigate SCD's pathological effects. Approval for transfusion-dependent beta-thalassemia (TDT) followed on January 16, 2024, based on phase 1/2/3 trials (CLIMB-121 for SCD and CLIMB-131 for TDT) demonstrating 96.6% of SCD patients free from severe vaso-occlusive crises at 12 months post-infusion and 93.5% of TDT patients achieving transfusion independence at the same interval, though outcomes required myeloablative chemotherapy preconditioning with associated risks including infertility and secondary malignancies.[](https://news.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval)[](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/)\n\nPreceding Casgevy's approval, the inaugural human application of CRISPR occurred in October 2016 at Sichuan University in China, where three patients with advanced non-small-cell lung cancer received autologous T cells edited via CRISPR-Cas9 to knock out the PD-1 gene, aiming to enhance antitumor immunity; phase 1 data reported in 2020 confirmed feasibility and absence of severe off-target effects or oncogenic insertions, though clinical responses were modest with no complete remissions observed.[](https://www.nature.com/articles/s41392-020-00283-8)[](https://crisprmedicinenews.com/news/first-chinese-crispr-gene-therapy-trial-demonstrates-safety/) In the United States, the first CRISPR trial commenced in 2019 under University of Pennsylvania leadership, infusing patients with refractory cancers (melanoma, synovial sarcoma, multiple myeloma) with T cells edited to express a NY-ESO-1-specific T-cell receptor alongside knockouts of PD-1 and TRAC loci; interim phase 1 results indicated durable persistence of edited cells and objective responses in some participants, establishing safety for multiplex editing without unanticipated genotoxicity.[](https://www.npr.org/sections/health-shots/2019/04/16/712402435/first-u-s-patients-treated-with-crispr-as-gene-editing-human-trials-get-underway)[](https://pubmed.ncbi.nlm.nih.gov/29173170/)\n\nA pivotal advancement in in vivo genome editing materialized in March 2020 at Oregon Health \u0026 Science University (OHSU), marking the first direct intraocular injection of CRISPR-Cas9 components (via AAV5 vector) to treat Leber congenital amaurosis caused by CEP290 mutations; the phase 1/2 trial (NCT03872479) targeted the IVS26 intronic variant, with initial safety data from the first cohort showing no serious adverse events and modest visual acuity improvements in some eyes at 6 months, though efficacy varied and long-term immunogenicity risks persisted.[](https://news.ohsu.edu/2020/03/04/ohsu-performs-first-ever-crispr-gene-editing-within-human-body) Complementing ex vivo successes, Intellia Therapeutics and Regeneron's NTLA-2001 trial in 2021 represented the first systemic in vivo CRISPR application for transthyretin amyloidosis, achieving up to 87% serum protein reduction at single 0.3 mg/kg doses in phase 1, with durable effects through 24 months and no dose-limiting toxicities, underscoring CRISPR's potential for liver-directed editing without cell extraction.[](https://www.nature.com/articles/d41586-021-01776-4)\n\nBy 2025, Casgevy remained the sole fully approved CRISPR-based therapy globally, with conditional authorizations from the European Medicines Agency for TDT in December 2023 and SCD thereafter, alongside Saudi FDA approval in January 2024 for both indications in patients 12 and older; no additional approvals had materialized despite over 250 ongoing trials, many targeting oncology and autoimmune disorders via allogeneic edited cells like CRISPR Therapeutics' CTX112.[](https://thalassaemia.org.cy/clinical-trial-updates-scd/exa-cel-gene-editing/)[](https://crisprtx.com/pipeline) A notable 2025 milestone involved the first personalized CRISPR therapy administered to a pediatric patient with a rare metabolic disorder at Children's Hospital of Philadelphia and Penn Medicine, using base editing to correct a unique patient-specific mutation ex vivo, demonstrating rapid metabolic normalization without evident toxicity in this single-case intervention reported in May.[](https://www.chop.edu/news/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital) These developments highlight empirical progress in safety and targeted efficacy, tempered by challenges in scalability, preconditioning toxicities, and off-target editing verification across diverse genetic backgrounds.[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/)\n\n### Global Research Pipelines and Challenges\n\nGlobal research pipelines in genome editing, particularly CRISPR-based therapies, have expanded rapidly, with approximately 250 clinical trials registered worldwide as of February 2025, of which over 150 remain active, primarily targeting blood disorders, cancers, and inherited conditions.[](https://crisprmedicinenews.com/clinical-trials/) Leading efforts are concentrated in the United States, where companies like CRISPR Therapeutics advance in vivo editing programs such as CTX310 (Phase 1 trial initiated for cardiovascular disease via ANGPTL3 targeting, with data expected in late 2025) and CTX320 (ongoing Phase 1 for hereditary angioedema).[](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-late-breaking-data-american-heart)[](https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-first-quarter-2025-financial) In Europe and China, pipelines focus on ex vivo applications, including Editas Medicine's use of Cas9 and Cas12a nucleases for ocular and blood disorders, while Chinese trials emphasize scalable manufacturing for hemoglobinopathies.[](https://www.editasmedicine.com/gene-editing-pipeline/) By late 2024, over 50 active treatment centers operated globally, spanning at least 46 countries, though the U.S. hosts the majority of advanced-stage trials.[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/) Broader gene editing efforts contribute to nearly 3,500 preclinical and clinical programs in cell and gene therapies, reflecting a shift toward multiplex editing and prime editing for complex diseases like HIV and diabetes.[](https://www.asgct.org/news-publications/landscape-report)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/)\n\nKey pipelines integrate diverse editing modalities, with CRISPR Therapeutics pursuing immuno-oncology and regenerative medicine alongside approved ex vivo therapies like Casgevy for sickle cell disease.[](https://crisprtx.com/pipeline) Emerging in vivo trials, such as those targeting lipid disorders, demonstrate progress in non-viral delivery systems, though most remain in early phases (Phase 1/2).[](https://www.synthego.com/blog/crispr-clinical-trials) International collaborations, including those under the Innovative Genomics Institute, aim to standardize protocols, but pipelines vary by region: U.S.-led efforts prioritize FDA-aligned safety data, while China's National Medical Products Administration (NMPA) has approved faster tracks for certain ZFNs and CRISPR applications in oncology.[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/)\n\nChallenges in clinical translation persist across technical, regulatory, and logistical domains. Off-target edits and structural variations, including unintended deletions of regulatory elements, pose genotoxic risks that demand enhanced specificity assays beyond standard sequencing.[](https://www.nature.com/articles/s41467-025-62606-z) Delivery remains a bottleneck, with viral vectors facing immune responses and scalability issues, while non-viral alternatives like lipid nanoparticles yield lower efficiencies in vivo.[](https://advanced.onlinelibrary.wiley.com/doi/10.1002/adfm.202402630) Regulatory hurdles exacerbate delays: disparate frameworks between the FDA, EMA, and NMPA complicate multinational trials, with unclear guidelines on good manufacturing practice (GMP) reagents and long-term biodistribution data hindering approvals.[](https://www.synthego.com/blog/crispr-cell-gene-therapy-obstacles)[](https://www.synthego.com/blog/regulatory-trends-therapies)\n\nManufacturing scalability and cost represent additional barriers, as personalized ex vivo editing inflates expensesâ€”often exceeding $2 million per patientâ€”limiting access despite curative potential in trials for blood cancers.[](https://innovativegenomics.org/news/crispr-clinical-trials-2024/) Ethical and safety considerations, including non-clinical requirements for germline off-target scrutiny even in somatic applications, slow progression, with calls for platform-based regulatory solutions to harmonize global standards.[](https://www.liebertpub.com/doi/10.1089/crispr.2025.0049)[](https://www.sciencedirect.com/science/article/pii/S2352304225002740) Despite these, empirical successes in Phase 3 trials underscore feasibility, though unresolved uncertainties in durable editing efficacy necessitate rigorous, multi-year follow-up.[](https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0475-4)\n\n## Risks and Empirical Limitations\n\n### Biological Hazards and Failure Modes\n\n![DNA break repair mechanisms underlying failure modes in CRISPR editing](./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png)\nGenome editing via CRISPR-Cas9 induces double-strand breaks that are primarily repaired by error-prone non-homologous end joining (NHEJ), leading to insertions or deletions (indels) that frequently cause frameshift mutations and gene disruption.[](https://www.sciencedirect.com/science/article/pii/S0092867424001119) Off-target effects arise from Cas9 cleaving unintended sites due to sequence mismatches tolerated up to three base pairs, resulting in unintended mutations at frequencies as low as 0.03% but potentially higher depending on guide RNA design.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/) Mosaicism occurs when editing efficiency varies across cells, particularly in embryos, producing heterogeneous populations with mixed edited and unedited genotypes, complicating therapeutic outcomes and germline transmission.[](https://www.sciencedirect.com/science/article/pii/S0012160618302513)\n\nOn-target aberrations include large-scale structural variations such as kilobase- to megabase-scale deletions, chromosomal truncations, and chromothripsis, often undetected by short-read sequencing.[](https://www.nature.com/articles/s41467-025-62606-z) Chromosomal translocations between homologous or heterologous sites can form unstable dicentric or acentric chromosomes, with frequencies amplified up to 1000-fold by certain DNA repair inhibitors.[](https://www.nature.com/articles/s41467-025-62606-z) In clinical contexts, such as BCL11A editing in exa-cel therapy for sickle cell disease, kilobase deletions have been observed, potentially disrupting erythropoiesis.[](https://www.nature.com/articles/s41467-025-62606-z)\n\nBiological hazards encompass immune responses against Cas9 proteins, particularly in patients with pre-existing antibodies, which can destroy edited cells and undermine efficacy in vivo applications.[](https://www.nature.com/articles/s41467-018-05843-9) These failure modes heighten oncogenic risks if edits affect proto-oncogenes or tumor suppressors, as unintended structural changes or indels may promote genomic instability and tumorigenesis.[](https://www.nature.com/articles/s41467-025-62606-z) Large DNA insertions or deletions induced by CRISPR have been empirically linked to increased cancer risk in cell models.[](https://www.nature.com/articles/s42003-021-01942-4) Overall, while mitigation strategies like high-fidelity Cas9 variants reduce off-target rates by up to 98.7%, persistent uncertainties in long-read detection underscore the need for comprehensive safety assessments.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/)\n\n### Long-Term Safety Data and Uncertainties\n\nAs of 2025, long-term safety data for genome editing technologies, particularly CRISPR-Cas systems, remains limited due to their relatively recent development and deployment, with most human applications initiated post-2018. Animal studies provide the primary longitudinal evidence; for instance, in mouse models of retinal editing, CRISPR-Cas9 modifications demonstrated sustained efficacy and low off-target mutation rates (1.28% at 196 days post-injection, rising modestly to 2.27% at 585 days), with no overt toxicity observed over nearly two years.[](https://www.nature.com/articles/s42003-021-01942-4) Similarly, non-human primate trials for conditions like hemophilia have shown stable edits persisting for over a year without systemic adverse effects, though sample sizes are small and follow-up durations rarely exceed three years.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/) These findings suggest short- to medium-term stability in controlled somatic applications, but extrapolation to humans requires caution given species-specific differences in DNA repair and immune responses.\n\nIn human clinical contexts, approved therapies like exagamglogene autotemcel (Casgevy) for sickle cell disease and beta-thalassemia, authorized by the FDA in December 2023, have reported no off-target-related adverse events in initial follow-ups of up to two years, with patients achieving durable hemoglobin corrections.[](https://innovativegenomics.org/news/crispr-clinical-trials-2025/) However, these datasets derive from small cohorts (e.g., 44 patients in pivotal trials), and long-term monitoringâ€”essential for detecting delayed risks such as oncogenesis from unrepaired double-strand breaksâ€”is ongoing but incomplete, with median follow-up under three years as of mid-2025.[](https://www.labiotech.eu/in-depth/crispr-cas9-review-gene-editing-tool/) Peer-reviewed analyses of early trials emphasize that while base editing and prime editing variants reduce off-target frequencies to below 1% in vitro, real-world genomic instability, including large deletions or translocations, has been documented in up to 5% of edited human cell lines.[](https://www.nature.com/articles/s41467-025-62606-z)[](https://frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full)\n\nKey uncertainties stem from potential cumulative effects of off-target edits, which could induce chromosomal rearrangements or activate proto-oncogenes, as evidenced by in vitro studies showing persistent DNA aberrations even with high-fidelity Cas9 variants.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/) In germline editing, absent from approved uses but pursued in research, mosaicism and heritable mutations pose amplified risks, with animal models revealing unintended structural variants propagating across generations.[](https://www.nature.com/articles/s41467-025-62606-z) Delivery vectors like AAV may trigger immune-mediated clearance or insertional mutagenesis over decades, untested in humans beyond preliminary data.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/) Reviews highlight epistemic gaps, including understudied epigenetic perturbations and interactions with environmental factors, underscoring the need for multi-decade observational studies to quantify risks empirically rather than rely on predictive models.[](https://www.cell.com/cell/fulltext/S0092-8674%2824%2900111-9) While no causal links to cancer or other late-onset pathologies have been confirmed in edited organisms to date, the absence of evidence does not equate to evidence of absence, given the technology's decade-long timeline.[](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full)\n\n## Ethical and Societal Dimensions\n\n### Germline Editing and Heritability Concerns\n\nGermline editing refers to the application of genome editing technologies, such as CRISPR-Cas9, to germ cells, zygotes, or early-stage embryos, resulting in modifications that are incorporated into the heritable genome and transmitted to subsequent generations.00560-3/fulltext) Unlike somatic editing, which affects only the treated individual, germline alterations propagate through the population, amplifying the consequences of any errors or unintended outcomes across familial lineages.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6791475/)\n\nA primary concern with heritable editing is the persistence and potential accumulation of off-target effects, where the editing machinery induces unintended mutations at non-target genomic sites. Studies have demonstrated that CRISPR-Cas9 can generate large structural variants, deletions, or insertions both on-target and off-target, with detection challenges in early embryos due to cellular heterogeneity and mosaicismâ€”where not all cells in an embryo carry the same edit.[](https://www.nature.com/articles/s41467-022-28244-5) [](https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-020-00487-1) In germline contexts, such mutations could lead to novel genetic disorders in offspring or descendants, as empirical data from model organisms indicate that off-target rates, though reduced by high-fidelity variants, remain non-zero and context-dependent.[](https://www.sciencedirect.com/science/article/pii/S216225311630049X) Heritability exacerbates these risks, as a single viable edited embryo implanted for reproduction could disseminate alterations unpredictably, without the selective pressures that mitigate harmful mutations in natural reproduction.[](https://www.nature.com/articles/s41599-022-01147-y)\n\nThe 2018 case of He Jiankui illustrates these heritability perils empirically. He, a Chinese biophysicist, announced the birth of twin girls whose embryos he edited using CRISPR to disrupt the CCR5 gene, aiming to confer HIV resistance by mimicking a natural delta-32 mutation. Subsequent analysis revealed mosaicism in the embryos, incomplete biallelic editing, and potential off-target risks, with no long-term health data available as of 2023; He was convicted in 2019 of illegal medical practice and sentenced to three years in prison.[](https://www.science.org/content/article/chinese-scientist-who-produced-genetically-altered-babies-sentenced-3-years-jail) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC6813942/) This incident underscored causal uncertainties: while the intended edit might offer partial protection, heritable mosaicism could result in variable expressivity across generations, potentially introducing fitness costs or oncogenic risks not observable in the initial cohort.[](https://www.sciencedirect.com/science/article/pii/S1098360021044956)\n\nRegulatory frameworks reflect these concerns, with heritable genome editing prohibited in the vast majority of jurisdictions due to unresolved safety and heritability issues. As of 2020, 75 of 96 surveyed countries explicitly ban the use of genetically modified embryos to initiate pregnancy, including statutory prohibitions in nations like Germany, Canada, Australia, and the European Union under the Oviedo Convention; no country permits clinical reproduction via germline edits.[](https://www.liebertpub.com/doi/10.1089/crispr.2020.0082) [](https://www.forbes.com/sites/farahqaiser/2020/10/31/study-there-is-no-country-where-heritable-human-genome-editing-is-permitted/) International bodies, including a 2019 call from scientific summits, advocate moratoriums until empirical evidence demonstrates negligible off-target rates and predictable intergenerational outcomes, prioritizing causal verification over speculative benefits.01260-0/fulltext) Despite theoretical potential for preventing monogenic diseases, the absence of comprehensive long-term human dataâ€”coupled with evidence of persistent editing inaccuraciesâ€”renders heritable applications empirically unjustified at present.[](https://www.sciencedirect.com/science/article/pii/S0015028225002535)\n\n### Enhancement Debates and Equity Issues\n\nThe debate over human enhancement through genome editing distinguishes therapeutic applications, which aim to correct genetic diseases, from non-therapeutic enhancements that seek to improve traits such as intelligence, physical prowess, or disease resistance beyond normal human variation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7747319/) Proponents of enhancement, including some bioethicists, contend that individuals should have autonomy to pursue genetic improvements, analogous to existing enhancements like education or nutrition, provided risks are managed and consent is informed.[](https://link.springer.com/article/10.1007/s11948-018-0048-y) Critics argue that enhancements risk commodifying human life, eroding genetic diversity, and reviving eugenic practices, with empirical precedents like the 2018 He Jiankui experimentâ€”where embryos were edited for HIV resistance via CCR5 deletionâ€”illustrating blurred lines, as the modification may confer unintended advantages like West Nile virus protection but also potential cognitive drawbacks.[](https://elsihub.org/collection/human-gene-editing-and-ethics-enhancement) These concerns are amplified in germline editing, where changes are heritable, prompting calls for moratoriums from bodies like the World Health Organization until safety and societal impacts are better understood.[](https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns)\n\nA central contention is the \"slippery slope\" argument, positing that permitting somatic (non-heritable) therapies inevitably leads to germline enhancements due to technological convergence and shifting norms, as the boundary between alleviating deficits and optimizing traits proves arbitraryâ€”e.g., editing for severe intellectual disability versus mild cognitive boosts.[](https://link.springer.com/article/10.1007/s11948-018-0048-y) Empirical analysis of this slope reveals logical weaknesses, as regulatory distinctions can be maintained through evidence-based criteria, yet historical precedents in reproductive technologies suggest normative drift where initial therapeutic intents expand to elective uses.[](https://pubmed.ncbi.nlm.nih.gov/8201288/) Philosophically, enhancement challenges egalitarian principles by potentially creating a genetic underclass, with first-principles reasoning highlighting causal risks: unequal adoption could entrench heritability of advantage, as modeled in population genetics simulations showing rapid divergence in trait distributions under selective editing.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9793437/) Despite these debates, no verified human enhancements beyond therapeutic trials exist as of 2025, confining discussions largely to prospective ethics.[](https://www.nature.com/articles/s41599-022-01147-y)\n\nEquity issues arise from genome editing's high development and delivery costs, restricting access primarily to affluent populations and high-income countries, thereby widening global health disparities. The first approved CRISPR therapy, Casgevy for sickle cell disease and beta-thalassemia, launched in 2023 at $2.2 million per patient, exceeds lifetime conventional treatment costs ($4-6 million for sickle cell) yet remains unaffordable for most, particularly in sub-Saharan Africa where sickle cell prevalence reaches 1-2% of births.[](https://www.liebertpub.com/doi/10.1089/crispr.2024.0042)[](https://sites.brown.edu/publichealthjournal/2024/03/21/gene-editing-for-rare-genetic-diseases-is-an-equitable-future-possible/) This pricing, driven by manufacturing complexities like ex vivo cell editing and chemotherapy conditioning, disadvantages low-resource settings despite the technology's potential to address endemic genetic burdens.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11024294/) For enhancements, equity concerns intensify: if viable, they could exacerbate class divides, as only elites afford \"designer\" traits, fostering a bifurcated society where genetic haves outcompete have-nots in labor markets and reproduction, per economic models of technological inequality.[](https://thebulletin.org/2024/10/crispr-therapies-can-treat-disease-but-cost-millions-an-equity-based-approach-could-bring-them-to-more-people/) Proposals for equitable scaling include value-based pricing and international funding mechanisms, but implementation lags, underscoring causal realism that without deliberate access reforms, editing reinforces existing socioeconomic gradients rather than mitigating them.[](https://www.nature.com/articles/s41434-023-00392-3)\n\n### Regulatory Responses and Innovation Barriers\n\nFollowing the 2018 revelation of unauthorized germline editing by He Jiankui in China, which resulted in the birth of edited infants, international bodies responded with calls for enhanced oversight. The World Health Organization's 2021 governance framework for human genome editing emphasized institutional, national, and global mechanisms to promote safety, transparency, and equity, while advising against heritable edits until scientific, ethical, and societal consensus is achieved.[](https://www.who.int/publications/i/item/9789240030060) This framework, developed by an expert advisory committee, prioritizes risk assessment and public engagement but lacks enforceable authority, relying on voluntary adoption by member states.[](https://www.who.int/publications/i/item/9789240030381)\n\nIn the United States, the Food and Drug Administration (FDA) oversees genome editing under its human gene therapy regulations, treating CRISPR-based products as biologics subject to Investigational New Drug applications and phased clinical trials. A March 2024 FDA guidance specifically addresses human gene therapy products incorporating genome editing of somatic cells, recommending preclinical assessments for off-target effects, immunogenicity, and genotoxicity to mitigate risks like unintended mutations.[](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing) Germline editing remains prohibited by congressional acts, with no federal protocols permitting heritable modifications, though somatic applications advanced with the December 2023 approval of Casgevy (exagamglogene autotemcel), the first CRISPR therapy for sickle cell disease and beta-thalassemia.[](https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-embryonic-germline-gene-editing/) FDA clinical holds, such as the temporary pause on Verve Therapeutics' VERVE-101 in 2022 due to delivery concerns (lifted in October 2023), exemplify precautionary scrutiny that delays trials.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/)\n\nThe European Union applies its 2001 GMO Directive to genome-edited organisms, classifying most edits as equivalent to transgenic GMOs requiring rigorous risk assessments, labeling, and traceability, which has stifled agricultural innovation by equating precise edits to foreign DNA insertions.[](https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/european-union-crops-food/) A February 2024 European Parliament vote proposed easing regulations for edits without foreign DNA or unintended changes, exempting them from GMO rules to foster competitiveness, but implementation remains pending amid member state opt-outs and environmental NGO opposition.[](https://www.science.org/content/article/european-parliament-votes-ease-regulation-gene-edited-crops) For human applications, heritable editing is banned under the 2001 Clinical Trials Directive and Oviedo Convention protocols ratified by several members.\n\nChina intensified restrictions post-He Jiankui, issuing a 2019 interim ban on heritable editing and enacting 2021 civil code provisions criminalizing clinical germline use, followed by a July 2024 Ministry of Science and Technology prohibition on all clinical germline research as \"irresponsible\" due to safety uncertainties.[](https://www.chemistryworld.com/news/all-clinical-research-using-germline-genome-editing-banned-in-china/4019847.article) These measures, enforced through institutional ethics reviews, contrast with permissive somatic trials but reflect reactive centralization amid prior lax oversight.\n\nSuch frameworks impose innovation barriers by creating regulatory asymmetry, prompting forum-shopping where researchers and firms relocate to jurisdictions like the US or Argentina with lighter crop editing rules, reducing European investment in biotech by an estimated 20-30% in affected sectors.[](https://www.tylerbpratt.com/s/Genes_August2022.pdf) Precautionary standards, including lengthy approvals (often 10-15 years for FDA gene therapies) and ambiguity in non-human applications like livestock, deter venture capital; a 2024 analysis linked stringent EU GMO equivalence to fewer commercialized gene-edited products and heightened R\u0026D costs.[](https://www.tandfonline.com/doi/full/10.1080/21645698.2023.2293510) Germline prohibitions, while addressing heritable risks, foreclose enhancements or population-level interventions, with empirical data showing off-target rates below 1% in optimized CRISPR systems yet insufficient for policy shifts amid uncertainty.[](https://eurofaang.eu/wp-content/uploads/2024/02/D5.3-Public.pdf) Proponents argue risk-proportionate rules could accelerate benefits, as somatic therapies demonstrate, but institutional inertiaâ€”exacerbated by biases toward alarmism in academic and media sourcesâ€”perpetuates barriers over evidence-based calibration.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12169205/)"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761887051326,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Genome-Editing Technologies: Concept, Pros, and Cons of Various ...\",\"description\":\"Apr 3, 2019 Â· Principally, genome-wide editing techniques can be interpreted as methods where DNA sequences are changed by deletions, mRNA processing, andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6454098/\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Genome Editing: Past, Present, and Future - PMC - NIH\",\"description\":\"Dec 19, 2017 Â· Genome Editing Issues. Remarkably, all that the genome editing nucleases do is to make a break in chromosomal DNA. The key, of course, is thatÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5733845/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"History of CRISPR-Cas from Encounter with a Mysterious Repeated ...\",\"description\":\"Mar 12, 2018 Â· To celebrate the 30th anniversary of the discovery of CRISPR, this minireview briefly discusses the fascinating history of CRISPR-Cas systems,Â ...\",\"url\":\"https://journals.asm.org/doi/10.1128/jb.00580-17\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"CRISPRâ€“Cas9: A History of Its Discovery and Ethical ... - NIH\",\"description\":\"Aug 15, 2022 Â· CRISPR-Cas9, or 'genetic scissors', is a genome editing technology that won a Nobel Prize. It protects prokaryotes and is used in medicine andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"CRISPR technology: A decade of genome editing is only ... - Science\",\"description\":\"Jan 20, 2023 Â· This Review covers the origins and successes of CRISPR-based genome editing and discusses the most pressing challenges.\",\"url\":\"https://www.science.org/doi/10.1126/science.add8643\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"THE PROMISE AND CHALLENGE OF THERAPEUTIC GENOME ...\",\"description\":\"Genome editing, involving precise manipulation of cellular DNA sequences to alter cell fates and organism traits, offers the potential to both understandÂ ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8992613/\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"What are the Ethical Concerns of Genome Editing?\",\"description\":\"Aug 3, 2017 Â· Most ethical discussions about genome editing center on human germline editing because changes are passed down to future generations.\",\"url\":\"https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Ethical Perspectives of Therapeutic Human Genome Editing ... - NIH\",\"description\":\"Nov 27, 2022 Â· This paper argues that allowing this procedure to be the norm would conflict with the research ethic principle of non-exploitation. Zang andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9793437/\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"Beyond safety: mapping the ethical debate on heritable genome ...\",\"description\":\"Apr 20, 2022 Â· In this article, we explore some of the key categorical as well sociopolitical considerations raised by the potential uses of heritable genome editingÂ ...\",\"url\":\"https://www.nature.com/articles/s41599-022-01147-y\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"\",\"description\":\"\",\"url\":\"https://doi.org/10.1073/pnas.76.10.4951\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"\",\"description\":\"\",\"url\":\"https://doi.org/10.1038/317230a0\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"\",\"description\":\"\",\"url\":\"https://doi.org/10.1038/292154a0\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"History of genome editing: From meganucleases to CRISPR\",\"description\":\"Feb 23, 2021 Â· We summarize the history of genome editing platforms, starting from enhanced integration of foreign DNA by meganuclease-mediated double-strand breaks to CRISPRÂ ...\u003c|separator|\u003e\",\"url\":\"https://journals.sagepub.com/doi/10.1177/0023677221994613\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"The Nobel Prize in Physiology or Medicine 2007 - Advanced ...\",\"description\":\"Capecchi, Martin J. Evans and Oliver Smithies for their discoveries of principles for introducing specific gene modifications in mice by the use of embryonicÂ ...\",\"url\":\"https://www.nobelprize.org/prizes/medicine/2007/advanced-information/\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Origins of Programmable Nucleases for Genome Engineering - PMC\",\"description\":\"We started by engineering two novel chimeric nucleases (which were later renamed as zinc finger nucleases or ZFNs) by fusing two three-finger proteins, Sp1-QNRÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4798875/\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"Nucleases in gene-editing technologies: past and prologue\",\"description\":\"The foundation of gene editing was established in the 1970s and 1980s when researchers successively performed precise gene modifications in yeast and mammalianÂ ...\",\"url\":\"https://www.nso-journal.org/articles/nso/full_html/2023/05/NSO20220072/NSO20220072.html\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"The discovery of zinc fingers and their development for ... - PubMed\",\"description\":\"Zinc fingers were discovered in 1985, arising from the interpretation of our biochemical studies on the interaction of the Xenopus protein transcription factorÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/20478078/\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"The discovery of zinc fingers and their development for practical ...\",\"description\":\"Aug 10, 2025 Â· Zinc fingers were discovered in 1985, arising from the interpretation of our biochemical studies on the interaction of the Xenopus proteinÂ ...\",\"url\":\"https://www.researchgate.net/publication/44607123_The_discovery_of_zinc_fingers_and_their_development_for_practical_applications_in_gene_regulation_and_genome_manipulation\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Gene knockout and knockin by zinc-finger nucleases\",\"description\":\"The invention of zinc-finger nucleases (ZFNs). While the zinc-finger motif was discovered in the 1980s [2], ZFNs have a shorter history. Prior to the inventionÂ ...Missing:  key | Show results with:key\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11113862/\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"TALE and TALEN genome editing technologies - ScienceDirect\",\"description\":\"Back in the 1990s, meganucleases and zinc finger nucleases (ZFNs) laid the groundwork for the concept of genome editing and initiated the development of theÂ ...2. Structure And Function Of... Â· 3. Genome Editing With Talen Â· 3.1. Talen Architectures\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2666388021000071\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"A Tale of How TALENs Launched the Genome Editing Revolution\",\"description\":\"Mar 11, 2025 Â· First identified in 1989 as individual proteins involved in pathogen virulence, TALEs and the response that some plants developed in response toÂ ...\",\"url\":\"https://www.the-scientist.com/a-tale-of-how-talens-launched-the-genome-editing-revolution-72719\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"TALEN and CRISPR/Cas Genome Editing Systems: Tools of Discovery\",\"description\":\"Although TALEN and CRISPR/Cas9 appeared recently, these systems have proved to be effective and reliable tools for genome engineering.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4207558/\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"A short, idiosyncratic history of genome editing - ScienceDirect\",\"description\":\"This article reviews some of the early events leading to the development of the first genome editing platform, zinc-finger nucleases.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2666388021000022\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"A Programmable Dual-RNAâ€“Guided DNA Endonuclease ... - Science\",\"description\":\"Jun 28, 2012 Â· Our study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA-Â ...\",\"url\":\"https://www.science.org/doi/10.1126/science.1225829\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"Press release: The Nobel Prize in Chemistry 2020 - NobelPrize.org\",\"description\":\"Oct 7, 2020 Â· Since Charpentier and Doudna discovered the CRISPR/Cas9 genetic scissors in 2012 their use has exploded. This tool has contributed to manyÂ ...\",\"url\":\"https://www.nobelprize.org/prizes/chemistry/2020/press-release/\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"A programmable dual-RNA-guided DNA endonuclease in adaptive ...\",\"description\":\"Aug 17, 2012 Â· Our study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA-Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/22745249/\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"CRISPR Timeline | Broad Institute\",\"description\":\"Zhang, who had previously worked on other genome editing systems such as TALENs, was first to successfully adapt CRISPR-Cas9 for genome editing in eukaryoticÂ ...\",\"url\":\"https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"CRISPRâ€“Cas9 wins Nobel | Nature Reviews Molecular Cell Biology\",\"description\":\"Oct 13, 2020 Â· That year, Emmanuelle Charpentier and Jennifer Doudna published their landmark paper describing the CRISPRâ€“Cas9 system (Science, 17 Aug 2012).\",\"url\":\"https://www.nature.com/articles/s41580-020-00307-9\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"CRISPR Statistics 2025 By Success Rate, Gene Editing, Sequencing\",\"description\":\"Similarly, the number of CRISPR-related scientific publications increased from 87 in 2011 to 3,917 in 2018.\",\"url\":\"https://media.market.us/crispr-statistics/\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Broad Institute awarded first patent for engineered CRISPR-Cas9 ...\",\"description\":\"Apr 15, 2014 Â· Zhang is also the senior author of the 2013 Science paper showing that Cas9 can be harnessed to modify DNA in mammalian cells.\",\"url\":\"https://www.broadinstitute.org/news/broad-institute-awarded-first-patent-engineered-crispr-cas9-system\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"Past, present, and future of CRISPR genome editing technologies: Cell\",\"description\":\"Feb 29, 2024 Â· Genome editing originally arose from advancements in the field of eukaryotic DNA repair. Pioneering studies in the early 1990s using homingÂ ...\",\"url\":\"https://www.cell.com/cell/fulltext/S0092-8674%2824%2900111-9\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"The hidden risks of CRISPR/Cas: structural variations and genome ...\",\"description\":\"Aug 5, 2025 Â· CRISPR/Cas technology has revolutionized gene editing by enabling precise and efficient sequence-specific DNA cleavage for targeted genomeÂ ...\",\"url\":\"https://www.nature.com/articles/s41467-025-62606-z\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Emerging trends in prime editing for precision genome editing - PMC\",\"description\":\"Jul 31, 2025 Â· Prime editing has rapidly become a versatile tool, supporting a wide range of genetic modifications, including point mutations, insertions andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12322275/\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Single-Base Editing Seems to Work | Science | AAAS\",\"description\":\"Mar 10, 2025 Â· This was a trial to correct alpha-1 antitrypsin deficiency (AATD), which is a genetically based condition involving a mutation in the SERPINA1 gene.\u003c|separator|\u003e\",\"url\":\"https://www.science.org/content/blog-post/single-base-editing-seems-work\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Current advancement in the application of prime editing - Frontiers\",\"description\":\"In 2019, David Liu's group developed a new technology named prime editing (PE), which significantly reduced the off-target editing and increased the scope ofÂ ...\",\"url\":\"https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1039315/full\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Highly targeted CRISPR delivery advances gene editing in living ...\",\"description\":\"Feb 8, 2024 Â· A new, precision-targeted delivery method for CRISPR-Cas9, published Jan. 11 in the journal Nature Biotechnology, enables gene editing on very specific subsetsÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.universityofcalifornia.edu/news/highly-targeted-crispr-delivery-advances-gene-editing-living-animals\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"Recent advances in therapeutic gene-editing technologies\",\"description\":\"Jun 4, 2025 Â· This review highlights recent developments of genetic and epigenetic editing tools and explores preclinical innovations poised to advance the field.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S152500162500200X\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"FDA Approves First Gene Therapies to Treat Patients with Sickle ...\",\"description\":\"Dec 8, 2023 Â· The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 yearsÂ ...\",\"url\":\"https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Press Release - CRISPR Therapeutics\",\"description\":\"Jan 16, 2024 Â· The FDA approved CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta thalassemia (TDT) in patients 12 and older.\",\"url\":\"https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-us-food-and-drug-administration\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Vertex Announces US FDA Approval of CASGEVY ...\",\"description\":\"Jan 16, 2024 Â· Vertex Announces US FDA Approval of CASGEVYâ„¢ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia Â· severeÂ ...\",\"url\":\"https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"CRISPR Therapeutics Highlights Strategic Priorities and Anticipated ...\",\"description\":\"Jan 13, 2025 Â· 2025 is an important inflection year for CRISPR Therapeutics as we establish CASGEVY and advance our pipeline candidates to human proof-of-concept and beyond.Missing:  2021-2025 | Show results with:2021-2025\",\"url\":\"https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"CRISPR-based Gene Editing Market | Industry Report, 2033\",\"description\":\"The global CRISPR-based gene editing market size was estimated at USD 4.01 billion in 2024 and is projected to reach USD 13.50 billion by 2033,Â ...\u003c|separator|\u003e\",\"url\":\"https://www.grandviewresearch.com/industry-analysis/crispr-based-gene-editing-market-report\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"CRISPR Clinical Trials: A 2025 Update - Innovative Genomics Institute\",\"description\":\"Jul 9, 2025 Â· An update on the progress of CRISPR clinical trials with the latest data and a survey of the CRISPR landscape in 2025.\",\"url\":\"https://innovativegenomics.org/news/crispr-clinical-trials-2025/\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"DNA repair pathway choices in CRISPR-Cas9 mediated genome ...\",\"description\":\"The two major pathways are error-free, template-dependent homologous recombination (HR), and the error-prone, template-independent classic non-homologous endÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8187289/\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Harnessing DSB repair to promote efficient homology-dependent and\",\"description\":\"Mar 24, 2022 Â· Here we exploit DNA double-strand break (DSB) repair to develop two strategies that install precise genomic insertions using an SpCas9 nuclease-based primeÂ ...\",\"url\":\"https://www.nature.com/articles/s41467-022-28771-1\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Simultaneous inhibition of DNA-PK and PolÏ´ improves integration ...\",\"description\":\"Aug 14, 2023 Â· Our study reveals DNA-dependent protein kinase (DNA-PK) as the most effective target to improve CRISPR/Cas9-mediated insertions, confirming previous findings.\",\"url\":\"https://www.nature.com/articles/s41467-023-40344-4\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Microhomology-mediated end-joining-dependent integration of ...\",\"description\":\"Nov 20, 2014 Â· MMEJ is a DSB repair mechanism that uses microhomologous sequences (5â€“25 bp) for error-prone end-joining. In the cell cycle, MMEJ repair isÂ ...\",\"url\":\"https://www.nature.com/articles/ncomms6560\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Modulation of the microhomology-mediated end joining pathway ...\",\"description\":\"Apr 29, 2024 Â· We found the microhomology-mediated end joining (MMEJ) DNA repair pathway plays a predominant role in Cas9-induced large deletions (LDs).\",\"url\":\"https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-024-01896-z\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Microhomology-mediated end joining: a back-up survival ...\",\"description\":\"Microhomology-mediated end joining (MMEJ) is an error-prone repair mechanism that involves alignment of microhomologous sequences internal to the broken endsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4638128/\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Genome-Editing Technologies: Principles and Applications - PMC\",\"description\":\"Targeted nucleases have provided researchers with the ability to manipulate virtually any genomic sequence, enabling the facile creation of isogenic cellÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5131771/\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Precise genome-editing in human diseases: mechanisms, strategies ...\",\"description\":\"Feb 26, 2024 Â· Precise genome-editing platforms are versatile tools for generating specific, site-directed DNA insertions, deletions, and substitutions.\",\"url\":\"https://www.nature.com/articles/s41392-024-01750-2\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR ...\",\"description\":\"Each zinc finger domain recognizes a 3- to 4-bp DNA sequence, and tandem domains can potentially bind to an extended nucleotide sequence (typically with aÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Meganucleases and Other Tools for Targeted Genome Engineering\",\"description\":\"Nuclease-based approaches, wherein an endonuclease is used to trigger site-specific genome editing, can significantly increase the percentage of targeted cells.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3267165/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Delivery methods for site-specific nucleases: Achieving the full ...\",\"description\":\"Meganucleases, or homing endonucleases, are naturally occurring endonucleases that recognize 12 to 40 nucleotide sequences with high specificity [46]. ThisÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0168365916305466\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Salient Features of Endonuclease Platforms for Therapeutic ...\",\"description\":\"Feb 16, 2016 Â· Meganucleases are unique among the gene-editing platforms in that their DNA binding and cleavage activities are integrated. The DNA target canÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4786926/\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"the Future: Pre-CRISPR Systems Are Driving Therapies to the Clinic\",\"description\":\"Feb 7, 2019 Â· TALENs and ZFNsâ€”the genome editing systems that preceded CRISPRâ€”are looking new again as clinical work shows off their unique advantages.\u003c|separator|\u003e\",\"url\":\"https://www.genengnews.com/topics/genome-editing/back-to-the-future-pre-crispr-systems-are-driving-therapies-to-the-clinic/\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Engineering of customized meganucleases via in vitro ...\",\"description\":\"In this chapter, we describe an approach to retarget meganucleases to DNA targets of interest (such as sequences found in genes and cis regulatory regions)\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4416406/\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Redesign of extensive proteinâ€“DNA interfaces of meganucleases ...\",\"description\":\"Specific gene-targeting nucleases are critical for genetic engineering and therapy. Meganucleases have been shown to harbor many properties, including smallÂ ...\",\"url\":\"https://www.pnas.org/doi/10.1073/pnas.1321030111\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Efficient design of meganucleases using a machine learning approach\",\"description\":\"Jun 17, 2014 Â· Meganucleases are important tools for genome engineering, providing an efficient way to generate DNA double-strand breaks at specific lociÂ ...\u003c|separator|\u003e\",\"url\":\"https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-15-191\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Advancements in genome editing tools for genetic studies and crop ...\",\"description\":\"Feb 2, 2025 Â· Meganucleases require the ability to design nucleases with a high level of sequence specificity to achieve exact genome modification. However,Â ...\",\"url\":\"https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1370675/full\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Genome editing with engineered zinc finger nucleases - Nature\",\"description\":\"Here we review the development of site-specific ZFNs and the application of these reagents to genome editing. We describe methods for engineering ZFNs andÂ ...\",\"url\":\"https://www.nature.com/articles/nrg2842\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Genome Engineering With Zinc-Finger Nucleases - PMC - NIH\",\"description\":\"Zinc-finger nucleases (ZFNs) are targetable DNA cleavage reagents that have been adopted as gene-targeting tools. ZFN-induced double-strand breaks areÂ ...Missing:  milestones | Show results with:milestones\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3176093/\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Diversifying the structure of zinc finger nucleases for high-precision ...\",\"description\":\"Mar 8, 2019 Â· Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res. 19, 1279â€“1288 (2009)Â ...\",\"url\":\"https://www.nature.com/articles/s41467-019-08867-x\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Recent developments and clinical studies utilizing engineered zinc ...\",\"description\":\"Zinc finger nucleases (ZFNs) are custom-designed artificial endonucleases that make DSBs at specific sequences and have been used as a tool for targeted geneticÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11113831/\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Sangamo Receives Fast Track Designation From The FDA For SB ...\",\"description\":\"Jul 13, 2017 Â· The US Food and Drug Administration (FDA) has granted Fast Track designation to SB-318 and SB-913, the Company's clinical stage in vivo genome editing productÂ ...\",\"url\":\"https://investor.sangamo.com/news-releases/news-release-details/sangamo-receives-fast-track-designation-fda-sb-318-and-sb-913\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"First-in-human in vivo genome editing via AAV-zinc-finger nucleases ...\",\"description\":\"Oct 25, 2022 Â· ZFN in vivo editing therapy was well tolerated at doses up to 5e13 vg/kg, the highest dose tested. Thirty-three treatment-related adverse eventsÂ ...\",\"url\":\"https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016%2822%2900622-0\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Zinc finger nuclease-mediated gene editing in hematopoietic stem ...\",\"description\":\"Oct 16, 2024 Â· In these studies, we show that ZFN-mediated editing is highly efficient and produces HSC capable of long-term multilineage engraftment in vivo,Â ...\",\"url\":\"https://www.nature.com/articles/s41598-024-74716-7\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"Current landscape of geneâ€editing technology in biomedicine ...\",\"description\":\"Jul 14, 2022 Â· Many advantages, including low immunogenicity and appropriate gene size, have prompted the widespread use of ZFNs as gene-editing tools forÂ ...\u003c|separator|\u003e\",\"url\":\"https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.155\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Recent advances in the use of ZFN-mediated gene editing for ... - NIH\",\"description\":\"This potentially has two drawbacks: 1) the plasmids continue to express the ZFNs that accumulate in high levels in cells, promoting promiscuous DNA binding andÂ ...Missing:  disadvantages | Show results with:disadvantages\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5736148/\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Pros and cons of ZNFs, TALENs, and CRISPR/Cas\",\"description\":\"ZNFs use DNA triplets, TALENs use single nucleotides, and CRISPR/Cas uses RNA. CRISPR/Cas is efficient, but all have off-site effects and mosaicism.\",\"url\":\"https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-cons-of-znfs-talens-and-crispr-cas\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"TALENsâ€”an indispensable tool in the era of CRISPR: a mini review\",\"description\":\"Aug 21, 2021 Â· TALEs proteins were first reported in 2009, derived from phytopathogenic bacterial genus Xanthomonas [26]. TALE is a special class of proteinsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8380213/\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"[PDF] Transcription Activator Like Effector Nucleases (TALENs)\",\"description\":\"This database gives you the option of selecting a range of dates (TALENs were first reported in 2010) and the ability to select entries from the relevantÂ ...\",\"url\":\"https://academicworks.cuny.edu/cgi/viewcontent.cgi?article=1536\u0026context=cc_pubs\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"TALENs | Summary - WhatisBiotechnology.org\",\"description\":\"TALENs: timeline of key events ; 5 Nov 2015, First successful use of gene therapy to treat baby dying from leukaemia, Vehs, Quasim ; 15 Apr 2016, Gene editingÂ ...Missing:  history | Show results with:history\",\"url\":\"https://whatisbiotechnology.org/index.php/science/summary/TALENs\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"A TALEN genome editing system to generate human stem cell ... - NIH\",\"description\":\"TALENs are engineered nucleases used to generate mutant alleles of genes in human stem cells, creating disease models. They are assembled in 1-2 days.Missing:  history | Show results with:history\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3570604/\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"The comparison of ZFNs, TALENs, and SpCas9 by GUIDE-seq in ...\",\"description\":\"Compared to ZFNs, the specificity of TALENs was considered better than that of ZFNs. Still, different TALEN target sites exhibited distinct off-target profiles.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S216225312100202X\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"[PDF] Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR ...\",\"description\":\"Zinc finger nucleases (ZFNs) are increasingly being used in academic and industry research for a variety of purposes ranging from the generation of animalÂ ...\u003c|separator|\u003e\",\"url\":\"https://dash.harvard.edu/bitstreams/7312037d-9d8e-6bd4-e053-0100007fdf3b/download\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"TALENs: a widely applicable technology for targeted genome editing\",\"description\":\"To date, TALENs have been used to make knockout mutations in Arabidopsis and to introduce resistance to infection by Xanthomonas bacteria in rice by disruptingÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3547402/\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"TALENsâ€”an indispensable tool in the era of CRISPR: a mini review\",\"description\":\"TALEN, on the other hand, has the ability to efficiently manipulate mtDNA (mitochondrial DNA) as a treatment for treating human mitochondrial diseases triggeredÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1687157X23006571\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"CRISPR-cas system: biological function in microbes and its use to ...\",\"description\":\"Jul 5, 2019 Â· The CRISPR-cas system is an adaptive immune system of bacteria and archaea, which protects the bacteria from invaders, including bacteriophagesÂ ...\",\"url\":\"https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-019-0317-x\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"CRISPR-Cas: biology, mechanisms and relevance - PMC - NIH\",\"description\":\"Type II CRISPR-Cas systems seem to play a significant role in regulating virulence of pathogenic bacteria. In Francisella novicida, a ribonucleoprotein complexÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5052741/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"CRISPR in Nature - Innovative Genomics Institute (IGI)\",\"description\":\"Sep 12, 2022 Â· CRISPR systems evolved to defend bacteria against bacterial viruses called phages. Learn how phages infect bacteria and how those bacteria use CRISPR and otherÂ ...\",\"url\":\"https://innovativegenomics.org/crisprpedia/crispr-in-nature/\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Origins and evolution of CRISPR-Cas systems - Journals\",\"description\":\"Mar 25, 2019 Â· The CRISPR-Cas systems consist of distinct adaptation and effector modules whose evolutionary trajectories appear to be at least partially independent.\",\"url\":\"https://royalsocietypublishing.org/doi/10.1098/rstb.2018.0087\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"What is CRISPR: Your Ultimate Guide | Synthego\",\"description\":\"The CRISPR system is the basis of adaptive immunity in bacteria and archaea. It utilizes Cas nucleases, which are enzymes that can bind and create doubleÂ ...Crispr Methods And... Â· Crispr In Disease Models And... Â· 7 Prominent Crispr...\",\"url\":\"https://www.synthego.com/learn/crispr\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Multiplex Genome Engineering Using CRISPR/Cas Systems - Science\",\"description\":\"We engineered two different type II CRISPR/Cas systems and demonstrate that Cas9 nucleases can be directed by short RNAs to induce precise cleavage atÂ ...\",\"url\":\"https://www.science.org/doi/10.1126/science.1231143\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Multiplex Genome Engineering Using CRISPR/Cas Systems - PMC\",\"description\":\"Functional elucidation of causal genetic variants and elements requires precise genome editing technologies. The type II prokaryotic CRISPR (clusteredÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3795411/\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"CRISPR Guide - Addgene\",\"description\":\"The CRISPR-Cas complex recruits the transposase proteins to the target location in the genome, where the transposase then carries out integration of donor DNA.\",\"url\":\"https://www.addgene.org/guides/crispr/\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"Importance of the PAM Sequence in CRISPR Experiments - Synthego\",\"description\":\"The PAM is required for a Cas nuclease to cut and is generally found 3-4 nucleotides downstream from the cut site.\",\"url\":\"https://www.synthego.com/guide/how-to-use-crispr/pam-sequence\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"A Review on the Mechanism and Applications of CRISPR/Cas9 ...\",\"description\":\"Sep 27, 2022 Â· This review aims to provide detail on two classes (class 1 and 2) of the CRISPR/Cas system, and the mechanisms of all Cas proteins, including Cas12, Cas13, andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9512960/\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"CRISPR 101: Cas9 vs. The Other Cas(s) - Addgene Blog\",\"description\":\"Dec 8, 2022 Â· Cas13 is an RNA-guided nuclease, however, unlike Cas9, it targets RNA instead of DNA. This makes it particularly useful in generating transientÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://blog.addgene.org/crispr-101-cas9-vs.-the-other-cass\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"CRISPR-Cas: Converting A Bacterial Defence Mechanism into A ...\",\"description\":\"This review illustrates the mechanisms behind CRISPR-Cas systems as a means of bacterial immunity against phage invasion and how these systems were engineeredÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6466564/\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Assessing and advancing the safety of CRISPR-Cas tools: from DNA ...\",\"description\":\"Jan 13, 2023 Â· Among them, most Cas9 and Cas12 variants possess DNA endonuclease activity, while Cas13 variants show preferential RNA-targeting and cleavageÂ ...\",\"url\":\"https://www.nature.com/articles/s41467-023-35886-6\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Base editing: precision chemistry on the genome and transcriptome ...\",\"description\":\"Oct 15, 2018 Â· Base editing is a newer genome-editing approach that uses components from CRISPR systems together with other enzymes to directly install point mutations intoÂ ...\",\"url\":\"https://www.nature.com/articles/s41576-018-0059-1\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Programmable editing of a target base in genomic DNA without ...\",\"description\":\"A new approach to genome editing that enables the direct, irreversible conversion of one target DNA base into another in a programmable manner.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4873371/\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Base editing: advances and therapeutic opportunities - Nature\",\"description\":\"Oct 19, 2020 Â· In this study, BE-PLUS demonstrated an average 5.6-fold decrease in indel formation and 3.6-fold decrease in Câ€¢G to non-Tâ€¢A editing across sevenÂ ...\",\"url\":\"https://www.nature.com/articles/s41573-020-0084-6\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Programmable base editing of Aâ€¢T to Gâ€¢C in genomic DNA without ...\",\"description\":\"Nov 1, 2017 Â· Now, David Liu and collaborators describe the next step in genomic base editing technology, designed to tackle the conversion of Aâ€¢T baseÂ ...\",\"url\":\"https://www.nature.com/articles/nature24644\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"From bench to bedside: cutting-edge applications of base editing ...\",\"description\":\"Dec 20, 2024 Â· This article reviews the current progress of base editors and prime editors, elaborating on specific examples of their applications in the therapeutic field.\",\"url\":\"https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05957-3\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Search-and-replace genome editing without double-strand ... - Nature\",\"description\":\"Oct 21, 2019 Â· Here we describe prime editing, a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site.\",\"url\":\"https://www.nature.com/articles/s41586-019-1711-4\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Prime editing for precise and highly versatile genome manipulation\",\"description\":\"In this Review, Chen and Liu discuss the latest developments in prime editing systems, including improvements to their editing efficiency and capabilities, asÂ ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10989687/\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"ProPE expands the prime editing window and enhances gene ...\",\"description\":\"Oct 10, 2025 Â· Prime editing (PE), which requires neither the generation of DNA double-strand breaks nor the use of donor DNA, reduces the production ofÂ ...\",\"url\":\"https://www.nature.com/articles/s41929-025-01406-6\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"David Liu Wins 2025 Breakthrough Prize for Base Editing and Prime ...\",\"description\":\"Apr 5, 2025 Â· David Liu, the inventor of base editing and prime editing, has been awarded the 2025 Breakthrough Prize in Life Sciences.\",\"url\":\"https://www.the-scientist.com/david-liu-wins-2025-breakthrough-prize-for-base-editing-and-prime-editing-72888\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"A laboratory-evolved CRISPR-associated transposase adapts to ...\",\"description\":\"Jun 16, 2025 Â· CRISPR-associated transposases (CASTs) are an attractive candidate for genome editing applications, as they enable the insertion of large DNA cargoes withoutÂ ...\",\"url\":\"https://www.nature.com/articles/s41587-025-02720-x\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Drag-and-drop genome insertion of large sequences without double ...\",\"description\":\"Nov 24, 2022 Â· We present programmable addition via site-specific targeting elements (PASTE), which uses a CRISPRâ€“Cas9 nickase fused to both a reverseÂ ...\",\"url\":\"https://www.nature.com/articles/s41587-022-01527-4\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"Unlocking the potential of CRISPR-associated transposons - PubMed\",\"description\":\"May 19, 2025 Â· CRISPR-associated transposons (CASTs) are emerging genome-editing tools that enable RNA-guided DNA integration without inducing double-strand breaks (DSBs).\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/40393858/\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.sciencedaily.com/releases/2025/10/251025084545.htm\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"Bacterial Retrons Enable Precise Gene Editing in Human Cells - PMC\",\"description\":\"Retrons, which reverse transcribe RNA into msDNA, are used with CRISPR-Cas9 to produce msDNA as donor DNA for precise gene editing in human cells.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8892976/\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"\",\"description\":\"\",\"url\":\"https://phys.org/news/2025-10-gene-tech-repurposes-bacterial-retrons.html\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"Programming cells by multiplex genome engineering and ... - NIH\",\"description\":\"MAGE provides a highly efficient, inexpensive and automated solution to simultaneously modify many genomic locations (for example, genes, regulatory regions)Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4590770/\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"Multiplex genome engineering in eukaryotes - Nature\",\"description\":\"Nov 27, 2017 Â· Multiplex automated genome engineering (MAGE) has been used in prokaryotes to simultaneously target many locations on the chromosome forÂ ...\",\"url\":\"https://www.nature.com/articles/nrg.2017.103\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"Viral and Non-Viral Systems to Deliver Gene Therapeutics to ... - NIH\",\"description\":\"Jul 4, 2024 Â· In this review, we describe the different delivery systems available for genome editing components, including viral and non-viral systems, highlighting theirÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"Viral vector platforms within the gene therapy landscape - Nature\",\"description\":\"Feb 8, 2021 Â· In this review, we will describe three viral vector platforms that have gained wide use for efficacious gene therapy and regulatory approval.\",\"url\":\"https://www.nature.com/articles/s41392-021-00487-6\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"CRISPR/Cas9 therapeutics: progress and prospects - Nature\",\"description\":\"Jan 16, 2023 Â· Since 2013, explosive growth has been recorded in the study of CRISPR technology, with tens of thousands of CRISPR-related articles published.\",\"url\":\"https://www.nature.com/articles/s41392-023-01309-7\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Advanced delivery systems for gene editing - ScienceDirect.com\",\"description\":\"We described the plethora of delivery systems available for genome editing components, including viral and non-viral systems, highlighting their advantages,Â ...Review Â· Introduction Â· Delivery Of Gene-Editing...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2162253125000113\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"Customizable virus-like particles deliver CRISPRâ€“Cas9 ... - Nature\",\"description\":\"Feb 10, 2025 Â· Here we develop a cell-tropism programmable CRISPRâ€“Cas9 ribonucleoprotein delivery system (RIDE) based on virus-like particles.\",\"url\":\"https://www.nature.com/articles/s41565-024-01851-7\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"Applications and challenges of CRISPR-Cas gene-editing to ...\",\"description\":\"The ex vivo gene editing method has three main potential applications in clinics: cancer immunotherapy, treatment of hereditary diseases (e.g. sickle cellÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8444435/\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo ...\",\"description\":\"Here we review recent advances in therapeutic genome editing of HSCs and T cells, focusing on the progress in ex vivo contexts, the promise of improved accessÂ ...\",\"url\":\"https://www.liebertpub.com/doi/10.1089/crispr.2024.0036\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"Advantages and challenges of ex vivo generation and ... - PubMed\",\"description\":\"Mar 12, 2025 Â· Despite advancements in this field, two primary challenges persist: low differentiation efficiency and difficulties in isolating and enrichingÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/40086687/\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"Editorial: Ex-vivo and in-vivo genome engineering for metabolic and ...\",\"description\":\"Jul 5, 2023 Â· Discuss the progress and challenges of ex vivo genome editing in HSPCs to treat non-hematological disorders. One of these challenges isÂ ...\",\"url\":\"https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2023.1248904/full\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"CRISPR Clinical Trials: A 2024 Update - Innovative Genomics Institute\",\"description\":\"Mar 13, 2024 Â· In late 2023, we saw the first-ever approval of CRISPR-based medicine: Casgevy, a cure for sickle cell disease (SCD) and transfusion-dependent beta thalassemiaÂ ...Missing:  patents | Show results with:patents\",\"url\":\"https://innovativegenomics.org/news/crispr-clinical-trials-2024/\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"Landscape of ex vivo gene therapies: Technological trends and ...\",\"description\":\"In vivo gene therapy delivers new or corrected genes using a vector directly into the body, either systemically or locally. The second approach, ex vivo geneÂ ...\",\"url\":\"https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501%2825%2900175-5\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Therapeutic in vivo delivery of gene editing agents - ScienceDirect\",\"description\":\"Jul 21, 2022 Â· In vivo gene editing, where cells are edited directly within the body, offers the greatest promise for treating genetic disorders. However, inÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0092867422003956\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"Revolutionizing in vivo therapy with CRISPR/Cas genome editing\",\"description\":\"Researchers are investigating the ability of CRISPR/Cas9 to precisely edit genes and address specific mutations and the potential to provide new cures andÂ ...Missing:  post- | Show results with:post-\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10867117/\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis\",\"description\":\"Jun 26, 2021 Â· We report evidence of CRISPR-Cas9â€“based in vivo gene editing in humans. Systemic administration of NTLA-2001 to six patients with hATTRÂ ...Missing:  examples | Show results with:examples\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2107454\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"How Scientists Used CRISPR to Edit Human DNA In Vivo\",\"description\":\"Apr 8, 2020 Â· This video explains the principles of DNA editing with CRISPR-Cas9 and the rationale for its use and testing as a therapy for LCA10 in the BRILLIANCE clinicalÂ ...Missing:  examples | Show results with:examples\",\"url\":\"https://edhub.ama-assn.org/jn-learning/video-player/18468298\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"In vivo delivery of CRISPR-Cas9 genome editing components for ...\",\"description\":\"The first clinical trial of CRISPR therapeutics in humans was initiated in 2016, aiming to use CRISPR-Cas9 engineered PD-1 knockout T cells for the treatment ofÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10018374/\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"The comparison of ZFNs, TALENs, and SpCas9 by GUIDE-seq in ...\",\"description\":\"We compared the efficiency and specificity of ZFNs, TALENs, and SpCas9 by GUIDE-seq. SpCas9 outperformed ZFNs and TALENs with higher efficiency and specificity.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8655392/\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"Off-target Effects in CRISPR/Cas9-mediated Genome Engineering\",\"description\":\"Here, we review the basic mechanisms underlying off-target cutting in the CRISPR/Cas9 system, methods for detecting off-target mutations, and strategies forÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S216225311630049X\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"Minimizing the off-target frequency of the CRISPR/Cas9 system via ...\",\"description\":\"Jun 14, 2023 Â· The rates of mutation at the selected off-target sites were very high, ranging from 9.4% to 93.6% when the cells were edited using native CRISPRÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10266473/\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Off-target effects in CRISPR/Cas9 gene editing - PMC - NIH\",\"description\":\"A major concern in the applications of the CRISPR/Cas9 system is about its off-target effects, namely the deposition of unexpected, unwanted, or even adverseÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"Recent Advancements in Reducing the Off-Target Effect of CRISPR ...\",\"description\":\"Jan 18, 2024 Â· In this review, we summarize the recent technological advancements in reducing the off-target effect of CRISPR-Cas9 genome editing.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10802171/\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"Beyond the promise: evaluating and mitigating off-target effects in ...\",\"description\":\"Each method has its own set of advantages and limitations; hence, no single method can provide a comprehensive assessment of CRISPR-Cas associated off-targets.Abstract Â· Introduction Â· Assessment of CRISPR... Â· Approaches to reduce off...\",\"url\":\"https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"Improvement of base editors and prime editors advances precision ...\",\"description\":\"Base and prime editors are genome engineering tools that introduce precise edits without DSBs, advancing plant research and crop breeding.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8968349/\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"Emerging trends in prime editing for precision genome editing - Nature\",\"description\":\"Jul 31, 2025 Â· Prime editing is a novel 'search-and-replace' genome editing technology that significantly advances the capabilities of the CRISPR system byÂ ...\",\"url\":\"https://www.nature.com/articles/s12276-025-01463-8\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"High-fidelity CRISPR-Cas9 variants with undetectable genome-wide ...\",\"description\":\"Here we describe SpCas9-HF1, a high-fidelity variant harboring alterations designed to reduce non-specific DNA contacts.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4851738/\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"Sniper2L is a high-fidelity Cas9 variant with high activity - Nature\",\"description\":\"Mar 9, 2023 Â· We developed an improved version of Sniperâ€“Cas9, Sniper2L, which represents an exception to this trade-off trend as it showed higher specificity with retainedÂ ...\",\"url\":\"https://www.nature.com/articles/s41589-023-01279-5\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity\",\"description\":\"Aug 4, 2016 Â· Selecting the most unique target site possible is thus a valuable strategy for improving specificity, because many gene editing applicationsÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1097276516303318\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Single-Base Resolution: Increasing the Specificity of the CRISPR ...\",\"description\":\"Mar 3, 2021 Â· Alternative Methods for Specificity Enhancement. Restriction of Cas nuclease abundance is a rational approach to increase the specificity ofÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1525001620306079\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"Methodologies for Improving HDR Efficiency - Frontiers\",\"description\":\"In order to modify the gene precisely, numerous methods arose by inhibiting NHEJ or enhancing HDR, such as chemical modulation, synchronized expression, andÂ ...Overview of CRISPR-Cas9... Â· HDR Pathway Â· Favoring the HDR Pathway...\",\"url\":\"https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00691/full\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"3 Tips to Improve HDR Efficiency for CRISPR Editing in Human Cells\",\"description\":\"Sep 5, 2017 Â· 1. Increasing HDR accuracy with CRISPR/Cas-blocking mutations Â· 2. Optimizing \\\"cut-to-mutation distance\\\" Â· 3. Optimizing \\\"cut-to-mutation distanceÂ ...\",\"url\":\"https://blog.addgene.org/3-tips-for-improving-hdr-efficiency-for-editing-human-cells-with-crispr\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"Enrichment strategies to enhance genome editing\",\"description\":\"Jul 1, 2023 Â· Reducing the size of the editing window with newer base editors to increase specificity might in turn reduce editing efficiency and limit theÂ ...\",\"url\":\"https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00943-1\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"Enhancing homology-directed repair efficiency with HDR-boosting ...\",\"description\":\"Aug 10, 2024 Â· By combining with an inhibitor of NHEJ or the HDRobust strategy, the modular ssDNA donors achieved 66.62%â€“90.03% HDR efficiency, offering aÂ ...\",\"url\":\"https://www.nature.com/articles/s41467-024-50788-x\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Î² ...\",\"description\":\"Dec 7, 2020 Â· CRISPR-Cas9 Gene Editing for SCD and TDT. Transfusion-dependent Î²-thalassemia (TDT) and sickle cell disease (SCD) are the most common monogenicÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2031054\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"Clinical applications of the CRISPR/Cas9 genome-editing system\",\"description\":\"CRISPR/Cas9 is used to treat cancers, hemolytic diseases, immunodeficiency, cardiovascular, visual, neurodegenerative, and some X-linked disorders.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10425811/\",\"favicon\":\"\"},{\"id\":\"143\",\"title\":\"Overview CRISPR Clinical Trials 2025 - Learn | Innovate | Access\",\"description\":\"Feb 28, 2025 Â· In 2023, therapeutic gene editing moved from promise to reality with the first approved CRISPR-based therapy, CASGEVY, which has since receivedÂ ...Missing:  ex | Show results with:ex\",\"url\":\"https://crisprmedicinenews.com/clinical-trials/\",\"favicon\":\"\"},{\"id\":\"144\",\"title\":\"Advancing CRISPR genome editing into gene therapy clinical trials\",\"description\":\"Ongoing research explores the potential of CRISPR technology for cancer therapies, HIV treatment and other complex diseases.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/\",\"favicon\":\"\"},{\"id\":\"145\",\"title\":\"FDA Approves Vertex \u0026 CRISPR's Gene Editing Therapy | CAF\",\"description\":\"The FDA has approved Vertex and CRISPR's gene-editing therapy Casgevy to treat Beta Thalassemia. Casgevy becomes the first therapy for the rare bloodÂ ...\",\"url\":\"https://thalassemia.org/FDA-Approves-Vertex-CRISPRs-Gene-Editing-Therapy\",\"favicon\":\"\"},{\"id\":\"146\",\"title\":\"Recent advances of CRISPR-based genome editing for enhancing ...\",\"description\":\"Sep 22, 2024 Â· This review highlights the transformative potential of CRISPR/Cas technology, emphasizing recent innovations such as prime and base editing, andÂ ...\",\"url\":\"https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1478398/full\",\"favicon\":\"\"},{\"id\":\"147\",\"title\":\"Adoption of CRISPR-Cas for crop production: present status and ...\",\"description\":\"Jun 7, 2024 Â· So far, more than 25 plant species and 100 genes have been successfully edited using CRISPR-Cas9 to achieve a range of desirable traits inÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11164064/\",\"favicon\":\"\"},{\"id\":\"148\",\"title\":\"Application of CRISPR/Cas-based gene-editing for developing ...\",\"description\":\"Aug 16, 2024 Â· ... yielding better banana with enhanced nutritional content and disease resistance. By integrating precision genetics with traditional breedingÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11362101/\",\"favicon\":\"\"},{\"id\":\"149\",\"title\":\"Engineering crops of the future: CRISPR approaches to develop ...\",\"description\":\"Nov 30, 2020 Â· Here, we discuss the latest developments in CRISPR technologies for engineering resistance to viruses, bacteria, fungi, and pests.\u003c|separator|\u003e\",\"url\":\"https://genomebiology.biomedcentral.com/articles/10.1186/s13059-020-02204-y\",\"favicon\":\"\"},{\"id\":\"150\",\"title\":\"CRISPR-Cas9 genome editing in crop breeding for climate change ...\",\"description\":\"Recently, a CRISPR-Cas9 system was utilized to edit gibberellin (GA) phytohormone-related mutants that confer a shorter stature to the barley plant [87].\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2666154324001698\",\"favicon\":\"\"},{\"id\":\"151\",\"title\":\"A Critical Review: Recent Advancements in the Use of CRISPR ...\",\"description\":\"The CRISPR/Cas9 has been used to improve the monocots and dicots crops for a variety of traits like yield, quality, disease resistance, and resistance toÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8929161/\",\"favicon\":\"\"},{\"id\":\"152\",\"title\":\"CRISPR-Cas9 Application in Crop Biotechnology: A Decade of ...\",\"description\":\"Aug 13, 2025 Â· Studies that focused on CRISPR-Cas9 edited crops showed improvement of Î²-carotene with its sixfold increase in rice and banana, GABA contentÂ ...\",\"url\":\"https://nhsjs.com/2025/crispr-cas9-application-in-crop-biotechnology-a-decade-of-research-2014-to-2024-toward-food-security-in-developing-countries/\",\"favicon\":\"\"},{\"id\":\"153\",\"title\":\"Gene-Edited Plants: Regulation and Issues for Congress\",\"description\":\"Sep 7, 2023 Â· The rule revised APHIS's regulations governing certain gene-edited plants (7 C.F.R. Â§340) and new genetically engineered plants. It exemptsÂ ...\",\"url\":\"https://www.congress.gov/crs-product/R47683\",\"favicon\":\"\"},{\"id\":\"154\",\"title\":\"[PDF] Plants produced using new genomic techniques\",\"description\":\"Oct 3, 2023 Â· On 5 July 2023, the Commission tabled a proposal for a regulation on certain new genomic techniques (NGTs). It establishes two categories ofÂ ...\",\"url\":\"https://www.europarl.europa.eu/RegData/etudes/BRIE/2023/754549/EPRS_BRI%282023%29754549_EN.pdf\",\"favicon\":\"\"},{\"id\":\"155\",\"title\":\"CRISPR in Agriculture: 2024 in Review - Innovative Genomics Institute\",\"description\":\"Dec 10, 2024 Â· CRISPR is being used in a wide breadth of ways in plant and animal agriculture, from reducing waste to adapting plants and animals to climate change.\",\"url\":\"https://innovativegenomics.org/news/crispr-in-agriculture-2024/\",\"favicon\":\"\"},{\"id\":\"156\",\"title\":\"Revolutionizing Agriculture With CRISPR Technology: Applications ...\",\"description\":\"Sep 11, 2025 Â· In summary, CRISPR enables precise genetic improvements in crops, spanning stress tolerance, yield, nutrition, and disease resistance.\",\"url\":\"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/biot.70113\",\"favicon\":\"\"},{\"id\":\"157\",\"title\":\"CRISPR in Animals and Animal Models - ScienceDirect.com\",\"description\":\"CRISPR-Cas9 has revolutionized animal genome editing, enabling genetic modification of embryonic stem cells and zygotes, and is used for gene inactivation andÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S1877117317301205\",\"favicon\":\"\"},{\"id\":\"158\",\"title\":\"Generation of gene-edited rats by delivery of CRISPR/Cas9 protein ...\",\"description\":\"Nov 29, 2017 Â· We report the optimization of an electroporation method for intact rat zygotes using sgRNAs and Cas9 protein in combination or not with ssODNs (~100 nt).\",\"url\":\"https://www.nature.com/articles/s41598-017-16328-y\",\"favicon\":\"\"},{\"id\":\"159\",\"title\":\"CRISPR/Cas9: a powerful genetic engineering tool for establishing ...\",\"description\":\"Aug 4, 2015 Â· Here we discuss the use of CRISPR/Cas9 technology to establish large animal models that can more faithfully mimic human neurodegenerative diseases.\",\"url\":\"https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-015-0031-x\",\"favicon\":\"\"},{\"id\":\"160\",\"title\":\"Redefining mouse transgenesis with CRISPR/Cas9 genome editing ...\",\"description\":\"Feb 28, 2018 Â· A new study shows that the in situ delivery of CRISPR/Cas9 reagents into pregnant mice results in a high efficiency of editing, and enables the rapidÂ ...\",\"url\":\"https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1409-1\",\"favicon\":\"\"},{\"id\":\"161\",\"title\":\"The Progress of CRISPR/Cas9-Mediated Gene Editing in ...\",\"description\":\"Here we review both mice and zebrafish models of human skeletal diseases generated by CRISPR/Cas9 system, and their contributions to deciphering the underpinsÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2001037019300443\",\"favicon\":\"\"},{\"id\":\"162\",\"title\":\"Base editors in zebrafish: a new era for functional genomics ... - NIH\",\"description\":\"May 21, 2025 Â· Base editing has revolutionized genome engineering by enabling precise single-nucleotide modifications without inducing double-strand breaksÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12133889/\",\"favicon\":\"\"},{\"id\":\"163\",\"title\":\"CRISPR-Cas9 in the Tailoring of Genetically Engineered Animals\",\"description\":\"CRISPR-Cas9 is used for targeted genome editing in animals, creating models for disease, protein production, and xenotransplantation, and improving livestockÂ ...\",\"url\":\"https://www.mdpi.com/1467-3045/47/5/330\",\"favicon\":\"\"},{\"id\":\"164\",\"title\":\"Use of CRISPR/Cas9 to model brain diseases - ScienceDirect\",\"description\":\"In this review, we focus on genomic editing tools that enable the generation of animal models of brain diseases by modifying endogenous genomes.\u003c|separator|\u003e\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0278584617300386\",\"favicon\":\"\"},{\"id\":\"165\",\"title\":\"CRISPR-based functional genomics tools in vertebrate models\",\"description\":\"Jul 31, 2025 Â· In popular vertebrate models, including mice and zebrafish, CRISPR has been adapted to high-throughput mutagenesis workflows, knock-in allelesÂ ...\",\"url\":\"https://www.nature.com/articles/s12276-025-01514-0\",\"favicon\":\"\"},{\"id\":\"166\",\"title\":\"Microbial Genome Editing with CRISPRâ€“Cas9: Recent Advances ...\",\"description\":\"Overall, combined CRISPRâ€“Cas9 platforms streamline the engineering of these species into microbial factories for amino acids, enzymes, solvents, and biofuels.\",\"url\":\"https://www.mdpi.com/2311-5637/11/7/410\",\"favicon\":\"\"},{\"id\":\"167\",\"title\":\"CRISPR-based gene editing technology and its application in ...\",\"description\":\"We summarize recent developments in the application of CRISPR-based gene editing tools for industrial microorganism and probiotics modifications.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2667370323000334\",\"favicon\":\"\"},{\"id\":\"168\",\"title\":\"CRISPR-Made Greener Products and Processes in Industrial ...\",\"description\":\"Apr 3, 2023 Â· One of the major applications of CRISPR in industrial biotechnology is the engineering of enzymes. CRISPR-guided DNA polymerases can be used toÂ ...\",\"url\":\"https://www.genengnews.com/resources/crispr-made-greener-products-and-processes-in-industrial-biotechnology/\",\"favicon\":\"\"},{\"id\":\"169\",\"title\":\"Vertex and CRISPR Therapeutics Announce US FDA Approval of ...\",\"description\":\"Dec 8, 2023 Â· â€œCASGEVY's approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the U.S.\",\"url\":\"https://news.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval\",\"favicon\":\"\"},{\"id\":\"170\",\"title\":\"Revolutionary breakthrough: FDA approves CASGEVY, the first ...\",\"description\":\"Casgevy is the first FDA-approved CRISPR/Cas9 gene therapy for sickle cell disease, offering a curative approach and eliminating the need for transfusions.\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/\",\"favicon\":\"\"},{\"id\":\"171\",\"title\":\"The first human trial of CRISPR-based cell therapy clears safety ...\",\"description\":\"Aug 25, 2020 Â· Lu et al. examined the feasibility and safety of using CRISPR-engineered T cells to treat late-stage lung cancer. They demonstrated very low off-target editingÂ ...\",\"url\":\"https://www.nature.com/articles/s41392-020-00283-8\",\"favicon\":\"\"},{\"id\":\"172\",\"title\":\"First Chinese CRISPR gene therapy trial demonstrates safety\",\"description\":\"Apr 28, 2020 Â· CRISPR gene therapy appears to be feasible and safe, and the stage is set for the next significant advances in cancer treatment.\",\"url\":\"https://crisprmedicinenews.com/news/first-chinese-crispr-gene-therapy-trial-demonstrates-safety/\",\"favicon\":\"\"},{\"id\":\"173\",\"title\":\"First U.S. Patients Treated With CRISPR As Human Gene-Editing ...\",\"description\":\"Apr 16, 2019 Â· There's now a clinical trial underway at the University of Pennsylvania using CRISPR for cancer treatment. It involves removing immune systemÂ ...\",\"url\":\"https://www.npr.org/sections/health-shots/2019/04/16/712402435/first-u-s-patients-treated-with-crispr-as-gene-editing-human-trials-get-underway\",\"favicon\":\"\"},{\"id\":\"174\",\"title\":\"First-in-human Phase 1 CRISPR Gene Editing Cancer Trials - PubMed\",\"description\":\"A prospective first-in-human Phase 1 CRISPR gene editing trial in the United States for patients with melanoma, synovial sarcoma, and multiple myeloma\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/29173170/\",\"favicon\":\"\"},{\"id\":\"175\",\"title\":\"OHSU performs first-ever CRISPR gene editing within human body\",\"description\":\"Mar 4, 2020 Â· The gene-editing tool CRISPR has been used to address a blindness-causing gene mutation at Oregon Health \u0026 Science University for a clinical trial.\",\"url\":\"https://news.ohsu.edu/2020/03/04/ohsu-performs-first-ever-crispr-gene-editing-within-human-body\",\"favicon\":\"\"},{\"id\":\"176\",\"title\":\"Landmark CRISPR trial shows promise against deadly disease\",\"description\":\"Jun 29, 2021 Â· Preliminary results from a landmark clinical trial suggest that CRISPRâ€“Cas9 gene editing can be deployed directly into the body to treat disease.\",\"url\":\"https://www.nature.com/articles/d41586-021-01776-4\",\"favicon\":\"\"},{\"id\":\"177\",\"title\":\"CASGEVYâ„¢ (gene editing) â€“ TIF\",\"description\":\"FDA has accepted Priority Review for BLA submission and set a PDUFA (the date by which the FDA must respond to the application) target date of 8 December 2023.\",\"url\":\"https://thalassaemia.org.cy/clinical-trial-updates-scd/exa-cel-gene-editing/\",\"favicon\":\"\"},{\"id\":\"178\",\"title\":\"Pipeline | CRISPR Therapeutics\",\"description\":\"Exa-cel, a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, has now been approved in some countriesÂ ...\",\"url\":\"https://crisprtx.com/pipeline\",\"favicon\":\"\"},{\"id\":\"179\",\"title\":\"World's First Patient Treated with Personalized CRISPR Gene ...\",\"description\":\"May 15, 2025 Â· A child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children's Hospital ofÂ ...\",\"url\":\"https://www.chop.edu/news/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital\",\"favicon\":\"\"},{\"id\":\"180\",\"title\":\"CRISPR Therapeutics to Present Late-Breaking Data at the ...\",\"description\":\"Sep 9, 2025 Â· Abstract Title: First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 ; Abstract Number: 4392851 ; SessionÂ ...\",\"url\":\"https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-late-breaking-data-american-heart\",\"favicon\":\"\"},{\"id\":\"181\",\"title\":\"Press Release - CRISPR Therapeutics\",\"description\":\"The Company plans to present the CTX310 Phase 1 data at a medical meeting in the second half of 2025. CTX320 is in an ongoing Phase 1 clinical trial targetingÂ ...\u003c|separator|\u003e\",\"url\":\"https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-first-quarter-2025-financial\",\"favicon\":\"\"},{\"id\":\"182\",\"title\":\"Research and Pipeline | Editas Medicine\",\"description\":\"Editas Medicine works with two distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). Both nucleases have distinct gene editing and targetingÂ ...\",\"url\":\"https://www.editasmedicine.com/gene-editing-pipeline/\",\"favicon\":\"\"},{\"id\":\"183\",\"title\":\"Quarterly Industry Landscape Report - ASGCT\",\"description\":\"The data show unequivocally that gene, cell, and RNA therapies continue to grow rapidly with nearly 3,500 therapies in preclinical and clinical developmentÂ ...\",\"url\":\"https://www.asgct.org/news-publications/landscape-report\",\"favicon\":\"\"},{\"id\":\"184\",\"title\":\"CRISPR Clinical Trials to Follow - Synthego\",\"description\":\"Apr 1, 2025 Â· CRISPR therapies are being developed for genetic disorders, cancer, and infectious diseases using various CRISPR nucleases like eSpOT-ON,Â ...\",\"url\":\"https://www.synthego.com/blog/crispr-clinical-trials\",\"favicon\":\"\"},{\"id\":\"185\",\"title\":\"Exploring the Potential and Challenges of CRISPR Delivery and ...\",\"description\":\"May 27, 2024 Â· The review outlines CRISPR's historical progression and highlights advancements in gene editing methods and delivery vehicles.\",\"url\":\"https://advanced.onlinelibrary.wiley.com/doi/10.1002/adfm.202402630\",\"favicon\":\"\"},{\"id\":\"186\",\"title\":\"CRISPR Cell and Gene Therapies: Key Challenges in Clinical ...\",\"description\":\"Feb 28, 2025 Â· Researchers face many hurdles when developing CRISPR therapy products, including the procurement of true GMP reagents, unclear regulatoryÂ ...\",\"url\":\"https://www.synthego.com/blog/crispr-cell-gene-therapy-obstacles\",\"favicon\":\"\"},{\"id\":\"187\",\"title\":\"Regulatory Trends in Cell and Gene Therapies - Synthego\",\"description\":\"Jun 28, 2022 Â· Researchers face many hurdles when developing CRISPR therapy products, including the procurement of true GMP reagents, unclear regulatoryÂ ...Recent Problems In Cell \u0026... Â· Expected Growth In Cell And... Â· Regulatory Harmonization And...\",\"url\":\"https://www.synthego.com/blog/regulatory-trends-therapies\",\"favicon\":\"\"},{\"id\":\"188\",\"title\":\"Moving Therapeutic Genome Editing into Global Clinical Trials and ...\",\"description\":\"May 22, 2025 Â· Moving CRISPR-based therapies from discovery to dosing patients in clinical trials and ultimately to approval involves navigating a challengingÂ ...\",\"url\":\"https://www.liebertpub.com/doi/10.1089/crispr.2025.0049\",\"favicon\":\"\"},{\"id\":\"189\",\"title\":\"Non-clinical safety considerations on genome editing using the ...\",\"description\":\"Jul 28, 2025 Â· Genome editing technologies are rapidly being adopted in clinical trials; however, critical non-clinical safety considerations are required toÂ ...Review Article Â· Advances In Crispr/cas Gene... Â· Crispr/cas9-Associated...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2352304225002740\",\"favicon\":\"\"},{\"id\":\"190\",\"title\":\"Key challenges in bringing CRISPR-mediated somatic cell therapy ...\",\"description\":\"Sep 25, 2017 Â· We identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediatedÂ ...\",\"url\":\"https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0475-4\",\"favicon\":\"\"},{\"id\":\"191\",\"title\":\"Past, present, and future of CRISPR genome editing technologies\",\"description\":\"Feb 29, 2024 Â· In this review, we discuss the current state of CRISPR gene editing technologies in both research and therapy, highlighting limitations that constrain them.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0092867424001119\",\"favicon\":\"\"},{\"id\":\"192\",\"title\":\"Mosaicism in CRISPR/Cas9-mediated genome editing - ScienceDirect\",\"description\":\"Jan 15, 2019 Â· CRISPR/Cas9-mediated mosaic mutations can result following DNA breaks and indel formations (via NHEJ) or oligonucleotide or transgene insertionsÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0012160618302513\",\"favicon\":\"\"},{\"id\":\"193\",\"title\":\"Cas9 immunity creates challenges for CRISPR gene editing therapies\",\"description\":\"Aug 29, 2018 Â· Preventing the immune destruction of CRISPR-Cas9-corrected cells could be more challenging in patients that already have pre-existing anti-Cas9Â ...\",\"url\":\"https://www.nature.com/articles/s41467-018-05843-9\",\"favicon\":\"\"},{\"id\":\"194\",\"title\":\"Efficacy and long-term safety of CRISPR/Cas9 genome editing in the ...\",\"description\":\"Mar 25, 2021 Â· One major long-term safety concern is tumorigenesis that might arise if off-targets involve oncogenes and tumor suppressor genes. It is knownÂ ...\",\"url\":\"https://www.nature.com/articles/s42003-021-01942-4\",\"favicon\":\"\"},{\"id\":\"195\",\"title\":\"CRISPR-Cas9: The gene editing tool changing the world\",\"description\":\"Jan 15, 2025 Â· While Casgevy has certainly demonstrated CRISPR can be safe and effective as a treatment, it will definitely take some time and additionalÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.labiotech.eu/in-depth/crispr-cas9-review-gene-editing-tool/\",\"favicon\":\"\"},{\"id\":\"196\",\"title\":\"\",\"description\":\"\",\"url\":\"https://frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full\",\"favicon\":\"\"},{\"id\":\"197\",\"title\":\"Societal and Ethical Impacts of Germline Genome Editing: How Can ...\",\"description\":\"Oct 9, 2019 Â· Genome editing has opened up the possibility of heritable alteration of the human germline. The potential of this powerful tool has spurredÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6791475/\",\"favicon\":\"\"},{\"id\":\"198\",\"title\":\"CRISPR-Cas9 induces large structural variants at on-target and off ...\",\"description\":\"Feb 2, 2022 Â· Such off-target mutations can have serious consequences as they might disrupt the function or regulation of non-targeted genes. In addition,Â ...\",\"url\":\"https://www.nature.com/articles/s41467-022-28244-5\",\"favicon\":\"\"},{\"id\":\"199\",\"title\":\"Human germline editing in the era of CRISPR-Cas\",\"description\":\"Sep 11, 2020 Â· At present, CRISPR-Cas does not work sufficiently precise, leading to so-called off-target effects, i.e. unintended changes in non-targetÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-020-00487-1\",\"favicon\":\"\"},{\"id\":\"200\",\"title\":\"Chinese scientist who produced genetically altered babies ... - Science\",\"description\":\"He Jiankui, the Chinese researcher who stunned the world last year by announcing he had helped produce genetically edited babies, has been found guilty ofÂ ...\",\"url\":\"https://www.science.org/content/article/chinese-scientist-who-produced-genetically-altered-babies-sentenced-3-years-jail\",\"favicon\":\"\"},{\"id\":\"201\",\"title\":\"CRISPR'd babies: human germline genome editing in the 'He ...\",\"description\":\"The world was shocked in Nov. 25, 2018 by the revelation that He Jiankui had used clustered regularly interspaced short palindromic repeats ('CRISPR') to editÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6813942/\",\"favicon\":\"\"},{\"id\":\"202\",\"title\":\"Responding to claims of germline gene editing in humans\",\"description\":\"In November 2018, the scientific community was rocked when He Jiankui, a Chinese biophysicist, claimed that he had overseen the birth of twin girls fromÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1098360021044956\",\"favicon\":\"\"},{\"id\":\"203\",\"title\":\"Human Germline and Heritable Genome Editing: The Global Policy ...\",\"description\":\"Oct 20, 2020 Â· Seventy-five of the 96 countries prohibit the use of genetically modified in vitro embryos to initiate a pregnancy (heritable genome editing).\",\"url\":\"https://www.liebertpub.com/doi/10.1089/crispr.2020.0082\",\"favicon\":\"\"},{\"id\":\"204\",\"title\":\"Study: There Is No Country Where Heritable Human Genome ...\",\"description\":\"Oct 31, 2020 Â· In contrast, 78 out of 96 countries have policies to address heritable genome editing (i.e. for reproduction), where 70 prohibit this type ofÂ ...\",\"url\":\"https://www.forbes.com/sites/farahqaiser/2020/10/31/study-there-is-no-country-where-heritable-human-genome-editing-is-permitted/\",\"favicon\":\"\"},{\"id\":\"205\",\"title\":\"The case for germline gene correction: state of the science\",\"description\":\"The greatest clinical potential for heritable genome editing is in the prevention of monogenic diseases that so far have proven intractable to other therapeuticÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0015028225002535\",\"favicon\":\"\"},{\"id\":\"206\",\"title\":\"Risks and benefits of human germline genome editing - NIH\",\"description\":\"There is an ongoing debate whether genetic enhancement is ethically acceptable. This an issue that surely needs a focused analysis that cannot be given here.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7747319/\",\"favicon\":\"\"},{\"id\":\"207\",\"title\":\"Gene Editing and the Slippery Slope Argument: Should We Fix the ...\",\"description\":\"Mar 21, 2018 Â· It seems that we are ultimately obliged (as is often the case) to trace a moral distinction on the therapy/enhancement dichotomy.\",\"url\":\"https://link.springer.com/article/10.1007/s11948-018-0048-y\",\"favicon\":\"\"},{\"id\":\"208\",\"title\":\"Human Gene Editing and the Ethics of Enhancement - ELSIhub\",\"description\":\"Dec 6, 2022 Â· It also underlined the importance of the debates over enhancement, by raising the question of whether providing superior resistance to HIVÂ ...\",\"url\":\"https://elsihub.org/collection/human-gene-editing-and-ethics-enhancement\",\"favicon\":\"\"},{\"id\":\"209\",\"title\":\"Debunking the slippery slope argument against human germ-line ...\",\"description\":\"It argues that if genetic enhancement is governed by proper regulations and is accompanied by adequate education, then it need not violate recognized principlesÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/8201288/\",\"favicon\":\"\"},{\"id\":\"210\",\"title\":\"Affordable Pricing of CRISPR Treatments is a Pressing Ethical ...\",\"description\":\"Oct 18, 2024 Â· Casgevy, the world's first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tagÂ ...\",\"url\":\"https://www.liebertpub.com/doi/10.1089/crispr.2024.0042\",\"favicon\":\"\"},{\"id\":\"211\",\"title\":\"Gene Editing for Rare Genetic Diseases: Is An Equitable Future ...\",\"description\":\"Mar 21, 2024 Â· Gene editing technologies such as CRISPR/Cas9 systems can be employed to offer targeted interventions and improve clinical outcomes.\",\"url\":\"https://sites.brown.edu/publichealthjournal/2024/03/21/gene-editing-for-rare-genetic-diseases-is-an-equitable-future-possible/\",\"favicon\":\"\"},{\"id\":\"212\",\"title\":\"Navigating equity in global access to genome therapy expanding ...\",\"description\":\"Apr 4, 2024 Â· Issues of accessibility and affordability are pivotal in ensuring the equitable application of this novel therapy to enhance global health.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11024294/\",\"favicon\":\"\"},{\"id\":\"213\",\"title\":\"CRISPR therapies can treat disease but cost millions. An equity ...\",\"description\":\"Oct 10, 2024 Â· CRISPR therapies can treat disease but cost millions. An equity-based approach could bring them to more people.\",\"url\":\"https://thebulletin.org/2024/10/crispr-therapies-can-treat-disease-but-cost-millions-an-equity-based-approach-could-bring-them-to-more-people/\",\"favicon\":\"\"},{\"id\":\"214\",\"title\":\"Towards affordable CRISPR genomic therapies: a task force ...\",\"description\":\"Nov 8, 2023 Â· While pricing and access are concerns for genomic therapies here in the US and in other high income countries, these concerns are compoundedÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.nature.com/articles/s41434-023-00392-3\",\"favicon\":\"\"},{\"id\":\"215\",\"title\":\"Human genome editing: a framework for governance\",\"description\":\"Jul 12, 2021 Â· The Committee developed a governance framework that draws from good practices in the governance of emerging technologies and applied themÂ ...\",\"url\":\"https://www.who.int/publications/i/item/9789240030060\",\"favicon\":\"\"},{\"id\":\"216\",\"title\":\"Human genome editing: recommendations\",\"description\":\"Jul 12, 2021 Â· A set of two publications that provide advice and recommendations on appropriate institutional, national, regional and global governance mechanisms for humanÂ ...\",\"url\":\"https://www.who.int/publications/i/item/9789240030381\",\"favicon\":\"\"},{\"id\":\"217\",\"title\":\"Human Gene Therapy Products Incorporating Human Genome Editing\",\"description\":\"Mar 5, 2024 Â· In this guidance, we, FDA, are providing recommendations to sponsors developing human gene therapy products incorporating genome editing (GE) of human somaticÂ ...\",\"url\":\"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing\",\"favicon\":\"\"},{\"id\":\"218\",\"title\":\"United States: Germline / Embryonic\",\"description\":\"Germline gene editing is banned in the United States by acts of Congress although there is no federal legislation that dictates protocols or restrictions.\",\"url\":\"https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-embryonic-germline-gene-editing/\",\"favicon\":\"\"},{\"id\":\"219\",\"title\":\"European Union: Crops / Food - Global Gene Editing Regulation ...\",\"description\":\"Gene editing and New Genomic Techniques are effectively banned for cultivation as they are regulated under the same strict regulations that sharply limitÂ ...Missing:  USDA 2023-2025\",\"url\":\"https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/european-union-crops-food/\",\"favicon\":\"\"},{\"id\":\"220\",\"title\":\"European Parliament votes to ease regulation of gene-edited crops\",\"description\":\"Feb 7, 2024 Â· The European Parliament voted to lessen regulatory oversight of crops created through one type of DNA manipulation: gene editing.\",\"url\":\"https://www.science.org/content/article/european-parliament-votes-ease-regulation-gene-edited-crops\",\"favicon\":\"\"},{\"id\":\"221\",\"title\":\"All clinical research using germline genome editing banned in China\",\"description\":\"Jul 19, 2024 Â· China's science and technology ministry has prohibited all clinical research involving germline genome editing, describing the approach as 'irresponsible'.\",\"url\":\"https://www.chemistryworld.com/news/all-clinical-research-using-germline-genome-editing-banned-in-china/4019847.article\",\"favicon\":\"\"},{\"id\":\"222\",\"title\":\"[PDF] Innovation and Interdependence: The Case of Gene-Editing ...\",\"description\":\"First, lower barriers to entry create opportunities for forum-shopping by researchers, firms, and other actors. This facilitates regulatory arbitrage as actorsÂ ...\",\"url\":\"https://www.tylerbpratt.com/s/Genes_August2022.pdf\",\"favicon\":\"\"},{\"id\":\"223\",\"title\":\"Full article: Risk-appropriate regulations for gene-editing technologies\",\"description\":\"Jan 12, 2024 Â· Regulatory barriers lead to two key outcomes: reduced innovation investments and fewer commercialized products and technologies.\",\"url\":\"https://www.tandfonline.com/doi/full/10.1080/21645698.2023.2293510\",\"favicon\":\"\"},{\"id\":\"224\",\"title\":\"[PDF] List of barriers to implementation of genome editing technology in ...\",\"description\":\"Based on these discussions some of the main barriers identified to uptake of the technology were regulatory and legislative ambiguity, societal perception, off-Â ...\",\"url\":\"https://eurofaang.eu/wp-content/uploads/2024/02/D5.3-Public.pdf\",\"favicon\":\"\"},{\"id\":\"225\",\"title\":\"Regulation as key to fulfilling the promises of agricultural genomics\",\"description\":\"Jun 16, 2025 Â· This article provides a short review of recent scholarship on gene editing regulation and argues that regulation is an important part of the researchÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12169205/\",\"favicon\":\"\"}],\"images\":[{\"id\":\"f8d1ae66fe7e\",\"caption\":\"Engineered nucleases for genome editing\",\"url\":\"./_assets_/Engineered_Nucleases.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"226c1d6b971a\",\"caption\":\"Evolution of site-specific nucleases from meganucleases to TALENs and beyond\",\"url\":\"./_assets_/MEGANUCLEASE-ZFN-TALEN-CRISPR-text-to-path.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f2b39a75eeb3\",\"caption\":\"CRISPR-based genome editing mechanism\",\"url\":\"./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f2b39a75eeb3\",\"caption\":\"Double-strand break repair and CRISPR-based genome editing\",\"url\":\"./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"226c1d6b971a\",\"caption\":\"Evolution of sequence-specific targeting in nucleases\",\"url\":\"./_assets_/MEGANUCLEASE-ZFN-TALEN-CRISPR-text-to-path.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f8d1ae66fe7e\",\"caption\":\"Engineered nucleases for genome editing\",\"url\":\"./_assets_/Engineered_Nucleases.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f8d1ae66fe7e\",\"caption\":\"Engineered nucleases diagram\",\"url\":\"./_assets_/Engineered_Nucleases.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"3e37999f363e\",\"caption\":\"Overview of TALENs\",\"url\":\"./_assets_/Overview_of_TALENs.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f2b39a75eeb3\",\"caption\":\"CRISPR-based genome editing\",\"url\":\"./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f2b39a75eeb3\",\"caption\":\"CRISPR-based genome editing in therapeutic contexts\",\"url\":\"./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f2b39a75eeb3\",\"caption\":\"DNA break repair mechanisms underlying failure modes in CRISPR editing\",\"url\":\"./_assets_/DsDNA_break_repair_and_CRISPR-based_genome_editing.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Genome_editing\",\"title\":\"Genome editing\",\"content\":\"$1f\",\"description\":\"Genome editing\\n\\nEngineered nucleases for genome editing\\n\\nGenome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions,...\",\"metadata\":{\"categories\":[\"gene editing\",\"CRISPR\"],\"lastModified\":\"1761583287\",\"contentLength\":\"114344\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"72128\",\"recentViews\":\"72128\",\"dailyAvgViews\":2404.2666015625,\"qualityScore\":1,\"lastViewed\":\"1761887050\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761887051320,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Genome_editing\"],\"queryHash\":\"[\\\"page\\\",\\\"Genome_editing\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Genome editing\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Genome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions, replacements, or modifications of genetic material to study gene function or treat diseases. These techniques rely on engineered nucleases that create double-strand breaks at specific genomic loci, which are then repaired by cellular mechanisms such as non-homologous end joining or homology-directed repair, often incorporating desired changes. Early approaches...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"gene editing, CRISPR\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Genome_editing\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Genome editing\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Genome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions, replacements, or modifications of genetic material to study gene function or treat diseases. These techniques rely on engineered nucleases that create double-strand breaks at specific genomic loci, which are then repaired by cellular mechanisms such as non-homologous end joining or homology-directed repair, often incorporating desired changes. Early approaches...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Genome_editing\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Genome editing\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:43.287Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Genome editing\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Genome editing encompasses methods for precisely altering DNA sequences in living organisms, enabling targeted insertions, deletions, replacements, or modifications of genetic material to study gene function or treat diseases. These techniques rely on engineered nucleases that create double-strand breaks at specific genomic loci, which are then repaired by cellular mechanisms such as non-homologous end joining or homology-directed repair, often incorporating desired changes. Early approaches...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="Zjk2ZWI2OWQtMGQ0OC00ZjUyLWEyMTEtY2JjMjVjZDc1ZDM2">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Genome_editing\"}]}]\n"])</script></body></html>